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Abstract 
 
Malaria, transmitted by Anopheles mosquitoes is responsible for millions of 
deaths worldwide, especially in the developing countries. The emergence of drug 
resistant parasites and insecticide resistant vectors has stimulated efforts to 
develop novel genetic strategies to modify the insect vector and reduce its 
competence to transmit the parasite. One proposed approach is the genetic 
manipulation of insect’s midgut symbionts to express anti-parasite molecules.  
 
Recombinant antibodies that target specific antigens expressed on the parasites’ 
surface could be used as anti-parasite molecules, especially if they could not 
only bind but agglutinate the target. The murine antibody 4B7 binds to Pfs25 
epitope expressed on the zygote and ookinette stages of the parasite. Pf-NPNA-
1 is a human antibody that specifically binds to the NPNA (Asn-Pro-Asn-Ala) 
repeats of the circumsporozoite protein expressed on the sporozoite stage of the 
malaria parasite. This study aimed to characterise these antibodies for their 
application in symbiont control. For this purpose, the antibodies have been codon 
optimised for bacterial expression and formatted as single chain variable 
fragments (scFv).  
 
Synthetic genes encoding the scFv 4B7 and Pf-NPNA-1 were constructed, with 
varying linker length, in the VH-VL and VL-VH orientation. The scFvs were cloned 
into different expression plasmids to evaluate a suitable expression system. The 
orientation of the variable domains on secretion of the scFv 4B7 was 
investigated. No secretion was observed for the scFv 4B7 in the VH-VL 
orientation. For the reverse orientation, scFv 4B7 (VL-VH) was poorly secreted 
with no antigen binding. Secretion was observed for a variant of scFv 4B7 but 
this did not show significant antigen binding. Pf-NPNA-1 scFv constructs, in the 
VH-VL orientation, were efficiently secreted and showed detectable binding to 
antigen. Multimeric assembly of the scFv constructs was evaluated by varying 
the linker length. 4B7 and Pf-NPNA-1 scFv constructs exhibited monomeric, 
dimeric and multimeric assembly. Fusion of the human kappa constant domain to 
the scFvs resulted in formation of monomeric and higher ordered forms. Transfer 
of the scFv gene fragments into a broad-host vector facilitated evalution of 
recombinant antibody expression in the acetic acid bacterium, Asaia SF2.1.  
 
In summary, the results from this study demonstrate the potential utility of the 
antibodies, 4B7 and Pf-NPNA-1, as anti-parasite molecules for blockade of 
malaria transmission via mosquito midgut symbionts.   
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1.1 INTRODUCTION 
 
Malaria, caused by the protozoan apicomplexan parasite of the genus 
Plasmodium and transmitted by Anopheles mosquitoes, still poses a global 
public health problem in the developing world, where more than a third (2.4 
billion) of the world’s population resides (Malkin et al., 2006) (Figure 1.1). Of 
the five Plasmodium species (P. falciparum, P. malariae, P. vivax, P. ovale, P. 
knowlesi) that infect humans, P. falciparum is the most virulent (Moorthy et al., 
2004; Singh et al., 2004). A child dies every 30 seconds and in 2008 a 
worldwide estimation of 250 million clinical cases resulted in 850,000 deaths 
of which 89% were in Africa (Malaria Report, 2010). Current control strategies 
such as the use of long-lasting insecticide treated nets and artemisinin 
combination therapy have reduced malaria transmission in some areas 
(Bhattarai et al., 2007; Ndiaye et al., 2009; Otten et al., 2009). However, the 
problem has been compounded by the increase in vector resistance to 
insecticides (Martinez-Torres et al., 1998; Hemingway et al., 2004; Pinto et al., 
2007) and emergence of multidrug-resistant P. falciparum parasites (Fidock et 
al., 2000; Sidhu et al., 2002; Picot et al., 2009; Witkowski et al., 2010) 
Although a promising vaccine is in development (Sacarlal et al., 2009; 
Vekemans et al., 2009), there is still an urgent need for additional and novel 
control strategies to augment current approaches. Novel control strategies 
include transgenic mosquitoes that are refractory to infection, application of 
biological agents that are capable of disrupting parasite life cycle or their 
engineering to secrete anti-parasite molecules, within the mosquito, that 
inhibit parasite development and the development of new insecticidal 
compounds.
                           General Introduction 
3 
 
 
Figure 1.1: Global distribution of malaria with low to high transmission areas. P. falciparum malaria transmission is displayed as a 
continuum of yellow to red 0% - 100% (map legend). The medium grey and grey areas are the unstable and stable areas of transmission, 
respectively (Hay et al., 2009).
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In order to appreciate the difficulties associated with the development of 
control strategies for malaria transmission, an understanding of the life cycle 
and developmental stages including the complex series of interactions 
between parasite, host and vector is required.  
 
All Plasmodium parasites require two hosts for their development. For the 
human malaria parasite (Figure 1.2) P. falciparum, acquisition of the parasite 
occurs when an infected female mosquito injects sporozoites with saliva into 
the skin during feeding. The sporozoites enter the blood stream and are 
transported to the liver where they invade hepatocytes and multiply asexually 
(exoerythrocytic schizogony) to form merozoites (Garcia et al., 2006). 
Merozoites released from the hepatocytes actively invade erythrocytes to 
undergo further multiplication and enlarge into ring shaped uninucleate cells, 
termed trophozoites. The trophozoites then divide asexually into multinucleate 
schizonts, which subsequently divide into mononucleated merozoites. 
 
 
Figure 1.2: Plasmodium life cycle in the vertebrate host and mosquito. The 
different antigens expressed during the developmental stages are highlighted 
(Winzeler, 2006). 
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The erythrocyte eventually ruptures, releasing 8–32 new merozoites, which 
can infect new erythrocytes. This stage marks the period when an infected 
person experiences periodic cycles of fever and chill lasting about 42–48 
hours (Bannister and Mitchell, 2003; Winzeler, 2006). The merozoites which 
do not infect new erythrocytes undergo gametocytogenesis, during which they 
differentiate into male and female gametocytes. Subsequently, the mosquito 
takes up the mature sexual forms during a blood meal, and sexual 
reproduction of the parasite occurs in the insect's midgut (Kappe et al., 2004). 
 
Within the mosquito vector, Plasmodium undergoes a complex developmental 
process differentiating into six distinct morphological forms: female and male 
gametes, zygote, ookinete, oocyst and sporozoite. Within minutes of being 
taken up, the gametocytes differentiate into male and female gametes. The 
male gametocytes (microgametes) undergo exflagellation, releasing eight 
haploid gametes. Fertilisation of the male and female (macrogamete) gametes 
ensues, leading to the formation of zygotes (Ghosh et al., 2000). 
Gametogenesis, the transformation and differentiation of the zygotes into 
motile ookinetes follows. The ookinetes then migrate through the blood meal; 
traverse the perithrophic matrix (PM), a chitinous membrane that surrounds 
the blood bolus. To cross the PM the parasite secretes a chitinase (Huber et 
al., 1991). Inhibition of chitinase activity by allosamidin prevents the parasites 
from invading the midgut epithelium (Shahabuddin et al., 1993).  
 
After crossing the PM, the ookinetes encounter another barrier – the midgut 
epithelia. In order to invade the midgut epithelia, ookinetes must attach 
themselves to the surface of the midgut microvilli (Ghosh et al., 2000). The 
ookinetes enter the epithelial cells, attach to the basal lamina where they 
differentiate into oocysts. The oocysts undergo multiple rounds of asexual 
replication resulting in the production of sporozoites. Each mature oocyts 
contains thousands of sporozoites that are released into the haemocoel and 
eventually invade the salivary glands (specifically distal lateral and medial 
lobes) (Shahabuddin and Costero, 2001; James, 2003; Moreira et al., 2004a). 
A number of laboratory studies have shown evidences to suggest that the 
attachment and invasion of salivary glands is a receptor-mediated process. 
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For instance, Rosenberg (1985) demonstrated the inability of P. knowlesi 
sporozoites to invade the salivary glands of A. freeborni but able to invade 
those of A. dirus (Rosenberg, 1985). Furthermore, polyclonal sera raised 
against Aedes aegypti salivary glands inhibited sporozoite invasion (Warburg 
et al., 1992; Barreau et al., 1995; Barreau et al., 1999; Brennan et al., 2000). 
Finally, A. stephensi sporozoites were inhibited from invading P. berghei 
salivary glands by the 12 amino acid peptide SM1 (Ghosh et al., 2001). Thus, 
it is apparent that successful establishment of Plasmodium in the mosquito is 
dependent on recognition of mosquito midgut and salivary epithelia.  
 
During its development in the mosquito, the parasite encounters various 
barriers: physical (membranes and receptors), biochemical (proteases, 
chitinases) and physiological (immunological factors). As a result large 
increases in parasite losses (3,000-160,000) occur during the transition of the 
parasites from the blood meal to the PM, the midgut epithelium and into the 
haemocoel (Shahabuddin and Costero, 2001) (Figure 1.3).  
 
 
Figure 1.3: Parasite losses and amplification in the mosquito. Parasite numbers 
during the critical steps of transformation of gametes to ookinetes and of ookinetes to 
oocysts. The initial number of ingested parasites was estimated to be 104. Adapted 
from (Blandin and Levashina, 2004). 
 
 
This loss is more evident during the zygote to ookinete transition (Vaughan et 
al., 1994). For every 1000 P. berghei gametocytes ingested, only two viable 
ookinetes successfully develop and invade the midgut which subsequently 
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develop into mature oocysts (Alavi et al., 2003). These decreases in parasite 
numbers are listed Table 1.1. 
 
 Stage of development Reference  
 Gametocyte to 
ookinete 
(decrease) 
Ookinete to 
oocyst 
(decrease) 
 
P. falciparum 
 
An. gambiae 316-fold 100-fold (Vaughan et al., 1994) 
An. gambiae 40-fold 69-fold (Vaughan et al., 1992) 
An. stephensi 490-fold 250-fold (Vaughan et al., 1992) 
An. dirus 1,223-fold 192-fold (Vaughan et al., 1992) 
    
P. vivax             
   
An. dirus 35-fold  5-fold (Zollner et al., 2006) 
    
P. gallinaceum 
   
An. gambiae 4,635-fold 5-fold (Alavi et al., 2003) 
An. stephensi 9,972-fold 127-fold (Alavi et al., 2003) 
    
P. berghei  
   
An. gambiae 470-fold 54-fold (Alavi et al., 2003) 
An. stephensi 531-fold 6-fold (Alavi et al., 2003) 
 
Table 1.1: Stage-specific differences in Plasmoduim parasite numbers in 
Anopheles mosquitoes (Adapted and modified from Ghosh et al., 2000). 
 
Clearly, the studies cited indicate the importance of the ookinete to oocyst 
transition on the successful development of the parasite within the mosquito. 
Thus, the low numbers of the ookinetes makes them an attractive stage to 
target in blocking parasite transmission. Efficient blocking of the parasite will 
require identification of parasite ligands or proteins expressed on the parasite 
surface that mediate cell adhesion. The sporogonic development of 
Plasmodium is characterised by distinct morphological forms, which express 
proteins on their surface. These proteins have been implicated in parasite 
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survival within the midgut, recognition, attachment and penetration of the 
midgut epithelium.  
 
P. falciparum sexual stage antigen Pfs25 (Figure 1.4) and its homologue in P. 
vivax, Pvs25, are members of the P25 family of cysteine-rich 25 kDa antigens 
expressed on the surface of zygotes, ookinetes and young oocysts. Structural 
homology of this protein has been observed in the human, bird and rodent 
Plasmodium parasites (Barr et al., 1991; Duffy et al., 1993; Duffy and Kaslow, 
1997; Tsuboi et al., 1997). 
 
 
Figure 1.4: Superimposed structures of Pfs25 (cyan colour) and Pvs25 (red 
colour). Conserved cysteines are represented as CPK representations. (Adapted 
from (Sharma, 2008) 
 
 
They are characterised by an N-terminal signal peptide that precedes four 
tandem epidermal growth factor-like (EGF) domains and a C-terminal 
glycophosphatidylinositol that anchors the protein to the parasite surface. P25 
proteins contain 22 cysteine residues, capable of forming 11 potential 
disulphide bonds (Stowers et al., 2000; Saxena et al., 2007). The P25 protein 
is involved in parasite recognition of and attachment to the mosquito midgut 
(Tomas et al., 2001; Siden-Kiamos and Louis, 2004). Using knockout 
parasites of P. berghei, lacking the P25 protein, Tomas et al. (2001) showed 
that P25 plays an important role in parasite survival in the harsh proteolytic 
environment of the midgut by providing a protective sheath around the 
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parasite, permitting penetration of the epithelium and transformation of the 
ookinetes into oocysts.   
  
P25 proteins are only expressed in the mosquito midgut and not in the 
vertebrate host and thus, have not been under selection pressure by the host 
immune system. Though insects have long been recognised to have effective 
innate (cellular and humoral) defense mechanisms they, however, lack the 
memory and specific recognition that are characteristic of the vertebrate 
immune system (Dong et al., 2006). The sequences of field isolates of P. 
falciparum and P. vivax, unlike blood stage antigens, show limited 
polymorphisms making P25 a potential target for blockade of transmission 
(Duffy and Kaslow, 1997). Studies conducted in mice and rhesus monkeys 
have shown that Pfs25 expressed in yeast is able to elicit antibodies that 
block development of P. falciparum oocysts in the midgut of the mosquito 
vector. (Barr et al., 1991; Stowers et al., 2000; Arakawa et al., 2005; Miura et 
al., 2007). Pfs25 antigen is a leading candidate for transmission blocking 
vaccines and Phase I clinical trials in humans have confirmed safety as a 
vaccine candidate (Kaslow, 2002; Wu et al., 2008). The third EGF-like domain 
contains a portion of a B-cell epitope and is the target of monoclonal 
antibodies 4B7 (Barr et al., 1991), ID2, IC7 (Quakyi et al., 1995) and 32F81 
(Vermeulen et al., 1985). 
 
Another parasite antigen that is a potential target for blockade of malaria 
transmission is the circumsporozoite (CS) protein expressed on the surface of 
sporozoites. This 45 kDa protein covers the entire surface of the sporozoites 
and is the most extensively characterised of the sporozoite proteins 
(Nagasawa et al., 1987; Boulanger et al., 1988; Nagasawa et al., 1988; Kappe 
et al., 2004). Two other sporozoite antigens that have well been characterised 
are the thrombospondin-related anonymous protein (TRAP), and membrane 
apical erythrocyte binding-like (MAEBL) (Garcia et al., 2006).  
 
CS protein shows structural homology in all species, consisting of three main 
domains. A striking feature of the P. falciparum CS (Figure 1.5) protein is the 
central domain, which is a major B-cell epitope, consisting of 37 tandem 
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repeats of asparagine-proline-asparagine-alanine (NPNA) and 4 repeats of 
asparagine-valine-aspartic acid-proline (NVDP). The central repeat tetramer 
peptide (Asn-Pro-Asn-Ala)n, (NPNA)n of CS protein is 100% conserved among 
P. falciparum isolates (Zavala et al., 1985a; Kappe et al., 2004; Garcia et al., 
2006). It has been suggested that the high number of repeats precludes the 
development of mutants which will evade recognition by a target antibody 
(Chappel et al., 2004b). CS protein is flanked at the amino and carboxyl 
terminals by region I and II, respectively. The protein is anchored to the 
parasite surface by a glycosyl phosphatdylinositol (GPI) anchor.  Region I 
consists of the conserved sequence KLKQP and has been shown to be 
involved in invasion of the mosquito’s salivary glands (Sidjanski et al., 1997). 
Region II, however, consists of 18 amino acids and is involved in binding to 
heparan sulphate proteoglycans (HSPGs) present on the surface of 
hepatocytes (Kappe et al., 2004).        
  
      
Figure 1.5: Schematic representation of the PfCS protein: SP, signal peptide; RI, 
region I; RII-plus, region II-plus; RIII, region III; TSR, thrombospodin type I repeat 
domain; GPI, glycosyl phosphatdylinositol (Kappe et al., 2004).  
 
 
Many reports have implicated CS protein in oocyst development and 
sporozoite differentiation (Menard et al., 1997),  maintenance of species 
specificity during infection (Rathore et al., 2003), attachment and invasion of 
liver cells (Frevert et al., 1993; Rathore et al., 2003), inhibition of host cell 
protein synthesis (Frevert et al., 1998) and facilitation of sporozoite passage 
into salivary glands of the mosquito (Sidjanski et al., 1997). Anti-CS protein 
antibodies have blocked salivary gland invasion by P. gallinaceum sporozoites 
(Warburg et al., 1992; Barreau et al., 1995; de Lara Capurro et al., 2000). 
Additional evidence suggests that a recombinant CS protein preferentially 
bound salivary glands but not Malpighian tubules or ovaries and this binding 
was inhibited by the peptide LRKPKHKKLKQPADG, which corresponds to the 
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conserved region I (Sidjanski et al., 1997). In subsequent experiments, the 
recombinant CS protein and the peptide inhibited sporozoite entry into salivary 
glands (Myung et al., 2004).   
 
The immunodominance of CS protein was shown when rodents, monkeys and 
humans vaccinated with radiation-attenuated sporozoites were protected 
against malaria infection or re-infection (Nussenzweig et al., 1967; Clyde et 
al., 1973; Clyde, 1975; Hoffman et al., 2002). The sporozoites though 
attenuated are capable of invading hepatocytes but do not develop fully to the 
merozoite stage. The presence of the partially developed parasites elicits an 
immune response which is mainly antibody mediated. This protection is sterile 
and long lasting compared to naturally acquired immunity, which allows 
intermittent episodes of infection to occur (Carvalho et al., 2002). Antibodies 
to the repeat epitope (NPNA) prevent infection by blocking entry of 
sporozoites into hepatocytes. High levels of anti-PfCSP repeat antibodies 
have been shown to correlate with protection in areas where malaria is 
endemic (Hoffman et al., 1986; Ballou et al., 1987; Jones et al., 1993). The 
CS protein has been incorporated in the RTS,S vaccine currently in phase III 
clinical trials (Ballou, 2009; Sacarlal et al., 2009; Vekemans et al., 2009). 
 
 
1.2 Application of biological agents for control of malaria  
 
Traditionally, success in the management of vector-borne diseases has been 
achieved through the controlled reduction of vector populations by use of 
insecticides. However, the continued application of insecticides has been 
hampered by increase in insecticide resistance. With recent progress in 
molecular biology, biocontrol measures are being developed to reduce vector 
capacity to transmit disease. This is based on the use of naturally occurring 
microorganisms. Insects, generally can be infected by a range of 
microorganisms: fungi, protozoa, viruses and bacteria.  
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1.2.1 Fungal biopesticides 
 
The use of fungal isolates, such as Bacillus thuringiensis and Bacillus 
sphaericus, against mosquito larvae have been attempted in numerous 
studies in the past (Padua et al., 1980; Lacey and Undeen, 1986; Federici, 
1995; Scholte et al., 2004). However, the renewed use of fungi against adult 
mosquitoes is based on the past successes and effectiveness of indoor 
residual spraying to reduce vector populations. Since the strategy involves 
spraying mosquitoes’ resting sites with suspensions of fungal spores, infection 
of the insect host only occurs through external contact and not by ingestion. 
The fungal conidia upon contact with the insect’s cuticle germinate and grow 
hyphae which penetrate the insect body. Within the insect’s haemocoel 
numerous organic compounds, such as destruxins, are produced that cause 
internal damage and paralysis. Nutrient depletion eventually results in the 
death of the insect (Howard et al., 2010). However, the time taken to kill the 
host may vary from 2 to 5 days or weeks based on the host-pathogen 
combination and environmental factors (Blanford and Thomas, 2001; Elliot et 
al., 2002). 
 
It has been suggested that malaria transmission rates are more dependent on 
the changes in adult mosquito survival rather than on changes in the survival 
of larval forms (Bukhari et al., 2010; Howard et al., 2010; Knols et al., 2010). 
Targeting adult females before they are capable of transmitting parasite would 
result in less exertion of the high selection pressure usually associated with 
the use of insecticides. Furthermore, the likelihood of resistance development 
is reduced due to the multiple modes of action of the fungus and the slow 
speed of kill (mosquitoes killed within 14 days). In addition, an entomological 
inoculation rate model estimated that the application of fungi as biopesticides 
may result in a reduction of annual mosquito bites per person from 262 to 64 
(Scholte et al., 2005).  
 
It was the independent work of Blanford et al. (2005) and Scholte et al. (2005) 
demonstrated the pathogenic effect of two entomopathogenic fungi, 
Metarhizium anisopliae and Beauveria bassiana, on adult mosquitoes. 
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Besides their effect on mosquito survival, they have also been demonstrated 
to inhibit parasite development in the mosquito (only 8% of infected 
mosquitoes had infectious parasites compared to 35% of control which were 
only infected with Plasmodium) (Blanford et al., 2005) and reduction in 
mosquito feeding propensity and fecundity (Scholte et al., 2006). In laboratory 
setting, Scholte et al. (2004) demonstrated horizontal transfer of Metarhizium 
anisopliae from infected males to females. In addition, a recent study has 
demonstrated increased susceptibility of insecticide resistant Anopheles 
mosquitoes to the insecticides permethrin and dichlorodiphenyltrichloroethane 
after preinfection with B. bassiana or M. anisopliae (Farenhorst et al., 2009). It 
has also been shown that pyrethroid resistant A. gambiae mosquitoes were 
more susceptible to B. bassiana and M. anisopliae infections than their non-
resistant counterparts (Howard et al., 2010). Subsequently, combinations of 
the insecticide, permethrin, with fungal formulations of B. bassiana and M. 
anisopliae were observed to have synergistic effects on the survival of 
mosquitoes. Simultaneous application of both agents had a higher effect than 
the use of a single agent (Farenhorst et al., 2010). More recently, transgenic 
strains of M. anisopliae have been engineered to express anti-parasite 
molecules, which target the sporozoite stages of the parasite, in the 
haemolymph of the mosquito. The anti-parasite molecules, SM1 (a midgut 
and salivary gland peptide that blocks sporozoites invasion of salivary glands), 
Pf-NPNA-1 (a single chain antibody that agglutinates sporozoites) and 
scorpine (an antimicrobial toxin) reduced sporozoite numbers by 71%, 85% 
and 90%, respectively. Sporozoite numbers were further reduced by 98% 
when an SM1-scorpine fusion protein was expressed (Fang et al., 2011).   
 
Numerous technical hurdles are yet to be surmounted despite the success 
achieved in the pioneering of a transgenic fungus capable of disrupting 
malaria transmission. Fungal spore viability, fungal specificity, infectivity and 
persistence of spores under field conditions and development of resistance 
have not been adequaltely evaluated (Howard et al., 2010; Knols et al., 2010). 
Howard et al. (2010) are of the view that any potential application method be 
evaluated in the field due to the biological nature of fungal spores. The 
ubiquitous nature of these fungi in the environment coupled with the lack of 
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specificity, their ability to infect a wide range of insects, may pose both 
environmental and health risks. However, the low survival rate of fungal 
spores when exposed to UV radiation and high temperatures may dampen 
this concern. Yet to be adequately investigated is the potential health risks 
immuno-compromised people, who are inhabitants of malaria endemic 
regions, may encounter due to exposure to fungal spores (Farenhorst and 
Knols, 2007).  
 
A major concern is the development of antifungal resistance. In the study by 
Blanford et al. (2005), using the murine malaria model and the fungus B. 
bassiana, the mosquito host was killed within two weeks, which is 
approximately the time the malaria parasite takes to develop into infectious 
sporozoites. This slow speed of kill, it has been suggested, will impose a 
limited selection pressure on the mosquitoes and reduce the development of 
antifungal resistance (Knols and Thomas, 2006). The likelihood of resistance 
development may also be limited as fungi can attack the mosquitoes by 
secreting chitinase, proteases and toxins (Hajek and St Leger, 1994). 
However, the two weeks within which the mosquito is killed, is long enough for 
the female Anopheles to acquire, develop and transmit the malaria parasite.  
 
Secondly, environmental factors such as temperature may also affect the 
growth of the fungi with a direct effect on its killing speed. This stems from the 
fact that studies using fungi as biopesticides for control of locust and 
grasshoppers have reported varying field results (Blanford et al., 1998; 
Blanford and Thomas, 1999; Klass et al., 2007). These have been associated 
with changes in environmental temperature. Though Blanford and colleagues 
have reported no changes in the speed of kill due to changes in the thermal 
behaviour of A. stephensi mosquitoes, Kikankie and colleagues are of the 
view that the temperature effect on the germination and growth rate within the 
mosquito warrants further study (Blanford et al., 2009; Kikankie et al., 2010).   
 
Another issue with use of fungi as biocontrol agents is the viability of the 
conidia. Scholte et al. (2005) estimated that a 63% decrease in viability occurs 
after 3 weeks when applied to surfaces. Thus, surfaces would have to be re-
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treated regularly, a requirement which is unsustainable during large scale 
implementation. Other barriers, such as fungal specificity and the 
development of resistance in the mosquitoes, need to be addressed before its 
widespread application (Kanzok and Jacobs-Lorena, 2006).    
 
Due to the aforementioned problems associated with the use of fungi as 
biocontrol agents, two other alternative strategies, transgenesis and 
paratransgenesis, are under development to control spread of the disease. 
These strategies, in contrast to the fungal biocontrol approach, do not aim to 
kill the arthropod vector but reduce its competence to support parasite 
development and transmission.   
 
 
 
1.2.2 Transgenesis 
 
Application of genetically modified mosquitoes to reduce or replace vector 
populations offers great opportunities for the control of mosquito-borne 
diseases. The genetic modification involves the introduction into the mosquito 
genome, genes whose products impair Plasmodium development. This has 
been made possible by advances in germ-line transformation of mosquitoes 
(Catteruccia et al., 2000), identification of effector molecules that interfere with 
parasite development (Possani et al., 1998; de Lara Capurro et al., 2000; 
Ghosh et al., 2001; Zieler et al., 2001; Arrighi et al., 2002; Nirmala and James, 
2003) and characterisation of tissue-specific promoters to express the effector 
molecule (Kokoza et al., 2000; Moreira et al., 2000). These milestones have 
led to the stable transformation of a number of Anopheles mosquitoes and 
more recently A. gambiae (Grossman et al., 2001; Ito et al., 2002; Nolan et al., 
2002; Perera et al., 2002).  
 
To evaluate the feasibility of this approach, some Anopheles mosquitoes have 
been transformed to express effector molecules. Ito and colleagues were the 
first to develop a transgenic mosquito that was refractory to P. berghei. The 
transgenic A. stephensi was transformed with a piggyBac transposable 
                           General Introduction 
16 
 
element that expressed SM1 (Ghosh et al., 2001), a 12 amino acid disulphide 
loop (PCQRAIFQSICN) peptide that binds to the distal lobe of the salivary 
gland and to the luminal side of the midgut epithelium required for parasite 
invasion, under the control of A. gambiae carboxypeptidase (AgCP) promoter. 
In this study, P. berghei oocyst formation was inhibited by 81.6% (Ito et al., 
2002). The piggyBac element was isolated from the cabbage looper moth, 
Trichoplusia ni, and has been used to transform a variety of insects.   
 
Subsequently, expression of the bee venom phospholipase A2 (PLA2) in A. 
stephensi resulted in 87% inhibition of oocyt formation compared to controls 
without PLA2. In addition, PLA2 transgenic mosquitoes failed to transmit 
parasites to naïve mice (Moreira et al., 2002). By replacing the AgCP 
promoter with an Ag perithrophin promoter to drive PLA2 expression, the P. 
berghei oocyst formation was inhibited by 80% (Abraham et al., 2005). 
Transgenic A. gambiae expressing cecropin A under the control of the Aedes 
aegypti CP promoter reduced P. berghei oocyst formation by 60% compared 
to nontransgenic controls (Kim et al., 2004). However, cecropin A expression 
was not observed in the midgut of transgenic mosquitoes. P. gallinaceum 
oocyst intensity was inhibited by 65% to 70% when Aedes aegypti was 
transformed with piggyBac expressing defensin A under the control of the Ag 
perithrophin promoter (Shin et al., 2003).    
 
Despite the significant progress made in the development of transgenic 
mosquitoes, the approach faces numerous challenges which must be 
addressed before its application in the natural environment. Firstly, there is an 
urgent need to develop transgenic mosquitoes capable of inhibiting 
development of human malaria parasites. This has been achieved for mouse 
parasite, P. berghei (Ito et al., 2002; Moreira et al., 2002) and avian malaria 
parasite, P. gallinaceum (Rodrigues et al., 2008). More recently, Corby-Harris 
et al. (2010) have reported a 95.6% inhibition of P. falciparum parasites in the 
midgut of transgenic A. stephensi compared to nontransgenic mosquitoes. 
Over-expression of the signalling protein, Akt, under the control of the AgCP 
promoter significantly decreased P. falciparum development and mosquito 
lifespan after a blood meal (Corby-Harris et al., 2010). Akt signalling protein 
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forms a key component of the insulin/insulin-like growth factor 1 signalling 
cascade, which regulates innate immunity and lifespan of vertebrates and 
non-vertebrates (Corby-Harris et al., 2010).      
 
Introduction of such engineered strains of mosquitoes with anti-pathogen 
refractory phenotypes into the native population would require an effective 
drive mechanism to spread the genes coding for refractoriness. Of the several 
genetic drive mechanisms, transposable elements (TEs) were the first to  gain 
increased attention based on the successful worldwide spread of the 
Drosophila P element (Anxolabehere et al., 1988). However, initial attempts to 
introduce TEs into Anopheles mosquitoes have failed (Marshall and Taylor, 
2009). Despite their extensive use TEs may not be unsuitable for use as a 
drive system due to the loss or deletion of internal sequences during 
replication, decline in activity due to increasing size of refractory genes and 
inactivation due to accumulation of mutations (Riehle and Jacobs-Lorena, 
2005; Marshall and Taylor, 2009). Other drive mechanisms currently being 
investigated include Medea (maternal-effect dominant embryonic arrest), 
homing endonuclease genes and the intracellular bacteria Wolbachia 
(Marshall and Taylor, 2009; Coutinho-Abreu et al., 2010).  
 
To overcome the limitations of TEs, the Streptomyces phage phiC31 integrase 
system, previously used for Drosophila melanogaster and Aedes aegypti, was 
recently used for successful site-specific transformation of An. gambiae. Site-
specific integration of Vida-3, an antimicrobial peptide that is active against 
early sporogonic stages and developing oocysts, into the phage phiC31 target 
site and its expression under the AgCP promoter in the midgut of An. gambiae 
resulted in 85% reduction in Plasmodium yoelii nigeriensis parasite intensity. 
There were, however, variations in the protection conferred against P. 
falciparum due to inconsistencies in the infection rates between experiments 
(Meredith et al., 2011). As proof-of-principle, the authors are of the view that, 
future applications of the system will require several modifications to enhance 
efficiency and extensive fitness studies.    
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Another important constraint associated with the release of transgenic 
mosquitoes into the environment is the potential fitness cost imposed by the 
transgene (Marrelli et al., 2006). However, laboratory studies have suggested 
that the nature of the refractory gene product is crucial for fitness. In the study 
by Moreira and colleagues, no fitness load was observed for transgenic 
mosquitoes expressing the SM1 peptide whereas mosquitoes expressing 
PLA2 were less fit and less fertile compared to nontransgenic ones (Moreira 
et al., 2004b).   
 
Although proof-of-concept studies have established the feasibility of 
developing transgenic mosquitoes, it may take many years before they can be 
released into wild populations. An effective drive mechanism has not yet been 
identified and no progress has been attained in developing a transgenic 
mosquito refractory to human malaria parasites. Due to the many challenges 
facing the development of transgenic mosquitoes, an alternative approach 
which utilises symbiotic bacteria to deliver anti-pathogen molecules, is also 
being developed. The paratransgenic approach has many advantages over 
transgenic mosquitoes. Firstly, it is compatible with current insecticide control 
programs. Secondly, the logistics involved in the genetic manipulation of 
bacteria and their growth in large quantities is simplified. Release of large 
quantities poses fewer risks compared to large scale release of transgenic 
mosquitoes. Thirdly, multiple effector molecules could be delivered using a 
mixture of genetically manipulated bacteria. Finally, the nature of the effector 
gene could be changed at any time during a control program (Durvasula et al., 
1997; Riehle and Jacobs-Lorena, 2005).   
 
 
1.2.3 Paratransgenesis 
 
Common to both paratransgenesis and transgenesis is the potential to reduce 
the competence of the host-vector to enable parasite development (Conte, 
1997; Beard et al., 1998; Beard et al., 2001; Beard et al., 2002). In contrast to 
transgenesis, the paratransgenic approach alters the host’s ability to transmit 
disease by genetically manipulating symbiotic microorganisms to express and 
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secrete effector molecules (i.e., recombinant anti-parasite molecules) that 
inhibit parasite invasion or development in the midgut (Riehle et al., 2003). 
Viral and bacterial symbionts have been included in numerous studies 
(Durvasula et al., 1999; de Lara Capurro et al., 2000; Yoshida et al., 2001; 
Riehle et al., 2007; Durvasula et al., 2008; Ren et al., 2008). Beard et al. 
(1992) suggested that the successful implementation of this approach 
depends on six main criteria:  
 
i) identification of culturable microbes amenable to genetic 
manipulation 
ii) existence of methods for isolating and transforming microbes 
iii) transformation of the symbiotic bacteria must result in stable 
mutants without the loss of reproductive fitness 
iv) genetic manipulation of the symbiont should not render them 
virulent, either to the vector or other organisms in the environment 
v) identification and engineering of anti-parasite or effector molecules 
that block parasite uptake and transmission in the arthropods, 
vi) spread of the transgene into natural vector populations to a level 
that is able to interrupt parasite transmission.   
 
This approach was initially developed and successfully used to suppress the 
transmission of Chagas’ disease (Beard et al., 1992). The symbiotic bacteria, 
Rhodococcus rhohnii, transformed with a shuttle vector encoding the gene for 
ceprocin A was introduced into the vector, Rhodnius prolixus. The expressed 
ceprocin A inhibited the development of Trypanosoma cruzi parasites by 99% 
without any fitness cost on the insect (Durvasula et al., 1997). Subsequently, 
a functional anti-progesterone antibody was expressed in the midgut of the 
vectors R. proxilus (Durvasula et al., 1999) and Triatoma infestans (Durvasula 
et al., 2008), respectively.  
 
Application of this strategy against African trypanosomes transmitted by tsetse 
flies has shown promising results. In the case of tsetse flies, the symbiont 
(Sodalis glossinidius) was transformed with a plasmid encoding green 
fluorescent protein (pGFPuv). Females bearing the pGFPuv plasmid vertically 
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transmitted it to their progeny, an indication of transstadial transfer of the 
symbiont across tsetse populations (Cheng and Aksoy, 1999; Aksoy et al., 
2008). Recombinant Sodalis expressing a Glossina attacin, an antimicrobial 
peptide effective against gram-negative bacteria and protozoa, significantly 
reduced parasite levels when fed a trypanosomal blood meal (Aksoy, 2003). 
This approach has gained widespread attention and is being developed to be 
used against the Mexican fruit fly Anastrepha ludens, which threatens citrus 
fruits (Kuzina et al., 2001), the glassy-winged sharp shooter, Homalodisca 
coagulata, which is a vector for Xylella fastidosa, the bacterium that causes 
Pierce’s disease of grape vines (Bextine et al., 2004), the kala azar vector, 
Phlebotomus argentipes, which transmits leishmaniasis (Hillesland et al., 
2008) and in the brine shrimp Artemia franciscana (Subhadra et al., 2010) for 
control of infectious diseases in shrimp aquaculture. 
 
The feasibility of a paratransgenic approach in Anopheles mosquitoes has 
been demonstrated in three laboratory studies (de Lara Capurro et al., 2000; 
Yoshida et al., 2001; Riehle et al., 2007). A viral paratransgenesis approach 
was undertaken by de Lara-Capurro et al. (2000) and used to successfully 
block transmission of the avian malaria parasite, P. gallinaceum. A single 
chain variable fragment (scFv) N2H6D5, that targets P. gallinaceum 
circumsporozoite protein (CSP) was expressed from a Sindbis virus vector 
and shown to reduce the number of parasites in the salivary glands by 99% 
(de Lara Capurro et al., 2000). Although this viral system was used to 
evaluate scFv N2H6D5 as an effector molecule, the variability in mosquito 
infections with the Sindbis virus vector would limit its application in 
transmission blocking studies. Furthermore, Sindbis viruses may not be 
suitable for use in paratransgenesis due to their broad specificity (Coutinho-
Abreu et al., 2010). They have been shown to infect a broad range of insect 
genera and vertebrates (Carlson et al., 1995; Blair et al., 2000). 
 
Alternatively, genetically modified denosonucleosis viruses (DNV), which are 
icosahedral parvoviruses with non-enveloped single stranded DNA, are being 
evaluated for application in paratransgenesis. Numerous characteristics make 
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DNV suitable vectors for this approach (Carlson et al., 1995; Carlson et al., 
2006; Ren et al., 2008). They: 
 
i) can be genetically manipulated 
ii) have narrow host range making them highly specific 
iii) are environmentally stable 
iv) are horizontally and vertically transmitted from infected adults to 
larvae 
v) can kill mosquito larvae in a dose-dependent manner and decrease 
life span of surviving adults. 
 
DNV were previously not considered for use in paratransgenesis with the 
main mosquito vector, A. gambiae, due to lack of infection when larvae were 
exposed to the Aedes aegypti DNV (Ward et al., 2001). However, a DNV was 
recently isolated from A. gambiae and genetically modified to express GFP in 
A. gambiae. The recombinant DNVs were detected in the midgut, fat body and 
ovaries and transmitted to other generations (observed in 20% of F2 and F3 
generations) (Ren et al., 2008). Although a transducing system for A. gambiae 
DNV has been established, its potential to express anti-Plasmodium effector 
molecules is yet to be determined.  
      
Bacteria have also gained widespread application for use in paratransgenesis. 
An identified culturable bacterium may be well adapted to the mosquito midgut 
and would not face stiff competition from other bacteria (Riehle and Jacobs-
Lorena, 2005). Secondly, it has been observed that the bacterial population 
increases immediately after a blood meal. Pumpuni et al. (1996) observed an 
11-fold and 40-fold increase in bacteria numbers of A. gambiae and A. 
stephensi, respectively, 24 h after a blood meal. Thirdly, reduction in oocysts 
density of P. falciparum (Pumpuni et al., 1993; Pumpuni et al., 1996) and P. 
vivax (Gonzalez-Ceron et al., 2003) infections has been associated with gram-
negative bacteria.  
   
Yoshida et al. (2001) evaluated in vivo the parasitic activity of a scFv 
immunotoxin on oocysts formation. The immunotoxin consisted of Shiva-1, a 
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synthetic peptide analogue of Cecropins that was previously shown to inhibit 
P. falciparum in vitro (Jaynes et al., 1988) and 13.1 scFv (Winger et al., 1988; 
Yoshida et al., 1999) directed against the P. berghei Pbs21 protein. A 
laboratory strain of E. coli was transformed with a plasmid expressing the 
scFv-immunotoxin and shown to inhibit oocyst formation by up to 95% 
(Yoshida et al., 2001) when fed to Anopheles stephensi. However, the E. coli 
control without the scFv immunotoxin also blocked sporogonic development 
by 76%. The inhibition of Plasmodium development by gram negative bacteria 
has been reported (Pumpuni et al., 1993; Pumpuni et al., 1996; Gonzalez-
Ceron et al., 2003) and associated with elicitation of mosquito innate immune 
responses (Dimopoulos et al., 1997). 
 
In the study of Riehle et al. (2007) a recombinant E. coli was engineered to 
secrete and display two anti-parasite molecules, SM1 (Ghosh et al., 2001) 
and phospholipase A2 (PLA2) whose mode of action is unknown but has 
been suggested to modify the membrane properties of the midgut epithelium 
(Zieler et al., 2001; Moreira et al., 2002). A. stephensi mosquitoes harbouring 
the engineered bacterium showed reduction (SM1 41%; PLA2 23%) in the 
development of P. berghei oocysts compared to control mosquitoes without 
the effector molecule. However, E. coli had a short life span (2 days) within 
the mosquito’s midgut. Thus, the paratransgenic approach requires 
identification of bacteria that can survive in the midgut over the life span of the 
mosquito.  
 
To be considered suitable for use in a paratransgenic approach, an ideal 
bacterium must meet certain criteria:  
 
i) should be dominant among insect-associated microbiota; 
ii) readily applicable to genetic characterisation and manipulation; 
iii) ease of cultivation in cell-free media; 
iv) co-localisation with the infectious agent in the relevant insect organs 
(gut and salivary glands);  
v) widespread distribution in the preadult and adult insect body; 
vi) capable of cross-colonising different hosts; 
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The mosquito midgut is known to be inhabited by a range of bacterial species 
(Pumpuni et al., 1996; Straif et al., 1998; Gonzalez-Ceron et al., 2003; Riehle 
et al., 2003; Lindh et al., 2005; Favia et al., 2007; Lindh et al., 2008; Rani et 
al., 2009). Some of the bacteria isolated from midgut of Anopheles 
mosquitoes (laboratory and field isolates) are listed in Table 1.2. In most of 
these studies, the midgut identified bacteria could not be cultivated in the 
laboratory.  
 
Mosquito 
species 
Bacterial species Reference  
 Gamma-
proteobacteria  
Enterobacteriaceae 
 
A. stephensi Pseudomonas 
cepacia 
Flavobacterium spp 
Serretia marcescens 
P. agglomerans        
Pumpuni et al. (1993) 
Rani et al. (2009) 
A. stephensi Asaia sp. 
 
Favia et al. (2007) 
A. albimanus Flavobacterium spp. Pantoea agglomerans        Pumpuni et al. (1996) 
 
 S. marcescens 
Enterobacter  cloacae 
Enterobacter  amnigenus 
Gonzalez-Ceron et al. 
(2003) 
A. gambiae 
(Giles) 
Ps. cepacia  
Ps. gladioli 
P. agglomerans        
Serretia spp. 
Pumpuni et al. (1996) 
A. gambiae Thorsellia anopheles 
Rhodococcus 
cornyebacteriodes 
Aeromonas sp. 
Enterobacteriaceae sp. 
Lindh et al. (2005) 
 
Bacillus cereus 
Bacillus mucoides 
Escherichia coli 
Pantoea agglomerans 
Straif et al. (1998) 
A. funestus Janibacter anophelis 
 
Lindh et al. (2005) 
 
Bacillus megaterium 
Gluconobacter cerinus 
Pantoea agglomerans 
Salmonella choleraesuis 
Straif et al. (1998) 
Ae. aegypti Elizabethkingia 
meningoseptica 
Pantoea stewartii 
S. marcescens 
Lindh et al. (2008) 
 
Table 1.2: Bacteria microbiota from different mosquito species 
 
 
Recently an acetic acid bacterium, Asaia sp., was identified, shown to be 
stably associated with larvae and adults of A. stephensi and dominated the 
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mosquito microbiota (Favia et al., 2007). Genetically modified Asaia 
expressing GFP was capable of colonising the gut, salivary glands (which are 
important compartments for the developmental stages of the parasite) and 
male and female reproductive organs. The fluorescently tagged strains were 
transmitted vertically from mother to progeny, horizontally (through feeding) 
and paternally by venereal transfer from male to female (Favia et al., 2007; 
Damiani et al., 2008). Asaia sp. has been isolated from laboratory and field 
samples of An. gambiae and GFP-tagged Asaia reintroduced into An. 
gambiae. The GFP-tagged bacteria showed similar distribution in both A. 
stephensi and A. gambiae (Damiani et al., 2010). It has been shown to 
colonise insects of two distant genera: Diptera (A. stephensi, A. maculipennis, 
A. gambiae, Ae. aegypti) and Hemiptera (Scaphoideus titanus, the leaphopper 
vector of phytoplasma that causes Flavescence Dorée in grapevines) (Crotti 
et al., 2009). These characteristics of Asaia satisfy the prerequisites of a 
paratransgenic approach making it an attractive bacterium for delivery of anti-
parasite molecules.  
 
 
 
1.3 Effector molecules 
 
A key component that determines the success of paratransgenesis is the 
identification of an appropriate effector molecule. An ideal effector molecule 
should block parasite development or kill it with 100% efficiency and should 
not impose any fitness cost to the mosquito (Jacobs-Lorena, 2003). Nirmala 
and James (2003) categorised effector molecules into five groups based on 
their targets.  
 
These targets include parasite ligands, mosquito tissue receptors, and 
parasite expressed proteins required for invasion of mosquito midgut tissues, 
components of the immune system and antiparasite toxins. Effector molecules 
identified that are specific to these targets and the parasites investigated are 
listed in Table 1.3. 
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Effector strategy 
(target)  
Molecule Target parasite Reference 
Parasite ligands Pbs21 scFv 13.1 P. berghei (Yoshida et al., 1999) 
CSP N2 scFv P. gallinaceum (de Lara Capurro et al., 
2000) 
4B7, Pfs25 MAb P. falciparum (Barr et al., 1991),  
(Stowers et al., 2000) 
CSP 2A10 
CSP Pf-NPNA-1 
P. falciparum 
P. falciparum 
(Nardin et al., 1982) 
(Chappel et al., 2004b) 
Tissue recognition 
(receptors) 
 
Lectins, MAbs P. gallinaceum 
P. berghei 
(Barreau et al., 1995), 
(Yoshida et al., 2007) 
SM1 peptide  P. berghei  
P. falciparum 
(Ito et al., 2002) 
Snake phospholipase 
A2a 
P. gallinaceum,  
P. falciparum  
(Zieler et al., 2001) 
Bee phospholipase A2a P. berghei (Moreira et al., 2002) 
Gomesin P. berghei 
P. falciparum 
(Moreira et al., 2007) 
Vida-3 P. berghei (Arrighi et al., 2002) 
Parasite gene 
expression 
 
Chitinase P. gallinaceum (Vinetz et al., 1999) 
Aminopeptidase N P. berghei 
P. falciparum 
(Dinglasan et al., 2007) 
Immune response 
effectors 
 
Magainins and cecropins  Variety of P. sp. (Gwadz et al., 1989) 
Defensins P. gallinaceum (Shahabuddin et al., 
1998) 
scFv 13.1 plus Shiva-1 P. berghei  (Yoshida et al., 2001) 
Nitric oxide synthase P. berghei  (Luckhart et al., 1998) 
Antiparasite toxins Scorpine  P. berghei (Conde et al., 2000) 
  
Table 1.3: Effector target, molecule and target parasite for engineering 
Plasmodium resistance in mosquitoes. aMolecules could also function as toxins. 
scFv: single chain fragment variable; MAb: monoclonal antibody. Adapted and 
modified from (Nirmala and James, 2003).  
 
Though insects have an array of inducible immunity molecules they, however, 
lack a defence system that is immunoglobulin mediated. Among the numerous 
effector molecules identified, single chain fragment variable (scFv) show 
promise for use in control of malaria and other vector-borne diseases (Vinetz 
et al., 1999; de Lara Capurro et al., 2000; Yoshida et al., 2001). scFv 
fragments (Figure 1.6) consist of the variable heavy (VH) and light chain (VL) 
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domains of an antibody that are linked with a hydrophobic and flexible peptide 
linker (15 – 20 amino acids) (Bird et al., 1988). Their simple structure, small 
size, ease of manipulation and specificity make them attractive candidates in 
selecting an effector molecule. In addition, they retain the binding properties of 
their parent antibody. 
 
 
Figure 1.6: Nomenclature of engineered antibody fragments in comparison with 
native IgG. Each oval represents an immunoglobulin folding domain. Disulfide bonds 
are represented as red lines, and the polypeptide linker of the scFv is represented by 
a blue connecting ribbon. VL indicates variable domain light chain; VH, variable 
domain heavy chain; CL, constant domain light chain; CH, constant domain heavy 
chain; Fc, Fc fusion; IgG, immunoglobulin G; F(ab’)2, dimeric antigen binding 
fragment; Fab, antigen binding fragment; scFv, single chain antigen binding fragment 
(Peterson et al., 2006). 
 
Pettigrew and O’Neill (1997) were of the view that application of scFv for 
paratransgenesis may lead to development of resistant mosquito strains. 
However, they stressed that identification of antibodies that target surface 
ligands or epitopes of proteins required by the pathogen for cell attachment or 
invasion of host tissues would be a way to overcome the problem (Pettigrew 
and O'Neill, 1997). Two target antigens, Pfs25, a sexual stage antigen 
expressed on the surface of ookinetes and Pf-CS protein, abundantly 
expressed on the surface of sporozoites are the focus of this study. Both 
target antigens exhibit characteristics that make them suitable candidates to 
which neutralising antibodies have been generated (Barr et al., 1991; Chappel 
et al., 2004b). Pfs25 has limited antigenic variation and most importantly it is 
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only expressed in the mosquito midgut thus, has not undergone prior immune 
selection (Gwadz et al., 1989; Shi et al., 1992; Duffy and Kaslow, 1997). The 
ookinete stage is considered as a weak link during parasite development as 
only a few develop from the thousands of gametocytes ingested (Ghosh et al., 
2000; Riehle et al., 2003). Thus, the low number of ookinetes coupled with the 
limited polymorphism makes Pfs25 a good target to block parasite 
development within the midgut.     
 
With the Pf-CS protein, the central repeat tetramer peptide (Asn-Pro-Asn-
Ala)n, (NPNA)n  is 100% conserved among P. falciparum species (Kappe et 
al., 2004). In addition, Pf-CS protein facilitates sporozoite passage into 
salivary glands of the mosquito (Sidjanski et al., 1997). The ookinete and the 
sporozoite stages of the parasite are temporally and spatially separated (2 
weeks) such that an antibody developed against the ookinetes would not 
function against sporozoites. As previously stated, the paratransgenic 
approach allows for the introduction of multiple effector molecules anytime 
during control programs. As a result, any parasites that may have escaped 
during the ookinete stage and eventually develop into sporozoites would be 
inhibited from invading the salivary glands to cause infection. Hence, the 
parasites are blocked at two fronts, ookinete and sporozoite stages.  
 
Targeting two antigens within the same mosquito is based on results of earlier 
paratransgenic models. Complete inhibition (100 %) of pathogen transmission 
has not been attained as these model systems utilised single effector 
molecules (de Lara Capurro et al., 2000; Yoshida et al., 2001; Riehle et al., 
2007). The application of two or more effector molecules may have an 
additive effect resulting in complete interruption of parasite transmission. This 
strategy would further delay the appearance of resistant pathogens. Recently, 
Kokoza et al. (2010) provided a proof of principle for complete disruption of 
parasite transmission in transgenic Aedes aegypti mosquitoes by co-
expression of two antimicrobial peptides (AMPs), Cecropin A and Defensin A. 
Over-expression of the AMPs, under the control of the vitellogenin promoter, 
and their cooperativity led to transgenic mosquitoes being resistant to 
infection by the pathogenic bacterium Pseudomonas aeruginosa. 
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Furthermore, P. gallinaceum oocyts numbers in the midgut were dramatically 
reduced resulting in the absence of sporozoites in the salivary glands (Kokoza 
et al., 2010).  
 
With the advent of recombinant DNA technology and display methods such as 
phage, ribosome and yeast display, MAbs may be isolated against almost any 
target antigen from a non-immune or immune library (Skerra and Pluckthun, 
1988; Huse et al., 1989; Sastry et al., 1989; Johnson and Bird, 1991). A 
number of transmission blocking antibodies have been developed against 
Pfs25: 4B7 (Barr et al., 1991) 32F81(Vermeulen et al., 1985), IC7 and ID2 
(Quakyi et al., 1995) of which 4B7 is the most potent.  MAb 4B7 recognized 
the third EGF-like domain (Stura et al., 1994b; Stowers et al., 2000). The 
binding site was mapped to the sequence, ILDTSNPVKTGV, located at the 
apex of the B loop of the third EGF-like domain (Stura et al., 1994b). MAb 4B7 
binds to its native protein in a conformation dependent manner as it 
recognises non-reduced Pfs25 strongly and reduced Pfs25 weakly (Barr et al., 
1991). The variable domains of 4B7 have been sequenced (Stura et al., 
1994a).  
 
To the central repeats of Pf-CS protein the antibodies IG3.4, 5G5.3, 2F1.1, 
IB2.2, 5C1.1 (Burkot et al., 1991), 2A10 (Nardin et al., 1982) and Pf-NPNA-1 
(Chappel et al., 2004b) have been isolated. With the exception of Pf-NPNA-1, 
the other antibodies are murine antibodies. These murine antibodies may not 
be suitable for use in paratransgenesis as they may elicit immune responses 
in humans bitten by mosquitoes carrying them in their salivary glands. A more 
appropriate antibody would be the human monoclonal antibody (MAb) Pf-
NPNA-1, which was cloned from a protected individual by repertoire cloning 
and antibody phage display (Chappel et al., 2004b). It is the most 
characterised having moderate affinity (~1-5M) for its target peptide antigen 
and able to inhibit sporozoites in an in vitro invasion assay in a dose 
dependent manner (20, 10, 5, 2.5 g/ml conferring 68, 74, 58 and 44%, 
inhibition respectively) (Chappel et al., 2004a). The antibody specifically 
labelled P. falciparum in an immunofluorescent assay (Chappel et al., 2004b). 
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Both 4B7 and Pf-NPNA-1 are candidates for targeting P. falciparum in 
Anopheles mosquitoes.  
 
Although the small size of scFv confers many advantages compared to a 
whole antibody, they are devoid of any biological functions (effector and 
complement) because they lack the Fc portion of a whole antibody. In 
addition, scFv with linkers greater than 12 amino acids (aa) exhibit low avidity 
due to their monovalent antigen binding kinetics (Holliger et al., 1993). 
However, effector function could be incorporated or mimicked by generating a 
bifunctional, bivalent or multivalent molecule. Yoshida et aI. (2001) 
constructed a bifunctional molecule by fusing the lytic peptide Shiva-1 to the 
scFv 13.1. They demonstrated enhanced effect of the immunotoxin (scFv 
13.1-Shiva-1) on P. berghei oocysts compared with the scFv 13.1 or Shiva-1 
peptide alone (Yoshida et al., 2001).    
 
Bivalent or multivalent scFv can be generated by shortening the linker 
connecting the variable domains. Generally, the VH and VL domains of scFvs 
with linkers greater than 12 aa, take on their natural Fv orientation and are not 
constrained (Holliger et al., 1993; Kortt et al., 1994). However, as the linker 
length is shortened below 12 aa, the VH domain is prevented from interacting 
with its attached VL. Interaction, however, occurs between the VH and VL 
domains of one scFv with the VH and VL domains of a second scFv to form a 
monospecific dimeric molecule (Holliger et al., 1993) or multivalent multimers 
(Iliades et al., 1997; Kortt et al., 1997; Atwell et al., 1999; Le Gall et al., 1999; 
Dolezal et al., 2000; Power et al., 2003) . Further reduction in linker length by 
directly linking the VH and VL domains results in a trimeric molecule termed a 
triabody (Iliades et al., 1997; Kortt et al., 1997). Thus multimerisation of the 
scFv is governed by the length of the linker joining the variable domains. The 
multimeriation of scFv (monomer, dimer and trimer) is depicted by the 
molecular models of the B72.3 monoclonal antibody in Figure 1.6. Generating 
scFv that are capable of multimeric assembly would further enhance their 
application in paratransgenesis. It is proposed that avidity effects due to the 
multimeric status of the scFv will improve agglutination of the parasites and 
thus potentially arrest development within the mosquito.    
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Figure 1.7: Molecular models of scFv monomer, dimer and trimer. The linker 
between VH (green) and VL (blue) domains is coloured red (Provided by Dr. A. 
Markiv).  
 
 
1.4 Prokaryotic expression of scFv fragments 
 
scFv fragments contain disulphide bonds that contribute to their stability and 
biological activity. To ensure the correct pairing of the cysteines and proper 
folding of the disulfide bonds, the eukaryotic folding and assembly of 
antibodies and their subsequent translocation into the endoplasmic reticulum 
can be mimicked by secretion of the scFv into the oxidising environment of the 
periplasm (Better et al., 1988; Skerra and Pluckthun, 1988) or extracellular 
medium (Wu et al., 1993; Fernandez et al., 2000; Fernandez and de Lorenzo, 
2001) of bacterial cells. The formation of the disulphide bonds within the 
periplasm is facilitated by the presence of the disulfide-binding proteins 
(DsbA, DsbB, DsbC, and DsbD) (Bardwell, 1994; Collet and Bardwell, 2002; 
Choi and Lee, 2004). Periplasmic or extracellular secreted scFv fragments 
would be advantageous to the paratransgenic approach because the secreted 
antibodies will be in direct contact with the infectious agent.  
 
The secretion of a scFv from the cytoplasm into the periplasm or extracellular 
medium requires the presence of a signal peptide (SP). The SP fused to the 
N-terminus of the scFv gene facilitates the translocation of the premature 
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protein from the cytoplasm into the periplasm. Subsequent cleavage of the 
SP, by a signal peptidase, results in a mature protein with an authentic N-
terminal methionine (Makrides, 1996). Numerous studies have employed the 
use of different leader peptides (Table 1.4) for efficient transportation of scFv 
to the periplasm.  
  
Signal sequences                                                        Amino acid sequences 
PelB (pectate lyase B) from Erwinia carotovora          MKYLLPTAAAGLLLLAAQPAMA 
OmpA (outer-membrane protein A)   MKKTAIAIAVALAGFATVAQA 
PhoA (alkaline phosphatase) MKQSTIALALLPLLFTPVTKA 
MalE (maltose-binding protein) MKIKTGARILALSALTTMMFSASALA 
OmpC (outer-membrane protein C) MKVKVLSLLVPALLVAGAANA 
 
Table 1.4: Signal sequences used for the secretory production of recombinant 
proteins in E. coli. The N-domains of signal sequences are shown in bold while the 
C-domains are underlined (Adopted from Choi and Lee, 2004). 
 
 
SPs differ in their primary sequences but share some structural features. SPs 
are composed of three main regions: basic N-terminal consisting of 1-3 
positively charged residues; hydrophobic region composed of 10-15 
hydrophobic amino acid residues and a C-terminal (serving as the cleavage 
site) consists of 5-7 less hydrophobic amino acid residues (Choi and Lee, 
2004). According to Makrides (1996), the efficient translocation of the target 
protein across the inner membrane is dependent on the primary structure of 
the protein to be secreted and the secretory machinery. Secretion of some 
recombinant antibodies may interfere with the secretory machinery of the cell 
and may be toxic to the host cell.    
 
 
 
1.5 Thesis aim and objectives 
 
Malaria affects millions of people worldwide and traditional control measures 
have not helped eradicate the disease. Thus, new control strategies are being 
investigated and developed to control transmission of the disease. 
                           General Introduction 
32 
 
Paratransgenesis, which utilises symbiotic microorganisms to secrete effector 
molecules, shows promise. Model systems have demonstrated the feasibility 
of the approach; however, there is the need for identification and evaluation of 
suitable effector molecules capable of neutralising the pathogen. The 
antibodies 4B7 and Pf-NPNA-1, which target Pfs25 and Pf-CS proteins 
expressed on the surface of ookinetes and sporozoites respectively, have 
been identified as suitable effector molecules. However, there is the need to 
evaluate these effector molecules in a prokaryotic system. Thus, the aim of 
this project is the engineering and characterisation of anti-malaria antibodies, 
scFvs 4B7 and Pf-NPNA-1, which target Pfs25 and CS protein, respectively.  
Four main objectives will be undertaken to achieve this aim.  
 
Firstly, both antibodies will be constructed in the scFv format with different 
linker lengths. The effect of linker length on multimerisation behaviour will be 
investigated. scFv orientation on antibody secretion will also be assessed.   
 
Secondly, expression and secretion of the scFv constructs will be evaluated.  
Studies with scFv fragments have demonstrated that not all antibodies 
secrete. In addition the level of expression of scFv is dependent on the 
primary sequence and yields may even vary between closely related 
sequences (Knappik and Pluckthun, 1995; Wall and Pluckthun, 1999). As a 
result the level of secretion of all the scFv constructs will be compared.  
 
Thirdly, purified scFv protein will be assessed for antigen binding. It has been 
demonstrated that not all multimeric scFvs or monovalent scFvs have 
functional antigen binding sites (Johnson and Bird, 1991; Kipriyanov et al., 
1997; de Haard et al., 1998; Le Gall et al., 1999).  
 
Fourthly, the scFvs evaluated for expression, secretion and antigen binding 
will be transferred into a broad-range host vector to evaluate expression in the 
symbiotic bacterium Asaia sp. 
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2.1 Materials and methods 
 
2.1.1 General chemicals and reagents 
 
All reagents were of analytical grade and purchased from Sigma-Aldrich 
(Poole, Dorset, UK). A full list is given in the Appendix. 
 
2.1.2 Bacterial strains 
 
E. coli XL1-Blue [recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZ∆M15 Tn10 (Tetr)K12] (Stratagene) was used for plasmid 
propagation. E. coli BL21 (DE3) pRARE, F´ ompT gal dcm lon hsdSB(rB- mB-) 
λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5] used for scFv expression was 
from Novagen (San Diego, CA). λDE3 denotes the lysogenic gene of T7 
bacteriophage gene I, encoding T7 RNA polymerase under the control of 
the lac UV5 promoter. pRARE contains tRNA genes for the rare codons 
arginine (argU, argW), isoleucine (ileX), glycine (glyT), leucine (leuW), proline 
(proL), methionine (metT), threonine (thrU, thrT) and tyrosine (tyrU). This 
strain is deficient in both lon and ompT proteases. 
 
2.1.3 Antibiotic stock solutions 
 
The following antibiotics were prepared: kanamycin 10 mg/ml in MilliQ water, 
tetracycline 625 µg/ml in 100% ethanol and chloramphenicol 34 mg/ml in 
100% ethanol. Stock solutions were filter sterilised and stored at -20°C until 
needed. Final working concentrations were kanamycin 50 µg/ml, tetracycline 
12.5 µg/ml and chloramphenicol 34 µg/ml. 
 
2.1.4 Buffers and media 
 
Luria Bertani (LB) broth was prepared using 1% w/v Bacto tryptone, 0.5 % w/v 
yeast extract and 1% w/v NaCl (pH 7.4), autoclaved (121°C, 15min) and 
stored at room temperature. 
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LB agar plates were prepared using1% w/v Bacto tryptone, 0.5 % w/v yeast 
extract and 1% w/v NaCl and 1.5% w/v Bacto agar (pH 7.4). The suspension 
was autoclaved, cooled to 50°C in a water bath and antibiotic added to the 
required concentration. The molten agar (25 ml each) was poured into Petri 
dishes, allowed to set and stored at 4°C. 
 
Super Optimal Broth (SOB) (Hanahan, 1983) was prepared using 2% w/v 
Bacto tryptone, 0.5% w/v yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgSO4 (pH 7.0) and autoclaved. To prepare SOC (SOB with catabolite 
repression), MgCl2 (1M) and filter sterilised 20% glucose were added to SOB 
to final concentrations of 10 mM and 20 mM, respectively. Aliquots of 1 ml 
were stored at -20°C.  
 
 
2.1.5 Antibodies and Enzymes 
 
2.1.5.1 Restriction Enzymes 
 
The restriction modification endonucleases: NcoI, NdeI, NotI, XbaI, XhoI and 
T4 DNA ligase were purchased from New England BioLabs (Hitchin, Herts, 
UK) and used with the buffers provided according to the manufacturer’s 
recommendation. 
 
2.1.5.2 Antibodies 
 
Rabbit anti-hexa-histidine tag antibody conjugated to horseradish peroxidase 
(HRP) (Abcam, UK; Cat. No. ab1187) was used in Western blots for detection 
of His-tagged proteins according to manufacturer’s recommendations. Murine 
monoclonal anti-polyhistidine−alkaline phosphatase (AP) antibody (Sigma, 
UK; Cat. No. A5588, clone HIS-1) was used in ELISA for the detection of His-
tagged proteins. A rabbit anti-tri FLAG antibody (Sigma, UK; Cat. No. F7425) 
was used primary antibody and goat anti-rabbit IgG conjugated to AP (Sigma, 
UK; Cat. No. A9919) as secondary antibody was used for detection 
recombinant proteins on membranes and in ELISA. Goat anti-Human kappa 
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light chains (bound and free) antibody conjugated to AP (Sigma, UK; Cat. No. 
A3813) was used for the detection of the human kappa light chain. 
Fluorescein isothiocyanate (FITC) (Abcam, UK; Cat. No. ab 1270) anti-His 
antibody was used detection of antibody binding to Pf-CS protein. 
 
2.1.6 DNA Vectors 
 
The pET-41b(+) plasmid (Novagen, UK) was modified for the construction of 
the scFv expression vectors. It lacks an N-terminal signal peptide but contains 
multiple cloning sites and an octa His-tag to facilitate the purification and 
detection of fusion proteins. Other plasmids, pUC-19 4B7, pUC-19 Pf-NPNA-1 
and pUC57-(NPNA)9-MKC were provided by Dr. Anatoliy Markiv and Dr. 
Angray Kang. The pSANG-103F plasmid was provided by Dr. John 
McCafferty (Martin et al., 2006).   
 
 
 
2.2 Molecular biology methods 
  
2.2.1 Separation of DNA using agarose gel electrophoresis 
 
Digested plasmid DNA and PCR products were separated by agarose gel 
electrophoresis (Sambrook, 2001). Agarose gels were prepared in 1X TAE 
buffer (40 mM Tris-HCl, pH 8.2, 1 mM EDTA and 20 mM acetic acid) at 1% 
w/v and 1.5% w/v depending on size of the target DNA. Ethidium bromide was 
added at a concentration of 0.2 µg/mL. The DNA samples were mixed with 6X 
sample buffer (0.4% w/v Orange G, 0.03% w/v Bromophenol blue, 0.03% w/v 
xylene cyanol FF, 15% w/v Ficoll 400 in TAE buffer, pH 8.2) before loading on 
gel. The gel was run at 100 V for 1 hour. For further cloning and sequencing, 
the DNA was excised from the gel using long wavelength UV light (315-400 
nm) whereas short wavelength UV light (200-280 nm) was used to take 
images of gels.     
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2.2.2 Gel purification of PCR products and plasmid DNA 
 
The desired DNA fragment was excised with a sterile scalpel and purified 
using the GenElute purification kit (Sigma, UK) according to the 
manufacturer’s recommendations. Briefly, to 1 volume of gel (100 mg~ 100 
µL) was added three volumes (300 µL) of solubilisation buffer (5.5 M 
guanidine thiocyanate, 20 mM Tris-HCl, pH 6.6, 0.0025% w/v Cresol Red) in a 
1.5 mL Eppendorf tube. The tube was incubated in a 50°C water bath for 10 
min to allow complete solubilisation of the gel slice, after which 1 volume (100 
µL) of isopropanol was added and mixed to homogeneity. The solubilised gel 
was loaded onto the binding column assembled in a 1.5 mL Eppendorf tube 
and centrifuged for 1 min at 13,000 rpm. The flow through was discarded and 
binding column assembled as before. To wash the column 700 µL of PE 
buffer (2mM Tris-HCl, pH 7.5, 20 mM NaCl, and 80% v/v ethanol) was added 
to the column and centrifuged at 13,000 rpm for 1 min. The flow through was 
discarded and the column centrifuged for 1 min at 13,000 rpm to remove any 
residual wash buffer. To elute the DNA, the binding column was transferred to 
a fresh 1.5 mL Eppendorf tube, 30 µL of nuclease free water added, 
incubated at RT for 1 min and centrifuged at 13,000 rpm for 1 min. The eluted 
DNA was stored at -20°C. 
  
 
2.2.3 Restriction endonuclease digestion 
 
Plasmid DNA and PCR products were double digested to generate compatible 
sticky ends and to release inserts for the purposes of cloning. The 
composition of the restriction endonuclease reaction mixture in a 1.5 mL 
Eppendorf tube was: 30 µL of DNA (8 µg), 5 µL of 10X NEB digestion buffer 
(optimal for both enzymes), 0.5 µL of BSA (10 mg/mL), 1 µL of each enzyme 
and 12.5 µL of nuclease free water. The reaction mixture was gently mixed 
and incubated at 37°C for 3 h. The digested product s were electrophoresed 
on a 1 or 1.5% agarose gel and purified.  
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2.2.4 Ligation of DNA fragments 
 
The ligation reaction was composed of the following: 2 µL of 10X T4 DNA 
ligase buffer, 1 µL of T4 DNA ligase (NEB, UK), 1 µL of digested plasmid (50 
ng), 10 µL of digested insert (150 ng) and reaction mixture made up to 20 µL 
with nuclease free water (Invitrogen, UK). The reaction mixture was left to 
incubate at room temperature (RT) for 1 hour, transferred onto ice and used to 
transform E. coli competent cells. Control ligations without digested insert 
were also set up. 
 
 
2.2.5 Preparation of E. coli chemical competent cells 
 
A single colony was inoculated into 10 mL of LB media supplemented with 
antibiotic specific for the cell type. E. coli XL1 blue cells were supplemented 
with tetracycline (12.5 µg/ml) and BL21DE3 pRARE with chloramphenicol (34 
µg/mL). The cultures were grown overnight (16 hours) at 37°C with shaking at 
250 rpm. The overnight culture was used to inoculate 200 mL of prewarmed 
LB medium (supplemented with chloramphenicol for BL21DE3 pRARE and no 
antibiotics for XL1 blue cells) and grown at 37oC with vigorous shaking 250 
rpm until the OD600 was 0.4 - 0.5. The culture was incubated on ice for 30 min 
and aliquoted into four prechilled 50 mL centrifuge tubes (Fisher Scientific, 
UK). The cells were harvested by centrifugation for 7 min at 3500 rpm (3120 x 
g) (4oC) using a Sorvall Super T21 centrifuge equipped with a ST-H750 swing 
bucket. The supernatant was discarded and the cells, in each tube, 
resuspended in 12.5 mL of cold 0.1 M MgCl2. Centrifugation was repeated as 
before, supernatant discarded and the cells, in each tube, resuspended in 25 
mL of cold 0.1 M CaCl2 and left to incubate on ice for 30 min. The cell 
suspension was centrifuged; the supernatant discarded and cells in each tube 
resuspended in 700 µL of 0.1 M CaCl2 and 300 µL of 50% glycerol. The cell 
suspensions were pooled, aliquoted 50 µL into prechilled 1.5 mL sterile 
microcentrifuge (Eppendorf) tubes on ice and stored at –80°C. 
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2.2.6 Transformation of E. coli using the heat-shock method 
 
Chemically prepared competent cells were transformed according to the 
procedure of Sambrook and Russell (2001) with modifications. An aliquot of 
the competent cells prepared above were thawed on ice for 5 min and 1 µL of 
super coiled plasmid or 10 µL of ligation mixture added and incubated for 5 
min on ice. The cells were heat shocked at 42°C in a water bath for 1 min and 
quickly transferred onto ice for 5 min. SOC medium (250 µL) was added and 
transformants selected on LB agar plates supplemented with the appropriate 
antibiotic. For ligation products, the transformants were plated out after 
growing transformed cells, supplemented with SOC, for 1 hour at 37°C.  
 
  
2.2.7 PCR colony screening 
 
Individual bacterial colonies were picked with a sterile 10 µL pipette tip and 
added into 10 µL of nuclease free water in a 1.5 mL Eppendorf tube. 3 µL of 
the suspended colony was added to 22 µL of PCR master mix (5 µL of 5X 
Taq&Go, 1.25 µL each 10 µM forward and reverse primers, 14.5 µL of 
nuclease free water). PCR was carried out in a MJ Mini gradient thermal 
cycler (Bio-Rad, UK) set with the thermal cycling conditions outlined in Table 
2.1  
 
Cycles  Temperature (°C) Time  
1 95 5 min 
22 95 1 min 
55 30 s 
72 1 min/kb 
1 72 10 min 
 4 ∞ 
 
Table 2.1: Amplification program for PCR colony screening 
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The amplified products were examined on a 1.5% agarose gel. For colonies 
confirmed for the presence of insert, the remaining bacterial suspension, 7 µL 
was used to inoculate 10 mL of LB broth, grown for 16 h at 37°C with shaking 
at 250 rpm. 
 
 
2.2.8 Preservation of bacterial cultures 
 
For long term storage of bacterial cultures, 700 µL of an overnight culture 
grown from a single colony was mixed with 300 µL of sterile 50% v/v glycerol 
in a 1.5 mL Eppendorf tube. The tube was labelled and stored at -80°C.  
 
 
2.2.9 Plasmid DNA extraction 
 
Plasmid DNA was extracted from 10 mL bacterial cultures grown overnight in 
antibiotic selective LB medium following Qiagen’s plasmid purification protocol 
with slight modifications. Buffers were prepared in-house and the silica 
membrane spin columns were obtained from Epoch Biolabs (Texas, USA). 
The overnight bacterial culture was centrifuged at 3500 rpm for 10 min, the 
supernatant discarded and the bacterial cells resuspended in 500 µL of buffer 
P1 (50 mM Tris-base, pH 8.0, 10 mM EDTA, 50 µg/mL RNaseA). The 
suspension was then transferred (250 µL) into two 1.5 mL sterile 
microcentrifuge tubes to which 250 µL of buffer P2 (0.2 M NaOH, 1% SDS) 
was added to lyse the cells and the tubes inverted 10 times. To neutralise the 
lysis buffer 350 µL of buffer N3 (4 M guanidine hydrochloride, 0.5 M 
potassium acetate, pH 4.2, 192 mM acetic acid) was added to each tube and 
mixed immediately by inverting the tubes 10 times. The tubes were 
centrifuged at 13,000 rpm for 10 min to pellet genomic DNA, cell membrane 
and proteins. The supernatant was applied to a spin column and the column 
centrifuged at 13,000 rpm for 1 min. The flow through was discarded and the 
spin column washed by addition of 500 µL buffer PB (5 M guanidine 
hydrochloride, 20 mM Tris-base, pH 6.6, 38% ethanol v/v) and centrifuged at 
13,000 rpm for 1 min. The flow through was discarded and the spin column 
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was again washed with 750 µL of buffer PE (20 mM NaCl, 2 mM Tris-base, 
pH 7.5, 80% ethanol v/v) and centrifuged twice at 13,000 rpm for 1 min to 
remove any residual ethanol. The spin column was transferred to a sterile 1.5 
mL microcentrifuge tube; 30 µL of nuclease free water (Invitrogen, UK) was 
added to the centre of the spin column and allowed to incubate for 1 min at 
RT. The plasmid DNA was eluted by centrifugation at 13,000 rpm for 1 min 
and stored at -20°C.     
    
 
2.2.10 DNA quantification and Sequencing  
 
The concentration of plasmid DNA was determined by preparing a 100 fold 
dilution (2 µL of DNA: 198 µL of TE) of plasmid DNA in TE buffer (10 mM Tris-
HCl, 1mM EDTA pH 8.0). The diluted DNA was transferred into an Eppendorf 
Uvette and the absorbance measured at 260 and 280 nm using an Eppendorf 
Biophotometer (Eppendorf, UK). The absorbance at 280 nm gave an 
indication of the level of protein contamination. The absorbance ratios at 260 
nm and 280 nm of the DNA preparations were in the range of 1.7 – 2.0. An 
aliquot (100 ng/µL) of the plasmid DNA was sent for sequencing at the 
Wolfson Institute for Biomedical Research Core Facility, University College 
London.    
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2.3 Construction of scFv expression vectors 
 
2.3.1 Construction of scFv expression vectors pBAK.1 and pBAK.1Hk 
 
DNA manipulations were carried out according to Sambrook and Russell 
(2001). The plasmid, pBAK.1Hk was constructed by using pET41b(+) 
(Novagen) as the parent plasmid. The gene encoding human kappa constant 
domain (HuCk) without the terminal cysteine was amplified from the phage 
display library, BRM1388 (Chappel et al., 2004b) using the primers BAK1 (5’- 
ACT GCG GCC GCA CCA TCT GTC TTC ATC TTC-3’) and BAK2 (5’-AGA 
AGC TTG CTC GAG TCC CCT GTT GAA GCT CTT TGT GAC-3’) which 
append NotI and XhoI restriction sites (in bold), respectively. The amplification 
reaction consisted of 5 µL of 5X Taq & Go, 1.25 µL of each 10 µM primer (5’ 
and 3’), 1 µL of template DNA and 16.5 µL nuclease free water. PCR was 
carried out as outlined in Table 2.1  
 
The PCR product (~300 bp) was gel purified, digested and ligated into a NotI-
XhoI digested pET41b(+) yielding pET41bHk. Modified plasmid pORFES (with 
a pelB leader sequence) (Stratmann and Kang, 2005) was digested with XbaI 
-NotI and ligated into a similarly digested pET41bHk to yield pBAK.1Hk. The 
expression plasmid was then confirmed by DNA sequencing (Wolfson Institute 
for Biomedical Research Core Facility, University College London, UK). 
Ligation of the XbaI –NotI digested fragment from modified pORFES directly 
into a similarly digested pET41b(+) yielded the expression vector pBAK.1. The 
expression vectors both have a pelB leader sequence and an octa-histidine 
tag.  
 
 
2.3.2 Cloning of synthetic DNA Constructs 
 
Synthetic codon optimised (NPNA)9MKC (mouse kappa constant domain), 
4B7 scFv-1, Pf-NPNA-1 scFv-12 genes were purchased from GenScript, 
USA. The scFv constructs were cloned from their respective cloning vectors 
as NcoI/NotI into pBAK.1, pBAK.1Hk and pSANG10-3F expression plasmids. 
The (NPNA)9MKC construct was cloned as NcoI/XhoI fragment into pBAK.1.  
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The ligation mixture was transformed into competent XL1Blue cells and 
transformants selected at 37°C on LB agar plates su pplemented with 
kanamycin. Transformants were screened by colony PCR (Section 2.2.6). 
 
 
2.3.3 Construction of 4B7 VL-VH scFv-0, scFv-20, scFv-0Hk and scFv-
20Hk 
 
To generate the 4B7 scFv-0 and scFv-20 (VL-VH), the VH and VL gene 
fragments of 4B7 scFv-1 (VH-VL) were PCR-amplified using the primers 
4B7VHF and 4B7VHNot for VH and 4B7VLNco and 4B7VLR for VL. The 
amplification reaction consisted of 5 µL of 5X Taq & Go, 1.25 µL of each 10 
µM primer (5’ and 3’), 1 µL of template DNA and 16.5 µL nuclease free water. 
The PCR amplifications were conducted as outlined in Table 2.1. The 
resulting PCR products were gel purified and constructed into an scFv-0 by 
overlap extension PCR (Horton et al., 1989). The resulting fragment has NcoI 
and NotI restriction sites at the 5’ and 3’ ends, respectively. The scFv-0 was 
then digested with NcoI and NotI restriction enzymes and cloned into the 
expression vectors pBAK.1, pSANG10-3F and pBAK.1Hk. The strategy for the 
design and construction of 4B7 scFv-0 VL-VH is shown in Figure 2.1.   
 
Cycles Temperature (°C)  Time 
1 95 5 min 
22 95 1 min 
55* 30 s 
72 1 min 
1 72 10 min 
 4 ∞ 
 
Table 2.2: PCR cycle profile for the amplification of 4B7 scFv-1 variable 
domains and assembly of scFv-0 and scFv-20. The annealing temperature, shown 
by the asterisks, was kept constant for the amplification of variable domains and 
assembly of scFvs.  
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Figure 2.1: Design and construction of 4B7 scFv-0 (VL-VH). The variable domains 
of 4B7 scFv-1 VH-VL were amplified by PCR. Two successive PCR products were 
assembled to generate the full length 4B7 scFv-0 VL-VH which was cloned into the 
pET-based vectors via NcoI and NotI sites. 
 
 
To generate 4B7 scFv-20, pSANG10-3F 4B7 scFv-0 (VL-VH) was used as 
template. The variable fragments were amplified using the primers 
4B7VLNcoF and 4B7VLLink5R for VL (generating VLLink5) and 
4B7VHLink5F and 4B7VHNotR for VH (generating VHLink5). The VLLink5 and 
VHLink5 PCR products were gel purified and the VHLink5 purified product 
used in a second PCR with the primers 4B7VLVHLink30 and 4B7VHNotR to 
generate VHLink30. The gel purified PCR products of VLLink5 and VHLink30 
were linked by overlap extension PCR. The purified product was then 
digested as previously described for 4B7 scFv-0 (VL-VH). 4B7 scFv-20 was 
also cloned into the expression vector pBAK.1, pSANG10-3F and pBAK.1Hk. 
The strategy for the design and construction of 4B7 scFv-20 VL-VH is shown in 
Figure 2.2. Constructs were confirmed by DNA sequencing. Sequences of 
primers are outlined in Table 2.4. 
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Figure 2.2: Design and construction of 4B7 scFv-20 (VL-VH). The variable 
domains of 4B7 scFv-0 VL-VH were amplified by PCR. Three successive PCR 
products were assembled to generate the full length 4B7 scFv-0 VL-VH which was 
cloned into the pET-based vectors via NcoI and NotI sites. G-S: glycine-serine linker. 
 
 
Primer  Sequence 5’ – 3’  
4B7VHNot 
 
AAGCTTGCGGCCGCGCTGCTCACGGTCAGGGTGGTG
CCCTGGCC 
4B7VLNcoI 
4B7VLR 
4B7VHF 
4B7VHLink5F 
 
4B7VLLink5R 
GCCATGGCCGATATTCAGATGATTCAGAGCCCGAC 
CGCTTTATTTTCCAGTTTGGTGCCGCTGCC 
GAAGTGAAACTGGTGGAAAGCGGCGGCGGC 
GGAGGTGGCGGAAGCGAAGTGAAACTGGTGGAAAGC
GGCGGCGGC 
CTACCGCCACCTCCCGCTTTAATTTCCAGTTTGGTG 
CCGCTGCC 
4B7VLVHLink30 
 
GGAGGTGGCGGTAGTGGAGGTGGCGGAAGCGGAGG
TGGCGGTAGTGGAGGTGGCGGAAGCGGAGGTGGCG
GTAGTGGAGGTGGCGGAAGC 
 
Table 2.3: Primer sequences used for the amplification of 4B7 scFv variable 
domains and for assembly of the scFv-0 and scFv-20. Restriction sites are in 
bold.  
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2.3.4 Site directed mutagenesis of 4B7 scFv 
 
Site directed mutagenesis was essentially performed as described by (Zheng 
et al., 2004). The strategies for mutagenesis are depicted in Figures 2.3 and 
2.4. Partially overlapping primers were designed to introduce mutations at 
target sequences.  PCR conditions were as described in Section 2.3.3. The 
plasmid pSANG10-3F 4B7 scFv-0 VL-VH was used as template. A range of 
PCR products were assembled to construct the 4B7 scFv-0 mutant. In Figure 
2.3 three successive PCR products were assembled to generate the scFv-0 
VH Q20R and VH T94F mutations. The template was then used to generate 
the mutations VLL85F, VLG86A, VLQ3E, VLI5T and VHL114V. The 
amplification reaction for introduction of all mutations consisted of 5 µL of 5X 
Taq & Go, 1.25 µL of each 10 µM primer (5’ and 3’), 1 µL of template DNA 
and 16.5 µL nuclease free water. The PCR amplifications were set with the 
conditions as outlined in Section 2.3.3. 
 
 
Figure 2.3: Design and construction of 4B7 scFv-0 mutants (VH Q20R and VH 
T94F). Mutations were introduced by PCR using partially overlapping primers. Three 
successive PCR products were assembled to generate the scFv-0 VH Q20R and VH 
T94F mutations.  
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Figure 2.4: Design and construction of 4B7 scFv-0 mutants (VLL85F, VLG86A, 
VLQ3E, VLI5T and VHL114V). Two PCR products were used to generate the VLL85F 
and VLG86A mutants. The template for this mutant was then used to generate the 
VLQ3E, VLI5T and VHL114V mutations.    
 
 
Primer  Sequence 5’ – 3’  
4B7VLQ3EI5TF    GATATTGAGATGACCCAGAGCCCGAGCAGCATGTTTGCG 
4B7VLQ3EI5TR    GCTCTGGGTCATCTCAATATCGGCCATGGCCGGCTGGGC 
4B7VLL85FG86AF    GCGAAGATTTTGCCGATTATTATTGCCTGCAGCGCAAC 
4B7VLL85FG86AR   
4B7VHQ20RF   
4B7VHQ20RR   
4B7VHT94AF    
4B7VHT94AR   
4B7VH 
4B7VHL114VNotIR   
GCAATAATAATCGGCAAAATCTTCGCTTTCCAGGCTGC  
GGCGGCAGCCGCAAACTGAGCTGCGCGGCGAGCGGC 
GCTCAGTTTGCGGCTGCCGCCCGGCTGCACCAGGCC 
GAAGATACCGCCATGTATTATTGCGCGCGCGGC 
GCAATAATACATGGCGGTATCTTCGCTGCGCAG 
GGCACCACCGTGACCGTGAGCAGCGCGGCCGCATCCGC 
GCGGATGCGGCCGCGCTGCTCACGGTCACGGTGGTGCC 
 
Table 2.4: Primer sequences for site directed mutagenesis of 4B7 scFv-1 (VL-
VH). 
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2.3.5 Construction of Pf-NPNA VH-VL scFv-0, scFv-12, scFv-0Hk and 
scFv-12Hk 
 
To generate the NPNA scFv-0 synthetic gene, the VH and VL gene fragments 
were PCR-amplified using the primers (Table 2.5) for VH, NcoF and PfVHR, 
and for VL, PfVLF and NotR. The amplification reaction consisted of 5 µL of 
5X Taq & Go, 1.25 µL of each 10 µM primer (5’ → 3’), 1 µL of template DNA 
and 16.5 µL nuclease free water. The PCR amplification was set with the 
conditions as outlined for Section 2.3.3.  
 
Primer  Sequence 5’ – 3’  
NcoF TCT AGA GCG GCC CAG CCG GCC ATG GCC 
PfVHR GCT GCT CAC GGT CAC CAG GGT GCC 
PfVLF GAA ATT GTG CTG ACC CAG AGC CCG 
NotR ATT ACG CCA AGC TTG CGG CCG C 
 
Table 2.5: Primer sequences used for the amplification Pf-NPNA-1 scFv-12 
variable domains and for assembly of the scFv-0. Restriction sites are in bold.  
 
 
 
 
 
Figure 2.5: Design and construction of Pf-NPNA-1 scFv-0 (VH-VL). The variable 
domains of Pf-NPNA-1 scFv-12 VH-VL were amplified by PCR. Two successive PCR 
products were assembled to generate the full length Pf-NPNA-1 scFv-0 which was 
cloned into the pET-based vectors via NcoI and NotI sites. 
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The resulting PCR products were gel purified and joined into an scFv-0 by 
overlap extension PCR using the primers NcoF and NotR (Horton et al., 
1989). The reaction mixture for the overlap extension PCR was composed of 
5 µL of 5X Taq & Go, 1.25 µL of each 10 µM primer (5’ and 3’), 2 µL each of 
purified VH and VL and 14.5 µL of nuclease free water. The PCR 
amplifications were set with the conditions outlined in Table 2.2. The strategy 
for the design and construction of 4B7 scFv-20 VL-VH is shown in Figure 
2.5.The scFv-0 and scFv-12 were then digested with NcoI and NotI restriction 
enzymes and cloned into the expression vectors pBAK.1, pSANG10-3F and 
pBAK.1Hk.    
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2.4 Protein expression and purification of recombinant proteins 
 
2.4.1 Expression and purification of (NPNA)9-MKC antigen 
 
Five colonies of BL21DE3 pRARE transformed with the plasmid pBAK1-
(NPNA)9-MKC were cultured in 10 mL of LB supplemented with kanamycin 
(50 µg/mL) and chloramphenicol (34 µg/mL) and grown overnight at 37ºC with 
shaking, 250 rpm. The overnight culture was used to inoculate 200 mL of pre-
warmed LB, supplemented with the appropriate antibiotics and grown until an 
OD600nm of 0.5–0.6. Isopropyl-β-d-thiogalactopyranoside (IPTG) was added to 
a final concentration of 0.3 mM and the culture was grown for up to 3 hours. 
The cells were then harvested in a Sorvall Super T21 bench top centrifuge 
(SL-250T rotor) at 5000 rpm (9520 x g) for 20 min at 4ºC. The supernatant 
was decanted and the pellet  resuspended in 5 mL of lysis buffer (100 mM 
NaHPO4, 10 mM Tris, 8 M Urea, pH 8) and subjected to 6 sonication cycles of 
30s each (20 kHz uniform sonic waves at 40% power). The suspension was 
incubated on ice for 1 hour and the insoluble material removed by 
centrifugation (SL-50T rotor) for 30 min at 18000 rpm (39800 x g). The 
supernatant containing the recombinant protein was purified using an AKTA 
prime plus (GE Healthcare, UK) equipped with a 1 mL HiTrap Chelating 
column charged with Ni2+. The cleared lysate (5 mL) was loaded onto the 
column previously equilibrated with 5 column volumes of binding buffer (100 
mM NaHPO4, 500 mM NaCl, 10 mM Imidazole, pH 8) at a flow rate of 1 
mL/min. The loaded column was washed with 5 column volumes of wash 
buffer (100 mM NaHPO4, 500 mM NaCl, 20 mM Imidazole, pH 8) Bound 
proteins were then eluted within 1 mL aliquots with elution buffer (100 mM 
NaHPO4, 500 mM NaCl, 500 mM Imidazole, pH 8). The purified recombinant 
antigen was analysed by SDS-PAGE.      
 
 
2.4.2 Soluble expression of recombinant scFv and scFv-Hk antibodies 
 
All the scFv constructs were evaluated for expression in the periplasm of E. 
coli using the expression vectors pBAK1, pSANG10-3F and pBAK1Hk (for 
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high level expression) under the control of the T7 promoter. For large scale 
expression the constructs were transformed into E. coli BL21DE3 pRARE 
cells (Novagen) selected on LB agar plates supplemented with the 
appropriate antibiotics. Transformants were cultured overnight at 37ºC in 50 
mL LB broth containing 50µg/ml kanamycin and 34 mg/ml chloramphenicol. 
The overnight culture was diluted 20 fold into 1 litre of LB broth containing 50 
µg/ml kanamycin and 34 µg/ml chloramphenicol grown at 37ºC until an OD600 
of 0.5 – 0.6. scFv expression was then induced by adding  IPTG (isopropyl-
beta-D-thiogalactopyranoside) to a final concentration of 0.3mM, with growth 
continued overnight at 20ºC. 
 
 
2.4.3 Isolation and purification of periplasmic extracts 
 
Periplasmic expressed scFvs were isolated by osmotic shock as follows: 
overnight induced cultures were harvested by centrifugation at 5000 rpm for 
20 mins. Cell pellets were resuspended in 1/20th volume of TS (30mM Tris-
HCl, 20% sucrose pH 8.0) supplemented with 0.5mM EDTA 
(ethylenediaminetetraacetic acid) and 0.1mM PMSF (phenylmethylsulphonyl 
fluoride) and incubated on ice for 30 minutes. The suspension was centrifuged 
(8000 rpm, 20mins at 4°C; SL-250T rotor), the super natant retained and the 
pellet resuspended in same volume of 5mM MgSO4 and left to incubate on ice 
for 30 minutes. The supernatants from the TES and MgSO4 treatments were 
pooled and centrifuged at 13,000 rpm (24750 x g) for 20 mins. The cleared 
supernatant was then passed through a 0.2m filter and stored at 4°C and 
used for purification on a Ni-NTA affinity resin. 
 
The recombinant scFv expressed proteins were purified in two stages: first by 
ion metal affinity chromatography (IMAC) on a 1 mL nickel agarose column 
fitted to a peristaltic pump and subsequently by ion exchange chromatography 
on a 1 mL HiTrapTM SP FF column (cation exchange) or HiTrapTM Q FF 
column (anion exchange). For IMAC purification, the 1 mL Ni column was 
equilibrated with 5 column volumes of binding buffer (100 mM NaHPO4, 500 
mM NaCl, 10 mM Imidazole, pH 8). The osmotic shock lysates, made up to 
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the composition of the binding buffer by a 1:1 ratio with 2X binding buffer, was 
loaded onto the column with the aid of a peristaltic pump at a flow rate of 
1mL/min. The column was washed with 5 column volumes of wash buffer (100 
mM NaHPO4, 500 mM NaCl, 20 mM Imidazole, pH 8). Bound protein eluted 
with 5 column volumes of elution buffer (100 mM NaHPO4, 500 mM NaCl, 500 
mM Imidazole, pH 8) in 1 mL fractions and analysed by SDS-PAGE. 
 
 
2.4.4 Desalting of IMAC purified proteins 
 
Desalting of IMAC purified proteins was performed on an AKTA prime plus 
(GE Healthcare, Amersham) using a 40 mL Sephadex G-25 column. A 2 mL 
fraction of IMAC purified proteins were applied onto the column pre-
equilibrated with 3 column volumes of 20 mM Tris-HCl pH 8.0. The proteins 
were eluted with 2 column volumes of 20 mM Tris-HCl pH 8.0 in 0.5 mL 
fractions.  
 
 
2.4.5 Anion exchange chromatography (AEC) 
 
AEC was performed on an AKTA Prime Plus using a 1mL HiTrapTM Q FF 
anion exchange column (GE Healthcare, Amersham, UK) following 
manufactures protocol. Five mL of the desalted protein was loaded on the 
column equilibrated with buffer A (20 mM Tris-HCl, pH 8.0). Proteins were 
eluted over a linear salt gradient with buffer B (20 mM Tris-HCl, 1 M NaCl, pH 
8.0). Fractions were pooled, concentrated with Amicon protein concentrators 
(MWCO 10 kDa) and analysed by SDS-PAGE. 
 
 
2.4.6 Cation exchange chromatography (CEC) 
 
CEC was performed on an AKTA Prime Plus using a 1mL HiTrapTM SP FF 
cation exchange column (GE Healthcare, Amersham, UK) following 
manufactures protocol. Five mL of the desalted protein was loaded on the 
column equilibrated with buffer A (50 mM sodium acetate, pH 5.5). Proteins 
                           Materials and Methods 
53 
 
were eluted over a linear salt gradient with buffer B (50 mM sodium acetate, 1 
M NaCl, pH 5.5). Fractions were pooled, concentrated with Amicon protein 
concentrators (MWCO 10 kDa) and analysed by SDS-PAGE. 
 
 
2.4.7 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed as described by (Laemmli, 1970). Proteins were 
electrophoresed on a 12% gel under reducing conditions.  
 
Resolving gel (12%) 
MilliQ water 3.9 ml 
1.5 M Tris-base pH 8.8 2.6 ml 
10% SDS 100 µl 
40% Acrylamide/Bis (29:1) 3.0 ml 
10% Ammonium persulphate 100 µl 
TEMED 20 µl 
Stacking gel (4%) 
MilliQ water 3.45 ml 
0.5 M Tris-base pH 6.8 625 µl 
10% SDS 50 µl 
40% Acrylamide/Bis (29:1) 500 µl 
10% Ammonium persulphate 50 µl 
TEMED 10 µl 
 
Table 2.6: Reagents used for SDS-PAGE 
 
To cast the gel with dimensions of 8 cm (W) x 7.3 cm (H), clean glass plates 
and spacers (0.75 mm) were assembled in a gel holder on a casting stand. 
The resolving gel mixture (3.5 ml) was poured between the glass plates, 
overlaid with water and left to polymerise for 10 minutes. The water was 
poured off, 1 ml of stacking gel added and a 10-well comb inserted 
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immediately. The gel was left to polymerise for 10 minutes. The protein 
samples were then prepared by mixing 15 µl of sample with 5 µl of 4X sample 
buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 5% β-mercaptoethanol, 0.05% 
Bromophenol blue, and 10% Glycerol) heated at 100ºC for 5minutes, 
centrifuged (13000 rpm, 1 min) and loaded on the gel. The gel was run at 200 
V for 40 min with 1X SDS running buffer (14.4 g/L Glycine, 3.03 g/L Tris Base 
and 1 g/L SDS). The procedure was performed using a Mini-Protean Tetra cell 
electrophoresis system (Bio-Rad Laboratories, UK). 
 
To analyse multimerisation of scFvs a semi-native SDS-PAGE was run. For 
semi-native SDS-PAGE, the sample buffer lacked β-mercaptoethanol but 
contained SDS (1 %) and the samples were not boiled. The gel was run at 
120 V for 3 hours at 4ºC with 1X SDS running buffer containing 0.1% SDS.   
 
 
2.4.8 Coomassie Brilliant Blue staining of protein gels 
 
The separated proteins from SDS-PAGE were visualised by Coomassie 
Brilliant Blue R-250 staining (Kurien and Scofield, 1998). The gel was stained 
in 0.025% w/v Coomassie Brilliant Blue R-250 in 10% v/v acetic acid by 
microwaving until boiling followed by 1 min on rocking table. The gel was 
destained in 10% v/v acetic acid in a microwave until the solution had boiled. 
 
 
2.4.9 Bradford assay 
 
Protein concentration was estimated by using Bradford assay (Bradford, 
1976) with bovine serum albumin (BSA) as the protein standard. The assay 
was performed as follows: 20 µL of protein solution was added to 780 µL of 
PBS and 200 µL of Bradford reagent. The mixture was vortexed and 
incubated at room temperature for 10 min and the absorbance read at 595 nm 
using a NovaSpec II spectrophotometer (GE Healthcare, UK). The BSA 
standards were prepared in the range 0 – 400 µg/ml in the same buffer as the 
proteins to be assayed.   
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2.4.10 Western blotting 
 
SDS-PAGE separated proteins were blotted onto polyvinylidene difluoride 
(PVDF) (Millipore, UK) membrane using a Trans-Blot semi-dry transfer cell 
system (Bio-Rad Laboratories, UK) using the method of (Towbin et al., 1979). 
The gel and membranes were soaked in transfer buffer (25 mM Tris-HCl, 192 
mM Glycine, 20% v/v methanol) for 15 min to remove electrophoresis salts 
and detergents. The PVDF membrane was activated by immersing in 
methanol for 15 sec, transferred into MilliQ water for 2 min and into transfer 
buffer for 15mins. The pre-wetted PVDF membrane was placed on top of four 
chromatography papers (Fisher Scientific, UK), cut to gel dimension. The 
equilibrated gel was then placed on the PVDF membrane and overlaid with 
four chromatography papers. Air bubbles were excluded in between stacks by 
rolling a pipette over the surface each paper or membrane. Protein transfer 
was performed at 25 V for 20 min. After the transfer, the membrane was 
blocked overnight at 4ºC with 10 ml of 5% dry non-fat milk in PBS. For 
detection of C-terminal His tag fusion proteins, a rabbit polyclonal hexa-
histidine tag antibody conjugated to HRP (1:10000) (Abcam, UK) was used.   
Novex sharp prestained marker (Invitrogen, UK) was used as molecular 
weight standard.                    
 
 
2.4.11 Enzyme-linked immunosorbent assay  
 
The recombinant virus-like particle (VLP) of Woodchuck Hepatitis virus core 
antigen (WHcAg) containing the P. falciparum sporozoite major repeat motif 
[NANPNVDP(NANP)3] peptide and recombinant Pfs25 (3D7) antigen were 
kind gifts from Prof. David Millich and Dr. Takafumi Tsuboi, respectively. The 
recombinant (NPNA)9-MKC antigen, in which the NPNA peptide sequence is 
fused to mouse kappa constant (MKC) was expressed and purified as 
described in Section 2.4.1. A solid phase ELISA was used to evaluate the 
antigen-binding activity of the purified scFvs. Briefly, Nunc MaxiSorp flat 
bottom polystyrene plates (Fisher, UK) were coated with recombinant antigen 
(100 ng/100 L/ well) in carbonate buffer (0.1 M Na2CO3 and 0.1 M NaHCO3, 
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pH 9.5) at 4°C for 16 h. The (NPNA) 9-MKC antigen was used at 1g/100 L/ 
well. Subsequently, the ELISA plates were washed three times with 200 L of 
phosphate buffered saline (PBS) -Tween 20 (0.05%) and blocked with 5% 
bovine serum albumin (BSA) in PBS for 1 h at room temperature (RT). 
Purified scFvs were diluted 2-fold in 1% BSA in PBST (0.1% Tween 20), such 
that final composition of Tween 20 was 0.05%, and stored on ice. After 
washing three times with PBST, 100 L of the diluted IMAC purified scFvs 
were added to the wells, in triplicates, and incubated at RT for 2 hours. Three 
negative controls were set up as outlined in Table 2.9. In the first two controls, 
1% BSA in PBST or a non-specific antibody (for 4B7 scFvs the Pf-NPNA-1 
scFvs were used and vice-versa) were added to antigen coated wells. In the 
third control, the specific scFv antibody, for which the ELISA was carried out, 
was added to wells previously coated with 5% BSA in carbonate buffer.  
 
Coated wells Test  Buffer composition (final) 
Antigen coated wells Test antibody 0.5% BSA, 0.05% Tween20, PBS 
Control antibody 0.5% BSA, 0.05% Tween20, PBS 
BSA 1% BSA, 0.1% Tween20, PBS 
BSA coated wells Test antibody 0.5% BSA, 0.05% Tween20, PBS 
 
Table 2.7: Outline of ELISA procedure on Nunc 96-well plates.   
 
The plates were washed five times with PBST followed by three washings with 
PBS only. The bound scFvs, expressed from pBAK.1 with a C-terminal octa-
His tag, were detected by incubation at RT for 1 h with 100 L of monoclonal 
anti-His-AP antibody (1:10,000). For pSANG10-3F expressed scFvs, a rabbit 
anti-tri FLAG antibody (1: 50,000) was used as primary antibody and goat 
anti-rabbit IgG-AP (1: 50,000) as secondary antibody. Goat anti-Human kappa 
light chains (bound and free) −AP antibody (1: 30,000) was used for the 
detection of pBAK.1Hk expressed scFv. After the last washing step, the plates 
were developed with p-nitrophenol phosphate (SIGMAFASTTM pNPP tablet, 
Sigma, UK) substrate in 0.2 M Tris buffer pH 8.0 containing 5 mM MgCl2. The 
plates were read at 405 nm. Results were expressed as OD units. 
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2.4.12 Size-exclusion chromatography (SEC) 
 
SEC was performed on an AKTA Prime Plus using a HiLoad 16/60 Superdex 
200 size-exclusion column (GE Healthcare) equilibrated with degassed 
phosphate buffered saline (PBS). The flow rate was 1 ml/min, and the 
absorbance of the eluted protein was monitored at 280 nm. The column was 
calibrated with the following protein standards: β-amylase (200 kDa), bovine 
serum albumin (66 kDa), carbonic anhydrase (29 kDa) and cytochrome C 
(12.4 kDa).   
 
 
2.4.13 Indirect Immunofluorescence Assay (IFA) on P. falciparum 
sporozoites  
 
The binding of purified Pf-NPNA-1 scFv-0 and scFv-12 proteins to native 
circumsporozoite protein (CSP) was assessed in an IFA (Chappel et al., 
2004). Acetone-fixed smears of P. falciparum X5 (progeny clone of a cross 
between 3D7 and HB3, provided by Prof. Lisa Ranford-Cartwright) salivary 
gland sporozoites on glass slides were blocked with 50 L of 5% BSA in PBS 
for 1 hour at 37°C. Slides were washed twice for 5 min with PBST. All other 
incubations were carried out at 37°C in a humid cha mber. The scFv 
antibodies were diluted in PBST (1:1), applied to the slides and incubated for 
2 h. A control slide was set up with 1% BSA. The slides were washed 5 times 
for 3 min with PBST and fluorescein isothiocyanate (FITC) anti-His antibody 
diluted 1:500 in 1%BSA-PBST applied for 1 h. Slides were washed, mounted 
in Vectashield anti-fade (Vector Laboratories) reagent and parasites 
visualized by fluorescence microscopy with a Zeiss Axioskop fluorescent 
microscope equipped with a 100X oil immersion objective.  
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2.4.14 Statistical Analysis 
 
Unpaired T-test, by using Graphpad T-test calculator software, was used to 
determine the level of significance of the observed binding activities of the 
expressed proteins (http://www.graphpad.com/quickcalcs/ttest1.cfm). P values 
< 0.05 were considered significant. 
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2.5 Preliminary evaluation of Pf-NPNA-1 and 4B7 scFvs in Asaia SF2.1 
 
2.5.1 Assessment of antibiotic resistance 
 
Minimum inhibitory concentration was determined by streaking untransformed 
bacterial cells on GLY agar (25 g/L glycerol, 10 g/L yeast extract and 15 g/L 
agar, pH 5) containing increasing concentrations of kanamycin (25, 50, 100, 
150, 200 and 300 g/mL). 
 
 
2.5.2 Preparation of Electrocompetent Asaia sp. 
 
Competent cells were prepared according to the method of Mostafa et al. 
(2002) with slight modifications. A single colony of Asaia sp. was inoculated 
into 10 mL GLY medium (25 g/L glycerol, 10 g/L yeast extract, pH 5) and 
grown overnight at 30°C with aeration (150 rpm). Th e overnight culture was 
inoculated into 200 mL of prewarmed GLY and grown at 30°C with aeration 
(150 rpm) until the OD600 was 0.5 - 0.8. After 15 min of incubation on ice, cells 
were transferred into chilled centrifuge tubes (4 x 50 mL) and harvested (5000 
rpm, 10 min, 4°C). The supernatant was discarded an d each pellet 
resuspended in 25 mL of cold 1 mM Hepes (pH 7.0). This step was repeated 
and the pellets resuspended in 25 mL of cold 10% (v/v) glycerol and 
harvested by centrifugation. The pellets were again resuspended in 25 mL of 
cold 10% glycerol, harvested and finally resuspended in 1/100 culture volume 
of 10% (vol/vol) glycerol. Competent cells were aliquoted (100 L) and stored 
at −80°C. 
 
For electroporation, 100 L of the competent cells were mixed with 10 L (50 
ng/L) of plasmid DNA and then transferred to an ice-cold electroporation 
cuvette (1-mm electrode gap) (Sigma, UK). After incubation for 2 min on ice, 
the cells were exposed to a single electrical pulse with a Gene-Pulser Xcell 
apparatus (Bio–Rad Laboratories, Richmond, CA) set at 25 F, 200  and 
1800 V. Immediately following the electrical discharge, 200 l of GLY medium 
was added, cells were incubated at 30°C for 3 h and  plated on GLY agar (25 
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g/L glycerol, 10 g/L yeast extract and 15 g/L agar, pH 5) containing 200 g/mL 
kanamycin. Plates were incubated for 48 hrs and transformants screened by 
colony PCR.  
 
2.5.3 Expression of Pf-NPNA-1 and 4B7 scFvs in Asaia sp. 
 
Small scale expressions were initially conducted to evaluate the optimal 
expression of the scFvs. Asaia sp. was electroporated with the constitutive 
expression vector pMAK031 (2P) harbouring the Pf-NPNA-1 and 4B7 scFv 
cassettes. After 48 h of incubation transformants were PCR screened for the 
presence of scFv insert. Positively screened transformants were incolulated 
into 10 mL of GLY medium supplemented with kanamycin (200 g/ml) and 
grown with shaking at 30°C for 4 days. Aliquots (1 mL) of bacterial culture 
were taken at days 2, 3 and 4 and centrifuged at 13,000 rpm for 1 min. The 
supernatants were discarded and the cell pellets saved to determine optimal 
day for scFv expression. Glycerol stocks were prepared samples collected on 
day 2 and stored at -80°C.         
 
For large scale expression, glycerol stocks of Pf-NPNA-1 scFv-0, 12 and 4B7 
scFv-0 were inoculated into 10 mL of GLY containing kanamycin (200 g/ml) 
and grown overnight at 30°C. The overnight culture was diluted into 200 mL of 
GLY supplemented with kanamycin and grown for 2 days at 30°C with 
aeration (150 rpm). The bacterial cells were centrifuged at 5000 rpm for 15 
min at 4°C and stored at -20°C.     
 
2.5.4 Isolation and purification of Pf-NPNA-1 (scFv-0 and 12) and 4B7 
scFv-0 
 
The bacterial pellets were thawed and resuspended in 5 mL of TS buffer 
(30mM Tris-HCl, 20% sucrose pH 8.0) supplemented with 0.1mM PMSF. The 
cell were incubated on ice for 30 minutes and sonicated six times for 30 sec 
(20 kHz uniform sonic waves at 40% power) to lyse the cells. To remove cell 
debris, the lysate was centrifuged at 18,000 rpm for 20 min at 4°C. The 
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supernatant was transferred to a fresh tube on ice and use for the purification 
of the recombinants scFv by IMAC. 
 
Purification was performed on an ÄKTA prime (GE Healthcare, UK) connected 
to a 1 mL HiTrap Chelating column charged with Ni2+. The cleared lysate (5 
mL) was loaded onto the column previously equilibrated with 5 column 
volumes of binding buffer (100 mM NaHPO4, 500 mM NaCl, 10 mM Imidazole, 
pH 8) at a flow rate of 1 mL/min. The loaded column was washed with 5 
column volumes of wash buffer (100 mM NaHPO4, 500 mM NaCl, 20 mM 
Imidazole, pH 8). Bound proteins were then eluted within 1 mL aliquots with 
elution buffer (100 mM NaHPO4, 500 mM NaCl, 500 mM Imidazole, pH 8). 
The purified recombinant scFvs were analysed by SDS-PAGE under reducing 
and non-reducing conditions. 
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3.0 RESULTS 
 
3.1 Introduction to results 
 
This chapter comprises experiments to express and characterise two scFvs in 
E. coli. The scFv used for these investigations are the anti-Pfs25 murine 
antibody, 4B7 and the human anti-CSP repeat antibody Pf-NPNA-1. For the 
purpose of inclusion of these antibodies as effector molecules in symbiont 
control, initial evaluation must be undertaken in E. coli and subsequently in 
the chosen symbiotic bacterium.  
 
Functionality of antibodies is dependent on the proper formation of the 
intrachain disulphide bonds. Thus, the expression vectors were designed to 
translocate the recombinant scFv into the oxidising melieu of the periplasm, 
where disulphide bond formation occurs (Better et al., 1988; Skerra and 
Pluckthun, 1988). To enhance the solubility of the recombinant scFv, 
expression was undertaken at a low temperature of 20°C. The expression and 
characterisation results are divided into two sections. 
 
Expression and characterisation of 4B7 scFv-0 and scFv-20 in E. coli 
 
The murine MAb 4B7 was chosen because of its transmission blocking 
properties. The codon optimised 4B7 scFv was expressed in both VH - VL and 
VL - VH orientations, purified and tested for functionality. Multimer formations 
by purified recombinant scFvs were assessed.   
 
Expression and characterisation of Pf-NPNA-1 scFv-0 and scFv-12 in E. 
coli 
 
The human anti-CSP repeat antibody, Pf-NPNA-1, was expressed in the VH - 
VL format, purified and functional activity evaluated. A recombinant antigen, 
(NPNA)9MKC ,which has nine repeats of NPNA fused to MKC (mouse kappa 
constant domain), was expressed and specificity of the purified Pf-NPNA-1 
scFvs tested against it.    
 
                           Results 
64 
 
Expression of 4B7 and Pf-NPNA-1 scFvs in Asaia sp 
 
Subsequently, the 4B7 and Pf-NPNA-1 scFvs were cloned into a broad-host 
range plasmid for expression and secretion in the symbiotic bacteria Asaia sp. 
Furthermore, functional analysis analyses of the secreted proteins were then 
evaluated.  
 
3.2 Construction of scFv expression vectors pBAK.1 and pBAK.1Hk 
 
The pET-based expression vectors pBAK.1 and pBAK.1HK were constructed 
to allow tightly regulated periplasmic expression of scFv and scFv-Hk. The 
vectors employ a T7 promoter, a pelB signal peptide (SP), to direct secretion 
of the expressed protein into the periplasm of E. coli, and an octa-His tag, at 
the C-terminus, to facilitate purification and detection. The expression 
cassette has unique NcoI, NotI and XhoI restriction sites for directional cloning 
and insertion of scFv DNA fragments.  
 
To construct pBAK.1Hk the light chain human kappa constant gene (HuCk) 
was amplified with the primers BAK.1 and BAK.2, which appended NotI and 
XhoI restriction sites at the 5’ and 3’ ends, respectively. The PCR product 
(Figure 3.1B) was digested with the restriction enzymes NotI and XhoI and 
cloned into pET41b(+) to give pET41b(+)Hk. The presence of the insert was 
confirmed by colony PCR. The pET41b(+)Hk plasmid was isolated and 
digested with XbaI and NotI restriction enzymes. Subsequently, the 5’ UTR, 
ribosome binding site and pelB signal peptide, from a modified pORFES, were 
cloned into the digested pET41b(+)Hk to yield pBAK1.Hk (Figure 3.1). A 
single step cloning of these gene sequences into pET41b(+) yielded 
pBAK.1(Figure 3.3).   
 
The sequences of pBAK.1Hk and pBAK.1 plasmids are shown in Figure 3.2 
and 3.4, respectively. The sequence confirmed the presence of the pelB 
leader sequence, the restriction sites NcoI, NotI and XhoI and the octa His 
tag. The scFv constructs were then cloned into the NcoI/NotI sites of the 
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plasmids. The generated plasmid maps for each construct are shown in the 
appendix.   
 
Figure 3.1: Cloning strategy and restriction maps of pET41b(+), pET41b(+)Hk, 
pORFES and pBAK.1Hk. The plasmids are based on the pET41b(+) plasmid system 
and has the T7 promoter for expression of scFv and scFv-Hk. Relevant genetic 
elements are: lac operator, pelB signal peptide, f1 origin of replication, T7 terminator, 
kanamycin resistance gene, ColE1pBR322 gene and lacI gene. The restriction sites 
and properties relevant for the construction and properties of the recombinant vector 
are shown.        
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Figure 3.2: Cloning strategy and restriction maps of pET41b(+), pORFES and 
pBAK.1. The plasmids are based on the pET41b(+) plasmid system and has the T7 
promoter for expression of scFv and scFv-Hk. Relevant genetic elements are: lac 
operator, pelB signal peptide, f1 origin of replication, T7 terminator, kanamycin 
resistance gene, ColE1pBR322 gene and lacI gene. The restriction sites and 
properties relevant for the construction and properties of the recombinant vector are 
shown.  
       
 
 
 
 
3.2.1 Cloning of 4B7 scFv-1 VH-VL gene into pBAK.1 and pBAK.1Hk 
 
To express 4B7 scFv-1 in the VH-VL orientation, the codon optimised gene 
synthesised as a pUC-19 insert was excised and subcloned into the NcoI and 
NotI restriction sites of pBAK.1 and pBAK.1Hk vectors. Transformants were 
colony screened by PCR using T7 promoter and terminator specific primers. 
Plasmids were purified and sequenced to ensure that the insert was inframe 
(Appendix). The expression plasmids encoding 4B7 scFv-1 were transformed 
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into E. coli BL21 (DE3) pRARE cells. Small scale expression in 50 mL LB 
induced with 0.3 mM IPTG was carried out. To investigate scFv secretion, 
periplasmic proteins were isolated and purified by IMAC. The expressed 
protein (cell pellet) and purified fractions were analysed by SDS-PAGE and 
Western blot. The blot was probed with monoclonal anti-His antibody as 
described in Section 2.4.10. The predicted molecular weight of the 
recombinant 4B7 scFv-1 was 27.8 kDa and 38.5 kDa for scFv-1Hk. SDS-
PAGE and Western blot showed that most of the expressed protein was 
retained within the cytoplasm (Figure 3.3A). No secretion into the periplasm 
was observed on the Western blots (Figure 3.3B & C). The orientation of the 
4B7 scFv-1 was reversed to VL – VH and its expression and secretion 
investigated. 
 
                      
Figure 3.3: SDS-PAGE analysis under reducing conditions (A) and Western blot 
of small scale purification of 4B7 scFv-1 VH - VL expressed from plasmids 
pBAK.1 (B) and pBAK.1Hk (C). 20 µL of each fraction was loaded, electrophoresed 
on a 12% gel and stained with Coomassie Brilliant Blue R-250 (A) and transferred 
onto PVDF membrane and probed with monoclonal anti His-AP labelled antibody (B 
and C). Expressed recombinant proteins are indicated by arrows. (A) Lane 1: 
molecular weight markers, Lane 2: pBAK1 induced cell pellet, Lane 3: pBAK1 purified 
periplasmic extract, Lane 4: pBAK1Hk induced cell pellet, Lane 5: pBAK1Hk purified 
periplasmic extract. (B) Lane 1: molecular weight markers, Lane 2: pBAK1 induced 
cell pellet, Lane 3: pBAK1 purified periplasmic extract. (C) Lane 1: molecular weight 
markers, Lane 2: pBAK1Hk induced cell pellet, Lane 3: pBAK1Hk purified periplasmic 
extract. 
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3.2.2 Cloning of 4B7 scFv-0 and scFv-20 VL - VH genes into pSANG10-3F 
and pBAK.1Hk 
 
To construct 4B7 scFv-0 in the VL – VH orientation, the variable domains were 
amplified with the primers 4B7VHF and 4B7VHNot for VH and 4B7VLNco and 
4B7VLR for VL using 4B7 scFv-1 VH – VL pUC-19 as template. The scFv-0 
was then assembled by overlap extension PCR using the primers 4B7VLNco 
and 4B7VHNot. The resulting PCR product was digested and inserted into the 
NcoI and NotI restriction sites of pSANG10-3F and pBAK.1Hk expression 
vectors and sequenced (Appendix).  
 
     
The 4B7 scFv-0 and scFv-20 gene inserts in the expression plasmids, 
pSANG10-3F and pBAK.1Hk, were transformed into E. coli BL21 (DE) pRARE 
cells and recombinant protein expression evaluated. Protein expression was 
conducted as described in Section 2.4.2. Recombinant proteins isolated from 
the periplasm were purified in two stages: firstly, by IMAC on a nickel agarose 
column (Section 2.4.3) and secondly, by anion exchange chromatography 
(Section 2.4.5). The protein fractions from the two purifications steps were 
analysed by SDS-PAGE and Western blot.    
 
The predicted molecular weights of 4B7 scFv-0 (Figure 3.4A) and scFv-20 
(Figure 3.4B), using pSANG10-3F plasmid, on SDS-PAGE were consistent 
with the estimated values of 30 and 31.2 kDa, respectively. The level of scFv-
0 expression, as indicated by the arrow of the induced band, was slightly 
lower than that of scFv-20. This corresponds with the scFv-0 level of secretion 
into the periplasm. The IMAC purified proteins also had other E. coli 
contaminants. Just below the secreted scFv-0 and scFv-20 is a 25 kDa E. coli 
protein.  
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Figure 3.4: Expression and purification of 4B7 scFv-0 and scFv-20 using 
pSANG10-3F plasmid. SDS-PAGE analyses under reducing conditions of Ni-NTA 
affinity purification of scFv-0 (A) and scFv-20 (B) respectively. 20 µL of each 
purification fraction was loaded, electrophoresed on a 12% gel and stained with 
Coomassie Brilliant blue R-250. (A and B) Lane 1: molecular weight marker; Lane 2: 
uninduced cell pellets; Lane 3: induced cell pellet; Lane 4: crude periplasmic fraction; 
Lane 5: Ni column flow through; Lane 6: Ni column wash with 10 mM Imidazole; 
Lanes 7-9: elutions with 500 mM Imidazole. 
 
 
 
The IMAC purified scFv proteins were further purified by AEC based on the 
isoelectric points (pI) of the scFvs. The scFv-0 and scFv-20 both have the 
same pI of 4.96. The AEC purified proteins were concentrated and the purity 
compared with IMAC purified proteins on SDS-PAGE (Figure 3.5A). A 
duplicate gel was used for Western blotting (Figure 3.5B). The AEC 
purification did not result in homogenously purified proteins as seen on SDS-
PAGE. The Western blot (Figure 3.5B) showed two species of the purified 
scFv proteins. The higher molecular weight protein indicates that the signal 
peptide was not cleaved during translocation of the scFv into the periplasm. 
The scFv-0 and scFv-20 with uncleaved SP would have predicted molecular 
weights of 32.6 (pI 4.92) and 33.9 kDa (pI 4.92), respectively. For the scFv-20, 
the lower band is more pronounced and may be the processed protein.     
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Figure 3.5: AEC of 4B7 scFv-0 and scFv-20 using pSANG10-3F plasmid. SDS-
PAGE analyses under reducing conditions of Ni-NTA affinity and AEC purification of 
scFv-0 and scFv-20 (A). (B) Western blot of duplicate gel of (A). Proteins were 
probed with rabbit anti-tri FLAG antibody as primary antibody and goat anti-rabbit 
IgG-AP as secondary antibody. BCIP/NBT was used as substrate. 20 µL of each 
purification fraction was loaded, electrophoresed on a 12% gel and stained with 
Coomassie Brilliant blue R-250 (A). (A and B) Lane 1: molecular weight marker; 
Lane 2: scFv-0 uninduced cell pellets; Lane 3: scFv-0 induced cell pellet; Lane 4: 
IMAC purified scFv-0 (Figure 3.9A Lane 8); Lane 5: AEC purified scFv-0; Lane 6: 
molecular weight marker; lane 7: scFv-20 uninduced cell pellets; Lane 8: scFv-20 
induced cell pellet (panel B, Lane 3); Lane 9: IMAC purified scFv-20 (Figure 3.9B, 
Lane 8) Lane 10: AEC purified scFv-20. Arrows indicate expressed recombinant 
proteins.   
 
 
 
Expression of the 4B7 scFv-0 and 20 were also carried out in the pBAK.1Hk 
plasmid. The molecular weights of 4B7 scFv-0Hk (Figure 3.6A) and scFv-
20Hk (Figure 3.6B) on SDS-PAGE were consistent with the estimated values 
of 38.4 (pI 5.59) and 39.6 (pI 5.59) kDa, respectively. The 25 kDa E. coli 
protein observed as a contaminant in the pSANG10-3F purified proteins was 
also observed for the scFv-0Hk and scFv-20Hk proteins. The affinity purified 
proteins were further purified by AEC (Figure 3.7A) similar to those of 
pSANG10-3F expressed proteins.  
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Figure 3.6: Expression and purification of 4B7 scFv-0 and 20 using pBAK.1Hk 
plasmid. SDS-PAGE analyses under reducing conditions of Ni-NTA affinity 
purification of scFv-0Hk (A) and scFv-20Hk (B) respectively. 20 µL of each 
purification fraction was loaded, electrophoresed on a 12% gel and stained with 
Coomassie Brilliant blue R-250. (A and B) Lane 1: molecular weight marker; Lane 2: 
uninduced cell pellets; Lane 3: induced cell pellet; Lane 4: crude periplasmic fraction; 
Lane 5: Ni column flow through; Lane 6: Ni column wash with 10 mM Imidazole; 
Lanes 7-9: elutions with 500 mM Imidazole. 
 
 
On the Western blot (Figure 3.7B) faint bands corresponding to the predicted 
size of each scFv-Hk were observed in the uninduced proteins fractions. This 
was, however, not evident on the SDS-PAGE. The scFv-Hk proteins isolated 
by IMAC were not observed in the AEC eluted proteins.    
 
        
 
Figure 3.7: AEC of 4B7 scFv-0 and 20 using pBAK.1Hk plasmid. SDS-PAGE 
analyses under reducing conditions of Ni-NTA affinity and AEC purification of scFv-
0Hk and scFv-20Hk (A). (B) Western blot of duplicate gel of (A). Proteins were 
probed with anti-His-HRP antibody. DAB was used as substrate. (A and B) Lane 1: 
molecular weight marker; Lane 2: scFv-0Hk uninduced cell pellets; Lane 3: scFv-0Hk 
induced cell pellet; Lane 4: IMAC purified scFv-0Hk (Figure 3.11A Lane 8); Lane 5: 
AEC purified scFv-0Hk; Lane 6: molecular weight marker; lane 7: scFv-20Hk 
uninduced cell pellets; Lane 8: scFv-20Hk induced cell pellet (panel B, Lane 3); Lane 
9: IMAC purified scFv-20Hk (Figure 3.11B, Lane 8) Lane 10: AEC purified scFv-
20Hk. Arrows indicate expressed recombinant proteins.   
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3.2.3 ELISA for functional analysis of 4B7 scFv-0 and scFv-20  
 
The binding activity of the pSANG10-3F and pBAK.1Hk expressed scFv-0 and 
scFv-20 were evaluated in an ELISA as described in Section 2.4.11. Though 
the scFvs were expressed and secreted in pBAK.1 binding activity could not 
be assessed as the recombinant Pfs25 antigen used has a C-terminal His-tag. 
Dilutions of the scFv proteins were carried out with 1% BSA in PBST (0.1% 
Tween-20). PBST (0.05% Tween-20) was included in the washing steps to 
prevent non-specific binding. Negative controls were also incorporated in the 
ELISA to further demonstrate the specificity of 4B7 scFv-0 and scFv-20 to 
Pfs25. The negative controls were BSA (1% w/v) and Pf-NPNA-1 scFv (scFv-
0 and scFv-12 used as controls for 4B7 scFv-0 and scFv-20, respectively).  
 
 
Figure 3.8: Specificity evaluation of 4B7 pSANG10-3F expressed scFv-0 and 
scFv-20 to Pfs25. Antigen was coated at 100ng per well and bound scFv detected 
with a rabbit anti-tri FLAG antibody (primary antibody) and goat anti-rabbit IgG-AP 
(secondary antibody). p-NPP was used as substrate and absorbance measured at 
405 nm. The error bars indicate the standard errors of the means (n = 3). Ag: codes 
for Antigen, Ab: for Antibody and Ab (IR): for irrelevant or non-specific antibody (Pf-
NPNA-1 scFv-0 and scFv-12 were used as controls for 4B7 scFv-0 and scFv-20, 
respectively).   
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Binding activity could not be established for the pSANG10-3F (Figure 3.8) and 
pBAK.1Hk (Figure 3.9) scFv proteins as the ELISA signals were very low. 
These results were not considered statistically significant. The Pf-NPNA-1 
scFv and scFv-Hk used as controls had higher ELISA signal than the 4B7 
scFvs. This was more evident when the Pf-NPNA-1 scFv-12Hk was probed 
with the goat anti-human kappa constant antibody.  
     
 
Figure 3.9: Specificity of soluble 4B7 scFv-0 and scFv-20 expressed from 
pBAK.1Hk to Pfs25. Antigen was coated at 100ng per well and bound scFv-Hk 
detected with monoclonal goat anti-Human kappa light chains (bound and free) −AP 
antibody. p-NPP was used as substrate and absorbance measured at 405 nm. The 
error bars indicate the standard errors of the means (n = 3). Ag: codes for Antigen, 
Ab: for Antibody and Ab (IR): for irrelevant or non-specific antibody (Pf-NPNA-1 scFv-
0Hk and scFv-12Hk were used as controls for 4B7 scFv-0 and scFv-20, 
respectively).   
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3.2.4 Site directed mutagenesis of 4B7 (VL - VH) scFv-0 and scFv-20 
 
Since no binding activity was observed for 4B7 scFv-0 and scFv-20 expressed 
from the two plasmids, the sequence was compared to another scFv 
sequence designated 4B7 (AJ) that was also obtained from the murine 
monoclonal antibody mAb 4B7. The previously expressed recombinant scFv 
designated 4B7 (AK) differed from 4B7 (AJ) by seven amino acids. There 
were four changes in the VL FR (Q3E, I5T, L85F and G86V) and three in the 
VH FR (Q18R, T92A and L114V).   
 
Mutated Frame work residues Effect 
VL Q3E; FR1 Conserved hydrophilic 
VL I5T; FR1 Hydrophobic → hydrophilic 
VL L85F; FR3  Conserved hydrophobic 
VL G86V; FR3 Hydrophilic → hydrophobic 
VH Q18R; FR1 Conserved hydrophilic 
VH T92A; FR3 Hydrophilic → hydrophobic 
VH L114V; FR4 Conserved hydrophobic 
 
Table 3.1: Amino acid substitutions in FR of 4B7 scFv and properties of the 
substituted residues.   
 
   VLCDR1 
           4B7AK  MKYLLPTAAAGLLLLAAQPAMADIQMIQSPSSMFASLGDRVSLSCRASQDIRGNLDWFQQ 
           4B7AJ  MKYLLPTAAAGLLLLAAQPAMADIEMTQSPSSMFASLGDRVSLSCRASQDIRGNLDWFQQ  
                  ************************:* ********************************* 
   VLCDR2  VLCDR3 
           4B7AK  KPGGTIKLLIYSTSNLNSGVPSRFSGSGSGSDYSLTISSLESEDLGDYYCLQRNAYPLTF  
           4B7AJ  KPGGTIKLLIYSTSNLNSGVPSRFSGSGSGSDYSLTISSLESEDFVDYYCLQRNAYPLTF  
                  ********************************************: ************** 
                                                  VHCDR1 
           4B7AK  GSGTKLEIKAEVKLVESGGGLVQPGGSQKLSCAASGFTFSDYGMAWFRQAPGKGPEWVAF  
           4B7AJ  GSGTKLEIKAEVKLVESGGGLVQPGGSRKLSCAASGFTFSDYGMAWFRQAPGKGPEWVAF  
                  ***************************:******************************** 
  VHCDR2 VHCDR3 
           4B7AK  INNLAYSIYYADTVTGRFTISRENAKNTLYLEMSSLRSEDTTMYYCARGNLYYGLDYWGQ  
           4B7AJ  INNLAYSIYYADTVTGRFTISRENAKNTLYLEMSSLRSEDTAMYYCARGNLYYGLDYWGQ  
                  *****************************************:****************** 
 
           4B7AK  GTTLTVSSAAASAHHHHHHKLDYKDHDGDYKDHDIDYKDDDDK  
           4B7AJ  GTTVTVSSAAASAHHHHHHKLDYKDHDGDYKDHDIDYKDDDDK  
         ***:*************************************** 
Figure 3.10: Amino acid sequence alignment of two variants of 4B7 scFv. 
Differences in amino acids are indicated in purple. The CDR sequences are in green. 
Sequences predicted to form hydrogen bonds with Pfs25 antigen during interaction 
are indicated in red.   
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Site directed mutagenesis was performed, using pSANG10-3F 4B7 scFv-0 in 
the VL–VH orientation as template. 4B7 scFv-20(AJ) was assembled as 
described (Section 2.3.3). The scFv-0(AJ) and 20(AJ) cassettes were cloned 
into the expression vectors pSANG10-3F and pBAK1.HK and expressed in 
BL21(DE3) pRARE cells. The expressed scFvs were purified by IMAC and 
purity assessed on a 12% SDS-PAGE gel (Figure 3.11A & B). As observed 
previously, higher molecular weight proteins (~66 kDa), a ~25 kDa E. coli 
protein and lower molecular weight proteins co-purified with the scFv-0 and 
scFv-20.  
       
     
Figure 3.11: Expression and purification of 4B7 (AJ) scFv-0 and scFv-20 using 
pSANG10-3F plasmid. SDS-PAGE analyses under reducing conditions of Ni-NTA 
affinity purification of scFv-0 (A) and scFv-20 (B) respectively. 20 µL of each 
purification fraction was loaded, electrophoresed on a 12% gel and stained with 
Coomassie Brilliant blue R-250. (A and B) Lane 1: molecular weight marker; Lane 2: 
uninduced cell pellets; Lane 3: induced cell pellet; Lane 4: crude periplasmic fraction; 
Lane 5: Ni column flow through; Lane 6: Ni column wash with 10 mM Imidazole; 
Lanes 7-9: elutions with 500 mM Imidazole. 
 
 
 
Purified recombinant 4B7 scFv were also evaluated under non-reducing 
conditions (semi-native). Under reducing conditions only the monomeric forms 
of the proteins were observed on the Western blot (Figure 3.12, Lanes 2 and 
3). However, under non-reducing conditions monomeric, dimeric and 
multimeric forms were observed for pSANG10-3F expressed 4B7 scFv-0 and 
20 (Figure 3.12, Lanes 4 and 5). The dimeric protein had an apparent 
molecular mass of 60 kDa. The molecular mass of the multimeric form could 
not be estimated on the Western blot as it exceeded 260 kDa. The 
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electrophoretic mobility of each scFv under non-reducing conditions was 
faster than that of its corresponding scFvs under reducing conditions. 
 
 
 
Figure 3.12: Western blot of IMAC purified proteins electrophoresed under 
reducing and non-reducing conditions. 20 µL of each purification fraction was 
loaded, electrophoresed on a 12% gel at 4°C. Protei ns were transferred onto PVDF 
membrane and were probed with rabbit anti-tri FLAG antibody as primary antibody 
and goat anti-rabbit IgG conjugated to alkaline phosphatase (AP) as secondary 
antibody. BCIP/NBT was used as substrate. Lane 1: molecular weight marker; Lane 
2: IMAC purified scFv-0 under reducing conditions; Lane 3: IMAC purified scFv-20 
under reducing conditions; Lane 4: IMAC purified scFv-0 under non-reducing 
conditions; Lane 5: IMAC purified scFv-20 under non-reducing conditions. Arrows 
indicate expressed recombinant proteins.   
 
 
 
The spontaneous assembly of the scFv-0 and scFv-20 into multimeric 
assembly was further ascertained by size-exclusion chromatography (SEC). 
Prior to SEC the scFv-20, which showed higher level of expression, was 
subjected to anion exchange chromatography (AEC) (Figure 3.13) to obtain a 
homogenous product that will facilitate investigation of multimeric assembly. 
AEC was chosen based on the earlier determination of the pI of the 
expression protein. IMAC purified fraction 7 to 9 (Figure 3.11B) were pooled 
and applied on a 1 mL HiTrap Q sepharose column. Prior to application on the 
HiTrap column, the IMAC purified proteins were desalted with PBS to remove 
excess NaCl present in the elution buffer.   
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Figure 3.13: Anion exchange chromatography of 4B7 scFv-20 a 1 mL HiTrap Q 
Sepharose column. IMAC purified protein was applied to the column, the flow rate 
was 0.5 mL/min and the fractions collected at 1 mL intervals. The blue shows 
absorbance at 280 nm, the green line shows addition of buffer from 0 to 1M NaCl and 
the red line indicates the fractions collected. Peak fractions 10 -12 were collected for 
further analysis.    
 
 
 
 
 
The peak fractions (10 to 12) were then analysed by SDS-PAGE to determine 
homogeneity of the proteins after AEC. Subsequently, the fractions were 
pooled, concentrated to 1 mL and applied to a Hi-Load 16/60 Superdex column 
pre-equilibrated with PBS and pre-calibrated with Sigma-Aldrich gel filtarion standard 
proteins (cytochrome c, 12.4 kDa; carbonic anhydrase, 29 kDa; bovine serum 
albumin, 66 kDa and β-Amylase, 200 kDa). The major peaks of the scFv-20 showed 
a higher molecular mass protein (peak 1, ~50 min), a dimer (~66 kDa, 90min) and 
monomer (~33 kDa; 100 min) (Figure 3.14). Insufficient amount of material did not 
permit further investigation of these protein forms. Peaks 4 and 5 may indicate 
degraded proteins.   
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Figure 3.14: Size exclusion HPLC on a calibrated Hi-Load 16/60 Superdex column 
of purified 4B7 scFv-20. The VL-VH protein eluted as a monomer at 100.7 min and 
dimer at 90.6 mins. The elution times are consistent with the calculated molecular 
weight of 31.2 and 62.4 kDa. The column was equilibrated with 1X PBS (3.2 mM 
Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH 8.0), run at a flow rate of 
1.0 ml/min. The high molecular mass multimer (peak 1), dimer (peak 2) and 
monomer (peak 3) were collected. Peaks 4 and 5 indicate degraded proteins.  
 
 
 
 
To evaluate expression of the 4B7 (AJ) scFv fused to the human kappa constant 
domain, 4B7 (AJ) scFv-0 and scFv-20 gene fragments were cloned into pBAK.1Hk 
expression plasmid. Both constructs were expressed and purified under similar 
conditions as described earlier in sections 2.4.2 and 2.4.3, respectively. The scFv-
0Hk was secreted with most of the expressed protein (38.4 kDa) retained in the 
cytoplasm (Figure 3.15A). On the other hand, scFv-20Hk (39.6 kDa) showed very 
high secretion level with less protein in the cytoplasm (Figure 3.16A). Both secreted 
proteins were subjected to SDS-PAGE under reducing and non-reducing conditions. 
The scFv-0Hk and scFv-20Hk both formed monomeric and multimeric forms 
(Figure 3.15B and 3.16B, respectively).  
                           Results 
79 
 
    
Figure 3.15: Expression and purification of 4B7 (AJ) scFv-0HK. SDS-PAGE 
analyses of Ni-NTA affinity purification of scFv-0Hk (A) and Western blot (B) under 
reducing and non-reducing conditions, respectively. Proteins were probed with anti-
Human kappa-AP antibody (1:30000). 20 µL of each purification fraction was loaded, 
electrophoresed on a 12% gel and stained with Coomassie Brilliant blue R-250. For 
Western blotting BCIP/NBT was used as substrate. (A) Lane 1: molecular weight 
marker; Lane 2: uninduced cell pellets; Lane 3: induced cell pellet; Lane 4: crude 
periplasmic fraction; Lane 5: Ni column flow through; Lane 6: Ni column wash with 10 
mM Imidazole; Lanes 7-9: elutions with 500 mM Imidazole. (B) Lane 1: molecular 
weight marker; Lane 2: IMAC purified scFv-0Hk (panel A Lane 8) under reducing 
conditions; Lane 3 and 4: IMAC purified scFv-0Hk (panel A Lane 8) under non-
reducing conditions.     
 
 
       
Figure 3.16: Expression and purification of 4B7 (AJ) scFv-20HK. SDS-PAGE 
analyses of Ni-NTA affinity purification of scFv-20Hk (A) and Western blot (B) under 
reducing and non-reducing conditions, respectively. Proteins were probed with anti-
Human kappa-AP antibody (1:30000). 20 µL of each purification fraction was loaded, 
electrophoresed on a 12% gel and stained with Coomassie Brilliant blue R-250. For 
Western blotting BCIP/NBT was used as substrate. (A) Lane 1: molecular weight 
marker; Lane 2: uninduced cell pellets; Lane 3: induced cell pellet; Lane 4: crude 
periplasmic fraction; Lane 5: Ni column flow through; Lane 6: Ni column wash with 10 
mM Imidazole; Lanes 8-10: elutions with 500 mM Imidazole. (B) Lane 1: molecular 
weight marker; Lane 2: IMAC purified scFv-20Hk (panel A Lane 8) under reducing 
conditions; Lane 3: IMAC purified scFv-20Hk (panel A Lane 8) under non-reducing 
conditions.     
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3.2.5 ELISA of 4B7 (AJ) scFv-0 (VL - VH) and scFv-20 (VL - VH)  
 
The binding activity of the pSANG10-3F and pBAK.1Hk expressed 4B7 (AJ) 
scFv-0 and scFv-20 were evaluated in an ELISA (Figure 3.17 and 3.18). The 
low signals obtained for both proteins could not suffice as binding to target 
antigen. However, the ELISA signal obtained for pSANG10-3F expressed 4B7 
(AJ) scFv-0 was higher than that of scFv-20 and does not correlate with the 
level of expression of both scFvs. The differences in binding to the scFvs to 
Pfs25 and BSA were considered statistically significant (p<0.001). 
 
 
Figure 3.17: Specificity evaluation of 4B7 (AJ) pSANG10-3F expressed scFv-0 
and scFv-20 to Pfs25. Antigen was coated at 100ng per well and bound scFv 
detected with a rabbit anti-tri FLAG antibody (primary antibody) and mouse anti-
rabbit IgG-AP (secondary antibody). BSA was used as a negative control. p-NPP 
was used as substrate and absorbance measured at 405 nm. The error bars indicate 
the standard errors of the means triplicate well for two independent studies. Asterisk 
denotes statistical significance (triple asterisk denotes p<0.001; paired t test) 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
pSANG10-3F 4B7 scFv-0 pSANG10-3F 4B7 scFv-20
A
b
s
o
r
b
a
n
c
e
 4
0
5
 n
m
Pfs25
BSA
***
***
                           Results 
81 
 
 
Figure 3.18: Specificity of soluble 4B7 (AJ) scFv-0 and scFv-20 expressed from 
pBAK.1Hk to Pfs25. Antigen was coated at 100ng per well and bound scFv-Hk 
detected with monoclonal goat anti-Human kappa light chains (bound and free) −AP 
antibody. p-NPP was used as substrate and absorbance measured at 405 nm. The 
error bars indicate the standard errors of the means of triplicate well for two 
independent studies. Asterisk denotes statistical significance (triple asterisk denotes 
p<0.001; paired t test) 
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3.3 Discussion on expression and characterisation of 4B7 scFv  
 
This section deals with three of the four objectives of this study, which are the   
characterisation of the scFv antibodies 4B7 and Pf-NPNa-1. Chapter two 
(section 2.3.3) describes the cloning and expression of the murine monoclonal 
antibody 4B7, that recognises the Pfs25 sexual stage protein expressed on 
the surface of ookinetes. The VH and the VL domains from the Fab antibody 
4B7 originally isolated from hybridoma cells were used as the building blocks 
to construct the scFv 4B7 (Appendix, Figure II). However, bioinformatic 
analysis showed the presence of rare codons, which can impede prokaryotic 
expression, in the DNA sequence of 4B7. To address this problem, the 
sequence was codon optimised for expression in E. coli. Two scFv formats, 
VH - VL or VL - VH orientations of which the former is more common, were 
constructed in this study. Some studies have demonstrated the superiority, in 
terms of higher yields of soluble protein (Desplancq et al., 1994; Tsumoto et 
al., 1994; Ayala et al., 1995; Hamilton et al., 2001; Albrecht et al., 2006) and 
higher binding characteristics (Lu et al., 2004), of the VL - VH orientation. 
Conversely, other studies have shown that the relative orientations of the VH 
and VL have no effect on the expression level but the VL - VH orientation nearly 
abolished antigen binding (Albrecht et al., 2006). Due to the variations in 
expression levels of the different scFv fragments cited, it has been suggested 
that the orientation of the VH and VL domains that results in optimum 
expression must be investigated for each fragment (Hu et al., 2005).  Hence, 
two versions of 4B7 scFv were generated in the VH - VL or VL- VH orientation 
to test the effect of domain order on expression and secretion. The scFv 
constructs were then expressed in E. coli and purified from periplasmic 
extracts by affinity chromatography. The V domain orientation had a 
significant effect on the secretion of the antibody into the periplasmic space of 
the bacterium. Although both scFv formats were expressed in the cytoplasm, 
periplasmic secretion was only detected for the scFv VL- VH format (Section 
3.2.2; Figure 3.6 A&B).  
 
Using the pET-based vectors, to facilitate periplasmic secretion, the scFv 4B7 
was initially expressed in the VH - VL orientation, which upon investigation 
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showed barely detectable levels in E. coli (Figure 3.5). The expressed scFv 
was retained in the cytoplasm, suggesting its association with the bacterial 
membrane. Efforts were then directed into isolation and refolding of inclusion 
bodies. However, the refolded inclusion bodies showed no antigen binding. 
Lack of secretion of scFvs into the periplasm, due to association with the 
bacterial inner membrane, has been reported in numerous studies (Pantoliano 
et al., 1991; Malby et al., 1993; Ayala et al., 1995). The lack of secretion of the 
anti-fluorescyl scFv 4.4.20 was attributed to the presence of charged residues 
within the amino terminus of the mature VH domain (Pantoliano et al., 1991). 
Malby et al. (1993) attributed the membrane association of the NC10 antibody 
to the presence of two lysines (positions 11 and 21) and an arginine (position 
17). Ayala et al. (1995) also had a similar problem with the scFv CB-Hep.1 
due to the presence of two lysines at position 3 and 19 and an arginine at 
position 16. The 4B7 scFv (VH - VL) used in this study has two lysines at 
positions 3 and 19 in its VH. The presence of these residues may have 
disrupted the correct processing of the signal peptide and thus preventing the 
translocation of the protein into the periplasm. Three main mechanisms have 
been hypothesized to explain the membrane assocation effect: interaction of 
the positively charged amino acids with membrane phospholipids, 
translocation impairment due to increase pKa and incorrect positioning of the 
signal peptide sequence (Li et al., 1988; Boyd and Beckwith, 1989; Ayala et 
al., 1995). In the case of other proteins, membrane association has been 
attributed to the presence of positively charged amino acids, such as arginine 
and lysine, 20-30 residues downstream of the signal sequence (Li et al., 1988; 
Boyd and Beckwith, 1989; Summers et al., 1989; Kajava et al., 2000). Li et al. 
(1988) reported a 50-fold decrease in protein translocation to the periplasm 
when amino acids arginine and glutamic acid at the N-terminal of the mature 
sequence of alkaline phosphatase were mutated to two arginines.  
 
The presence of other charged residues, such as glutamate (E) and glutamine 
(Q) should be taken into consideration during bacterial expression of scFvs 
(Benhar and Pastan, 1995; de Haard et al., 1998). These amino acid 
residues, which are mainly present in the framework regions, may give rise to 
an altered specificity or affinity of the antibody to its antigen by altering the 
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conformation of the CDR loops (McCartney et al., 1995). The residues may 
also affect the yield and stability of the antibody (Johnson and Bird, 1991; 
Soderlind et al., 1992; Kipriyanov et al., 1997; de Haard et al., 1998). The 
parent mAb 4B7 was isolated from hybridoma cell lines and the N-terminal 
sequences of the variable domains determined by N-terminal sequencing. 
However, only the first five amino acids (EVKLV) of the heavy chain and 
seven (DIQMIQS) of the light chain were obtained by N-terminal amino acid 
sequencing. The sixth amino acid of the VH obtained by PCR was glutamate 
(E) (Stura et al., 1994a). The presence of such a residue in the N-terminus of 
the scFv 4B7 in the VH-VL orientation may have impeded correct processing of 
the signal peptide and subsequent translocation of the expressed protein into 
the periplasm. A detailed search of the literature and Kabat database revealed 
that 45% of mouse VH sequences have E at position 6, whereas 55% have Q 
at this position (Kabat and Wu, 1991; Kabat et al., 1991). Thus, position 6 of 
VH FR1 (H6) could be occupied by either a glutamate (E) or a glutamine (Q), 
which is buried and conserved within the immunoglobulin variable domain 
(Langedijk et al., 1998; Honegger and Pluckthun, 2001). Although glutamate 
at this position of mAb 4B7 may be an inherent property of subgroup IIIA 
antibodies, previously determined by Stura et al. (1994a) by comparison with 
sequences in the Kabat database, its presence instead of Q in some 
bacterially expressed scFvs has resulted in drastic reduction in production 
yield, instability and loss of binding of the recombinant scFv to its antigen 
(McCartney et al., 1995; Kipriyanov et al., 1997; de Haard et al., 1998; Li et 
al., 2000a).  
 
In the study of deHaard et al. (1998) antigen binding activity was restored by 
replacing E (introduced by PCR) with Q, which is well conserved in subgroup 
IIA to which the VH of the anti-human chorionic gonadotropin belongs.            
Not only did the presence of E at this position affect the affinity of the antibody 
but also the level of bacterial expression. The restoration of the amino acid (E) 
to Q led to a 30-fold increase in the soluble OKT3 derived scFv (VH subgroup 
IIA) (Kipriyanov et al., 1997). This substitution led to a significant increase in 
the stability of the scFv but had no effect on its binding to CD3 antigen. 
Significant stabilisation and refolding yield (more than 10 fold) was also 
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observed for Tras-SE, a scFv derived from the murine monoclonal antibody 
03/01/01 directed against the musk odorant traseolide (6-acetyl-1-isopropyl-
2,3,3,5-tetramethyl-indane), when Q-H6 was restored (Langedijk et al., 1998). 
In the case of the scFv and Fab fragment derived from the murine anti-gastric 
cancer mAb 3H11 (VH subgroup IIIB), the presence of E in the FR1 of VH6 
resulted in loss of antigen binding activity but had no effect on expression (Li 
et al., 2000a; Li et al., 2000b). Conversely, other studies have shown no effect 
on the properties of antibodies with E present in the VH FR1 (Froyen et al., 
1995; Brégérère et al., 1997). Brégérère et al. (1997) had contrasting results 
with the murine antibodies mAb19 (VH subgroup IIB) and mAb93 (VH 
subgourps VA, IIB or IIA) directed against the TrpB2 subunit of E. coli 
tryptophan synthase. Substitution of the VH-Q6 residue with E, introduced by 
the degeneracy of the primers, resulted in decreased affinity for TrpB2 and 
increased degradation of the mAb93. However, the properties of the mAb19 
were not affected by this change. In the case of Froyen et al. (1995), no 
functional (binding and neutralising) differences were observed between the 
scFvs D9D10 and D9D10N, derived from the same mouse anti-human 
interferon-gamma antibody D9D10, although they differed by three amino 
acids in the VH (E in position 6 of D9D10) and three in the VL (E in position 3 
of D9D10). The variable domain sequences of D9D10 were obtained by PCR 
and that of D9D10N by traditional cDNA synthesis.    
 
It is clear from the above studies that E in the VH may be the natural sequence 
of a particular antibody subtype and its presence may or may not affect the 
properties of the antibody. This particular residue is, however, absent in the 
VLFR1 of scFv 4B7. According to Spada et al. (1998) QVL6 in lamda and 
kappa variable light chain domains is highly conserved as the cysteine 
residues in immunoglobulin domains (Spada et al., 1998). Since it has 
suggested that the folding problems of scFv antibodies can be associated with 
the VH (Knappik and Pluckthun, 1995) and the VL of antibodies can act as a 
chaperone in the folding of the VH (Freund et al., 1996), the scFv orientation of 
4B7 was changed to a VL-VH format (position 6 of the scFv 4B7 VL is occupied 
by Q). In this study, switching of the scFv domain to a VL-VH format resulted in 
secretion of the expressed protein into the periplasm (Figure 3.6 A&B) 
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although three arginine residues (positions 18, 24 and 30) are located in the 
variable light chain domain. By changing the scFv orientation, Ayala et al. 
(1995) observed substantial improvement in the secretion of their scFv. 
Improvements in expression yields have also been observed in other studies 
when the scFv orientation was changed to a VL-VH format (Tsumoto et al., 
1994; Hamilton et al., 2001). Hamilton et al. (2001) observed a 150% 
improvement in the expression level upon reversal of the variable domain 
orientation. In the case of anti-lysozyme scFv HyHEL10, Tsumoto et al. (1994) 
observed a higher level of expression of the VL-VH format compared to the VH-
VL. High level expression of both formats of the scFv HyHEL10 were only 
observed after expression of the scFvs in an E. coli cell-free expression 
system that was supplemented with educed and oxidized glutathione, protein 
disulfide isomerase (PDI), and chaperones (Merk et al., 1999).  
 
 
3.3.2 Site-directed mutagenesis of scFv 4B7 framework residues 
 
The work presented in this thesis showed that although reversal of the 4B7 
scFv orientation to a VL-VH format resulted in secretion, antigen binding 
activity could not be determined. Subsequently, sequence alignment the scFv 
4B7 with that of another mAb, isolated from the same hybridoma cell line, 
designated 4B7 (AJ) showed seven differences (4 in FR of VL and 3 in FR of 
VH, Table 3.1) in their amino acid sequences. These amino acid differences 
were only identified in the framework residues (Figure 3.12). Framework 
residues, which form the conserved β-sheet framework of immunoglobulin 
domains, have been known to play a part in maintaining the conformation of 
the CDR loops (Chothia et al., 1992) and in determining the protein structure 
and stability (Chowdhury et al., 1998). Studies have shown that FR residues 
that interact with CDR residues can affect the antigen binding by altering the 
conformation of the CDR loops (Kettleborough et al., 1991; Foote and Winter, 
1992; Lavoie et al., 1992; Xiang et al., 1995). To improve the binding 
characteristics of an antibody two main approaches may be used: CDR 
grafting and directed evolution. The latter approach was chosen and site-
directed mutagenesis was performed at the seven FR positions (VL: Q3E, I5T, 
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L85F, G86V and VH: Q18R, T92A, L114V) to evaluate any influence these 
residues may have on binding activity. The additive rather than the individual 
effects of these residues on secretion and antigen binding was investigated. 
Although substitutions in the CDRs have been shown to enhance affinity, it 
was considered important to maintain their canonical structures and rather 
mutate the framework residues. Replacement of the amino acids, which 
resulted in 4B7(AJ) scFv, did not lead to any dramatic alteration in antigen 
binding. Although both scFv variants were expressed, very little secretion was 
observed for scFv 4B7 compared to 4B7(AJ). With scFv 4B7 induced cells did 
not grow beyond the optical density at which induction was carried out. A 
likely explanation for this observation could be that the scFv 4B7 was toxic to 
the cells, which may lead to leakiness and eventual lysis of the cells. Knappik 
and Pluckthun (1995) identified beneficial framework residues that could affect 
cell physiology (cell growth and leakiness) during experimental analysis of two 
scFv antibodies that were 75% identical in the VL and 78% in the VH. (Knappik 
and Pluckthun, 1995). Based on the findings of Knappik and Pluckthun 
(1995), Forsberg et al. (1997) further showed the importance of the beneficial 
framework residues in preventing periplasmic leakiness, folding and yield of 
expressed protein (Forsberg et al., 1997). However, none of the replacement 
residues were identified as beneficial residues when compared to the studies 
of Knappik and Pluckthun (1995) and Forsberg et al. (1997). 
 
On the other hand, high secretion of the scFv 4B7(AJ) was observed on SDS-
PAGE (Figure 3.11) and Western blot (Figure 3.12). Despite the high level of 
secretion very low antigen binding was observed (Figure 3.17 and 3.18). It is 
not known whether the changes made in the framework residues of the 
mutant 4B7 scFv had any effect on the expression level. However, it has been 
demonstrated that some framework residues play a key role in the CDR 
conformation (Krauss et al., 2004). In the case of Krauss et al. (2004), 
alteration of the VH-71Arg in FR3, considered a key determinant for the CDR-
H1 and CDR-H2 structures, had a tremendous effect on the stability of the 
scFv huHMFG1. deHaard et al. (1999) also observed that the vernier zone 
residue 4 of the murine subgroup II kappa light chain plays a critical role in 
antigen recognition. However, none of the mutated framework residues of 
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scFv 4B7 can be considered as constituents of the ‘Vernier’ zone residues. 
Vernier residues, often located on the borders of the CDRs, comprise 
residues in the β-sheet framework that support the CDR loop structures. 
Although these residues are not in direct contact with the antigen they play an 
important role in fine tuning the antibody-antigen interaction (Foote and 
Winter, 1992).   
 
As previously stated, Pfs25 consists of four epidermal growth factor-like 
domains that contain three putative N-linked glycosylation sites and 22 
cysteine residues that form 11 disulphide bonds. The presence of these 
disulphide bonds presents difficulties during recombinant expression leading 
to production of heterogeneous molecules that lack correctly folded protein 
(Barr et al., 1991; Kaslow and Shiloach, 1994; Stowers et al., 2000; Zou et al., 
2003; Tsuboi et al., 2008). Using wheat germ-cell free extracts Tsuboi et al. 
(2008) produced homogeneous recombinant Pfs25 that reacted with the anti-
Pfs25 conformational dependent antibody 4B7. Pfs25 produced by this means 
was provided for use in ELISA. An oversight of this study was the inability to 
assess the binding of Pfs25. As a positive control the mAb 4B7, purified from 
mouse ascites, should have been used in the initial stages of this study to 
confirm antibody binding to recombinant Pfs25.  
 
 
3.3.3 Assessment of 4B7 scFv-0 and 20 multimer formation 
             
Monovalent binding of scFvs may limit their effectiveness and sensitivity 
during immunological applications such as ELISA. To provide increased 
avidity to target antigens, attention has focused on the design of linkers which 
generate multivalent scFv molecules (Iliades et al., 1997; Kortt et al., 1997). 
To achieve stable multimeric scFv molecules, the linker length joining the 
variable domains is shortened such that domain swapping occurs, in which 
the VH is incapable of interacting with its adjoining VL (Arndt et al., 1998)(Arndt 
et al., 1998). In this study, the different patterns of oligomerisation were 
investigated by constructing 4B7 scFv-0 and scFv-20. Unexpectedly, scFv-0 
and scFv-20 both formed similar patterns of oligomerisation: monomer, dimer 
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and multimer under native conditions (native SDS-PAGE) (Figure 3.12) and 
by size exlusion chromatography (Figure 3.14). This observation contrasts 
previous studies which have shown the predominant species of scFv-0 
antibodies to be trimers and tetramers. The oligomerisation of the scFv-20 
was unexpected based on observations from previous studies (Holliger et al., 
1993; Desplancq et al., 1994; Iliades et al., 1997; Kortt et al., 1997; Atwell et 
al., 1999; Le Gall et al., 1999; Dolezal et al., 2000; Power et al., 2003). This is 
in contrast with the general rule that monovalent forms of a scFv predominate 
when a linker length greater than 12 amino acids is used (Griffiths et al., 1993; 
Kortt et al., 1994; Whitlow et al., 1994). On the other hand, linkers of 3 to 10 
residues result in predominately dimeric forms whereas less than 3 residues 
results in the trimeric forms (Power et al., 2003). Although similar patterns of 
multimeric assembly were observed for 4B7 scFv-0 and scFv-20, the scFv-20 
showed increased expression level (Figure 3.11 A&B). The decrease in level 
of soluble affinity purified protein as the linker length was shortened was 
observed in Dolezal et al. (2000) investigation of the NC10 scFv.  
Desplancq et al. (1994) observed only dimeric and monomeric forms of the 
tumor binding antibody B72.3 scFv-20 (VL-VH). The dimer-monomer formation 
by this antibody was concentration dependent. However, scFvs with less than 
10 amino acids formed mainly dimers and oligomers. Although multimerisation 
results from non-covalent interactions, Desplancq et al. (1994) do not exclude 
the fact that the constraints posed on folding by the shorter linkers may lead to 
exposure of hydrophobic patches that are usually concealed within the 
immunoglobulin domain. In the case of Le Gall et al. (1999) the anti-CD19 
(HD37) scFv-18 in the VH-VL orientation formed monomers, dimers and 
tetramers, whereas the scFv-0 formed trimers. When the anti-neuraminidase 
NC10 antibody was assembled in the scFv format, the scFv-15 (VH-VL or VL-
VH) existed mainly as monomers. However, the NC10 scFv-0 (VL-VH) protein 
consisted of a mixture of tetramer (major component) and trimer (minor 
component) (Kortt et al., 1994; Dolezal et al., 2000). Similar oligomerisation 
patterns have been reported for the anti-sperm antibody, RASA, derived from 
the murine antibody S19 (Norton et al., 2001). The RASA scFv-15 (VH-VL) 
consisted of monomer, dimer and trimers. The RASA scFv recognised the 
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human sperm agglutination antigen on Western blots and in indirect 
immunofluorescence assay.   
 
 
 
3.3.4 Effect of HuCk on 4B7 scFv expression 
 
The low periplasm yield of scFv antibodies have been attributed to 
aggregation prone intermediates of the unfolded polypeptide chain. This 
problem has been addressed by fusion of the scFv polypeptide to carrier 
proteins such as maltose-binding protein, alkaline phosphatase and human 
immunoglobulin-kappa constant domain (HuCk) (Hayhurst, 2000; Palmer et 
al., 2006). This strategy is used as a means to improve the solubility and 
stability of heterologous proteins (Maynard et al., 2000; Maynard et al., 2002). 
To this end, the 4B7 scFv-0 and scFv-20 were fused to the HuCk in this study. 
Investigation of the expressed proteins revealed significant improvement in 
the total amount of protein detected and extracted from the periplasm of the 
scFv-20Hk (Figure 3.16). Enhanced secretion was also observed for a model 
scFv antibody (Appendix). The lower secretion of the scFv-0Hk (Figure 3.15) 
may be attributed to aggregation of the polypeptide within the cytoplasm 
before secretion commences. Aggregation may have occurred as a result of 
the close promixity of the variable domain brought about by the absence of a 
linker. It should be noted that the scFv-HuCk (VL-VH orientation) which 
showed improved expression level is in contrast to that of Hayhurst (2000) 
and McGregor et al. (1994), which are in the VH - VL orientation. This indicates 
that the improved expression, due to HuCk, is independent of scFv 
orientation.  
The positive effects of HuCk on expression have been observed for other 
scFvs (Hayhurst, 2000; Maynard et al., 2002; Palmer et al., 2006) and single-
chain αβ T-receptors (Maynard et al., 2005). However, the authors are of the 
view that the effect is dependent on the primary sequence of the scFv. 
Though speculative, the enhanced secretion by HuCk has been ascribed to 
effects on transcription, translation, mRNA structure and stability. In addition, 
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the HuCk may stabilise the scFv-HuCk fusion protein by shielding the 
hydrophobic residues on the surface of the scFv, thereby allowing a higher 
proportion of the expressed scFv to fold properly (Hayhurst, 2000; Maynard et 
al., 2002; Palmer et al., 2006). According to Hayhurst (2000), HuCk may also 
act as a ribosomal chaperone to prevent translational jamming, a 
consequence of the binding of hydrophobic residues of the scFv to the 
ribosome. Since transcription and translation are tightly coupled in bacteria, 
an increase in the translational activity may prevent the mRNA from 
degradation by exonucleases, resulting in further enhancement of translation 
(Sletta et al., 2007). 
The HuCk domain was added in an effort to increase the affinity, through 
avidity effects, of the 4B7 scFv. This investigation was undertaken as 
McGregor et al. (1994) found that the anti-herbicide atrazine scFv upon fusion 
to the HuCk domain existed in dimeric forms. However, the scFv-0Hk and 
scFv-20Hk both showed monomeric and multimeric forms (Figure 3.15B and 
3.16B) in contrast to the study anti-herbicide atrazine scFv when fused to the 
kappa constant domain (McGregor et al., 1994; Byrne et al., 1996). In this 
study, the higher ordered oligomer could be due to an interaction between the 
variable domains and not the human kappa constant domain. On the other, 
the model scFv protein (Appendix) used in this study formed a monomer and 
dimer consistent with the study of McGregor et al. (1994).  
Though an improvement in the expression level was observed no significant 
increase was observed in the antigen binding capacity of 4B7 scFv-HuCk 
(Figure 3.18) compared to its scFv counterpart (Figure 3.17). The scFv-0 and 
scFv-20 both showed slight antigen binding activity in ELISA. The ELISA 
signal obtained for pSANG10-3F expressed 4B7 (AJ) scFv-0 was slightly 
higher than that of scFv-20. A similar observation was made for scFv-0Hk and 
scFv-20Hk. These differences, based on expression levels, could be due to 
differences in protein concentration of the scFv and not due to avidity effects.  
Despite scFv-0 and scFv-20 showing similar oligomerisation patterns, the 
dimer and higher multimers may be exhibiting monovalent binding properties. 
Le Gall et al. (1999) reported monovalent binding of the anti-CD19 scFv-0 
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triabody. The authors attributed the monovalency to improper folding of the 
triabody which prevented formation of a trivalent molecule.  
In summary, the 4B7 scFvs were easily expressed and secreted into E. coli 
periplasm after extensive bioinformatic analysis, domain swapping and 
application of site-directed mutagenesis. The secreted proteins formed 
monomers, dimers and higher multimeric forms. Fusion to HuCk also 
enhanced the secretion of recombinant protein into the periplasm. However, 
further investigation is required to enhance the affinity of this antibody to its 
target antigen.  
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3.4 Results for expression and characterisation of Pf-NPNA-1 
 
3.4.1 Cloning, expression and purification of (NPNA)9-MKC antigen 
 
The (NPNA)9-MKC (mouse kappa constant) gene sequence was synthesised 
as a pUC-57 insert, excised as NcoI and XhoI fragment and inserted into 
pBAK.1 digested with the same enzymes. The purified and sequenced 
pBAK.1- (NPNA)9-MKC plasmid (Appendix) was transformed into E. coli 
BL21(DE3) cells and expressed as described in Section 2.4.1. The 
recombinant protein was purified from a 200 mL culture induced with 0.3 mM 
IPTG for 3 hours at 37°C using a HiTrap chelating 1  mL column (charged with 
Ni2+) connected to an ÄKTAprime plus purification system (GE Healthcare, 
UK). Bound protein was eluted with 500 mM imidazole. The elution profile of 
the antigen is shown in Figure 3.19. 
 
  
Figure 3.19: Ni-NTA purification of (NPNA)9-MKC antigen. Crude lysate was 
loaded onto a 1 mL nickel resin at a flow rate of 1 mL/min and fractions were 
collected at 1 mL intervals. The blue line shows the absorbance at 280 nm, the green 
line shows addition of elution buffer and the fractions collected are shown in red. 
Peak 1 indicates unbound protein (flow through) and peak 2: bound proteins eluted 
with elution buffer (100 mM NaHPO4, 500 mM NaCl, 500 mM Imidazole, pH 8). 
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The eluted fractions (1, 2, 3, 4) from peak 2 were analysed by SDS-PAGE. 
The predicted molecular weight of 20 kDa for the (NPNA)9-MKC antigen was 
consistent with the protein bands observed on SDS-PAGE (Figure 3.20).   
 
 
 
Figure 3.20: SDS-PAGE analysis of Ni-NTA affinity purified (NPNA)9-MKC 
antigen from pBAK1. 10 µL of each purification fraction was loaded and 
electrophoresed on a 12% gel and stained with Coomassie Brilliant blue R-250. Lane 
1: molecular weight marker; Lane 2: uninduced cell pellets; Lane 3: induced cell 
pellet; Lane 4: crude lysate; Lane 5: Ni column flow through; Lane 6: Ni column wash 
with 10 mM Imidazole; Lanes 7-10: elutions with 500 mM Imidazole. Arrows indicate 
expressed recombinant proteins.     
 
 
Protein concentration was estimated by using a Bradford assay with BSA as 
protein standard. The final protein concentration was estimated as 1.065 
mg/ml. Secretion of the recombinant antigen into the periplasm was observed 
(data not shown).    
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3.4.2 Cloning of Pf-NPNA-1 scFv-12 VH - VL genes into pBAK.1 and 
pSANG10-3F  
 
The Pf-NPNA-1 scFv-12 synthesised as a pUC-19 insert was subcloned into 
pBAK.1 and pSANG10-3F expression plasmids. Transformants were colony 
screened by PCR using T7 promoter and T7 terminator specific primers. 
Plasmids were purified and sequenced (Appendix) to ensure that the insert 
was in-frame.  
           
The expression plasmids pBAK.1 Pf-NPNA-1 scFv-12 and pSANG10-3F Pf-
NPNA-1 scFv-12 were transformed into E. coli BL21 (DE3) pRARE cells. 
Small scale expression in 50 mL LB induced with 0.3 mM IPTG was carried 
out. Periplasmic proteins were isolated and purified by IMAC. The expressed 
protein (cell pellet) and purified fractions were analysed by SDS-PAGE and 
Western blot. The blot was probed with monoclonal anti-His antibody as 
described in section 2.4.10.  
 
                                   
 
Figure 3.21: SDS-PAGE analysis under reducing conditions (A) and Western 
blotting (B) of small scale purification Pf-NPNA-1 VH – VL scFv-12 expressed 
from plasmids pSANG10-3F and pBAK1. 20 µL of each fraction was loaded, 
electrophoresed on a 12% gel and stained with Coomassie Brilliant Blue R-250 (A) 
and a duplicate gel (B) transferred onto PVDF membrane and probed with 
monoclonal anti His-AP labelled antibody. Expressed recombinant proteins are 
indicated by the arrows. Lane 1: molecular weight markers, Lane 2: pSANG10-3F 
induced cell pellet, Lane 3: pSANG10-3F purified periplasmic extract, Lane 4: pBAK1 
induced cell pellet, Lane 5: pBAK1 purified periplasmic extract. 
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The predicted molecular weight of the recombinant Pf-NPNA-1 scFv-12 was 
27.2 kDa (from pBAK.1, Figure 3.21A) and 30.1 kDa (from pSANG10-3F, 
Figure 3.21A). Secretion of the recombinant protein from plasmids, pBAK.1 
and pSANG10-3F, into the periplasmic space was observed on Western blot 
(Figure 3.21B). 
 
 
3.4.3 Cloning of Pf-NPNA-1 scFv-0 VH-VL 
 
A Pf-NPNA-1 scFv-0 (VH-VL) (Appendix) was generated in two PCR steps by 
using Pf-NPNA-1 scFv-12 as template. All PCR products were separated on a 
1.5% agarose gel and gel purified. In the first step, the variable domains were 
amplified with the primers NcoF and PfVHR for VH and PfVLF and NotR for 
VL. The scFv-0 was then assembled by overlap extension PCR using gel 
purified VH and VL with the primers NcoF and NotR. The PCR product was 
gel purified, digested NcoI and NotI and subcloned into the pET-based 
vectors.         
 
The Pf-NPNA-1 scFv-0 and scFv-12 gene inserts in the expression plasmids, 
pBAK.1, pSANG10-3F and pBAK.1Hk, were transformed into E. coli BL21 
(DE) pRARE cells and recombinant protein expression evaluated. Protein 
expression was conducted as described in Section 2.4.2. Recombinant 
proteins isolated from the periplasm were purified in two stages: firstly, on a 
nickel agarose column and secondly by cation exchange chromatography. 
The protein fractions from the two purifications steps were analysed by SDS-
PAGE and Western blot.   
 
The predicted molecular weights of Pf-NPNA-1 scFv-0 (Figure 3.22A) and 
scFv-12 (Figure 3.22B) using plasmid pBAK.1 were estimated to be 27 (pI 
8.64) and 27.7 kDa (pI 8.64), respectively. These were consistent with protein 
bands observed on SDS-PAGE. The level of expression of both scFv-0 and 
scFv-12 as observed on Western blot (Figure 3.23B) were the same; 
however, scFv-12 secretion into the periplasm was higher than that of scFv-0.  
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Figure 3.22: Expression and purification of Pf-NPNA-1 scFv-0 and 12 using 
pBAK.1 plasmid. SDS-PAGE analyses under reducing conditions of Ni-NTA affinity 
purification of scFv-0 (A) and scFv-12 (B) respectively. 20 µL of each purification 
fraction was loaded, electrophoresed on a 12% gel and stained with Coomassie 
Brilliant blue R-250. (A and B) Lane 1: molecular weight marker; Lane 2: uninduced 
cell pellets; Lane 3: induced cell pellet; Lane 4: crude periplasmic fraction; Lane 5: Ni 
column flow through; Lane 6: Ni column wash with 10 mM Imidazole; Lanes 7-9: 
elutions with 500 mM Imidazole. 
 
 
       
 
Figure 3.23: CEC of Pf-NPNA-1 scFv-0 and 12 using pBAK1 plasmid. SDS-
PAGE analyses under reducing conditions of Ni-NTA affinity and CEC purification of 
scFv-0 and scFv-12 (A). (B) Western blot of duplicate gel of (A). 20 µL of each 
purification fraction was loaded and electrophoresed on a 12% gel. Proteins were 
probed with anti-His-HRP antibody. DAB was used as substrate. (A and B) Lane 1: 
molecular weight marker; Lane 2: scFv-0 uninduced cell pellets; Lane 3: scFv-0 
induced cell pellet; Lane 4: IMAC purified scFv-0 (Figure 3.26A, Lane 8); Lane 5: 
CEC purified scFv-0; Lane 6: molecular weight marker; lane 7: scFv-12 uninduced 
cell pellets; Lane 8: scFv-12 induced cell pellet (panel B, Lane 3); Lane 9: IMAC 
purified scFv-12 (Figure 3.26B, Lane 8) Lane 10: CEC purified scFv-12. Arrows 
indicate expressed recombinant proteins.   
 
 
 
Both scFvs were subjected to CEC and purity compared to IMAC purified 
proteins on SDS-PAGE (Figure 3.23A).  However, no proteins were recovered 
from CEC as observed on Western blot (Figure 3.23B). Lane 4 (Figure 3.23B) 
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showed barely detectable levels for periplasmic expression of pBAK.1 Pf-
NPNA-1 scFv-0. However, the IMAC purified protein sample showed binding 
activities in an ELISA (Figure 3.30). Degraded protein of the scFv-12 Pf-
NPNA-1 was also observed (Figure 3.23B, Lane 9).   
 
The molecular weights of Pf-NPNA-1 scFv-0 (Figure 3.24A) and scFv-
12(Figure 3.24B), using pSANG10-3F plasmid, on SDS-PAGE were 
consistent with the estimated values of 29.5 (pI 6.4) and 30.3 kDa (pI 6.4), 
respectively.  
 
       
 
Figure 3.24: Expression and purification of Pf-NPNA-1 scFv-0 and 12 using 
pSANG10-3F plasmid. SDS-PAGE analyses under reducing conditions of Ni-NTA 
affinity purification of scFv-0Hk (A) and scFv-20Hk (B) respectively. 20 µL of each 
purification fraction was loaded, electrophoresed on a 12% gel and stained with 
Coomassie Brilliant blue R-250. (A and B) Lane 1: molecular weight marker; Lane 2: 
uninduced cell pellets; Lane 3: induced cell pellet; Lane 4: crude periplasmic fraction; 
Lane 5: Ni column flow through; Lane 6: Ni column wash with 10 mM Imidazole; 
Lanes 7-9: elutions with 500 mM Imidazole. 
 
 
 
The IMAC purified scFvs were then analysed under reducing and non-
reducing conditions (Figure 3.25). Dimeric and multimeric forms of the scFvs 
were observed. It was more evident in the case of the scFv-12. Further 
confirmation of the multimeric patterns, by gel filtration, could not be carried 
out due to the low amount of protein purified from the periplasm. Functionality 
of the recombinant proteins were analysed in an ELISA (Figure 3.29). 
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Figure 3.25: Western blot of expressed and purified Pf-NPNA-1 scFv-0 and 
scFv-12 using pSANG10-3F under reducing and non-reducing conditions. 20 
µL of each purification fraction was loaded, electrophoresed on a 12% gel at 4°C. 
Proteins were transferred onto PVDF membrane and were probed with rabbit anti-tri 
FLAG antibody as primary antibody and goat anti-rabbit IgG conjugated to alkaline 
phosphatise (AP) as secondary antibody. BCIP/NBT was used as substrate. Lane 1: 
molecular weight marker; Lane 2: IMAC purified scFv-0 under reducing conditions; 
Lane 3: IMAC purified scFv-12 under reducing conditions; Lane 4: IMAC purified 
scFv-0 under non-reducing conditions; Lane 5: IMAC purified scFv-12 under non-
reducing conditions. Arrows indicate expressed recombinant proteins.   
 
 
 
 
 
The Pf-NPNA-1 scFv-0 and scFv-12 were also expressed in the pBAK.1Hk 
plasmid. The molecular weights observed on SDS-PAGE (Figure 3.26 A&B) 
were consistent with the predicted values of 37.5 (pI 8.62) and 38.2 kDa (pI 
8.62) for scFv-0Hk and scFv-12Hk, respectively. The IMAC purified scFv-Hk 
proteins were further purified by CEC based on the pI. CEC purified proteins 
analysed on SDS-PAGE (Figure 3.27A) showed that they co-purified with an 
E. coli protein with an estimated size of 60 kDa and a lower molecular weight 
of about 27 kDa. Both the IMAC and CEC purified proteins were observed as 
doublets. The purified proteins were analysed on a Western blot (Figure 
3.27B) and ELISA (Figure 3.28 and 3.31). Degraded protein, equivalent to the 
molecular weight of a scFv-12, was observed on the western blot (Figure 
3.31, Lanes 9 & 10). This was absent for the scFv-0Hk. 
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Figure 3.26: Expression and purification of Pf-NPNA-1 scFv-0 and 12 using 
pBAK.1Hk plasmid. SDS-PAGE analyses under reducing conditions of Ni-NTA 
affinity purification of scFv-0Hk (A) and scFv-12Hk (B) respectively. 20 µL of each 
purification fraction was loaded, electrophoresed on a 12% gel and stained with 
Coomassie Brilliant blue R-250. (A and B) Lane 1: molecular weight marker; Lane 2: 
uninduced cell pellets; Lane 3: induced cell pellet; Lane 4: crude periplasmic fraction; 
Lane 5: Ni column flow through; Lane 6: Ni column wash with 10 mM Imidazole; 
Lanes 7-9: elutions with 500 mM Imidazole. 
 
 
 
 
 
                                                                
 
Figure 3.27: CEC of Pf-NPNA-1 scFv-0 and 12 using pBAK.1Hk plasmid. SDS-
PAGE analyses of Ni-NTA affinity and CEC purification of scFv-0Hk and scFv-12Hk 
(A). (B) Western blot of duplicate gel of (A). 20 µL of each purification fraction was 
loaded and electrophoresed on a 12% gel. Proteins were probed with anti-His-HRP 
antibody. DAB was used as substrate. (A and B) Lane 1: molecular weight marker; 
Lane 2: scFv-0Hk uninduced cell pellets; Lane 3: scFv-0Hk induced cell pellet; Lane 
4: IMAC purified scFv-0Hk (Figure 3.30A Lane 8); Lane 5: CEC purified scFv-0Hk; 
Lane 6: blank well; lane 7: scFv-12 uninduced cell pellets; Lane 8: scFv-12Hk 
induced cell pellet (panel B, Lane 3); Lane 9: IMAC purified scFv-12Hk (Figure 
3.30B, Lane 8) Lane 10: CEC purified scFv-12. Arrows indicate expressed 
recombinant proteins.   
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3.4.4 ELISA for functional analyses of Pf-NPNA-1 scFv-0 and scFv-12   
 
The binding activities and specificities of the pBAK.1, pSANG10-3F and 
pBAK.1Hk Pf-NPNA-1 scFv-0 and scFv-12 purified proteins to the Ni-NTA 
purified (NPNA)9-MKC antigen and Woodchuck Hepatitis core antigen 
(WHcAg) containing the P. falciparum sporozoite major repeat motif 
[NANPNVDP(NANP)3] peptide antigen were evaluated in ELISA as described 
in Section 2.4.11. Dilutions of the scFv proteins were carried out with 1% BSA 
in PBST (0.1% Tween-20). PBST (0.05% Tween-20) was included in the 
washing steps to prevent non-specific binding. Negative controls were also 
incorporated in the ELISA to further demonstrate the specificity of the Pf-
NPNA-1 scFv-0 and scFv-12 to (NPNA)9-MKC and WHcAg. The negative 
controls were BSA (1% w/v) and 4B7 scFv (scFv-0 and scFv-20 used as 
controls for Pf-NPNA-1 scFv-0 and 12, respectively). 
 
Initial ELISA studies (Figure 3.28) were evaluated with the (NPNA)9-MKC 
antigen using Pf-NPNA-1 scFv-0 and scFv-12 protein samples expressed 
from the vector pBAK.1HK. The scFv-Hk fusion proteins were then probed 
with goat anti-Human kappa light chains (bound and free)−AP antibody since 
both fusion proteins and the antigen bear C-terminal His-tags. The ELISA data 
of Pf-NPNA-1 scFv-0Hk was in agreement with the level of protein expression 
observed on both SDS-PAGE and Western blot. A low signal was detected for 
the scFv-0Hk in comparison to that of scFv-12Hk. The scFv-12Hk, on the 
other hand, showed specificity to the repeat motif on the (NPNA)9-MKC 
antigen. Statistical significance of the ELISA data was calculated with 
GraphPad software using the paired t test. 
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Figure 3.28: Specificity of soluble Pf-NPNA-1 scFv-0 and scFv-12 expressed 
from pBAK.1Hk to (NPNA)9-MKC. Antigen was coated at 1µg per well and bound 
scFv-Hk detected with monoclonal goat anti-Human kappa light chains (bound and 
free) −AP antibody. p-NPP was used as substrate and absorbance measured at 405 
nm. The error bars indicate the standard errors of the means (n = 3). Asterisk 
denotes statistical significance (double asterisk denotes p<0.01; paired t test). Ag: 
codes for Antigen, Ab: for Antibody and Ab (IR): for irrelevant or non-specific 
antibody (4B7 scFv-0 and scFv-20).   
 
 
Subsequently, the pSANG10-3F, pBAK.1 and pBAK.1Hk expressed and 
purified Pf-NPNA-1 scFv-0 and scFv-12 proteins were evaluated in ELISA 
using WHcAg (Figures 3.29, 3.30 and 3.31). Negative controls were set up as 
described for the scFv-Hk ELISA. The negative controls were 4B7 scFv-0 for 
Pf-NPNA-1 scFv-0 and 4B7 scFv-20 for Pf-NPNA-1 scFv-12, respectively. 
The WHcAg + BSA and BSA + Ab controls eliminated non-specific binding of 
BSA to antigen and of Pf-NPNA-1 scFvs to BSA, respectively. Furthermore, 
the absence of a signal in the WHcAg + BSA control wells indicated that the 
WHcAg lacked any terminal His tag. Comparison of the ELISA data for the Pf-
NPNA-1 and 4B7 scFvs showed that the Pf-NPNA-1 scFvs specifically 
recognised the repeat epitiope. The ELISA signals obtained for each antibody 
reflected the level of expression from the vectors pSANG10-3F, pBAK.1 and 
pBAK.1Hk. 
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Figure 3.29: Specificity of soluble Pf-NPNA-1 scFv-0 and scFv-12 expressed 
from pSANG10-3F to WHcAg. Antigen was coated at 100 ng per well and bound 
scFv detected with monoclonal anti-His-AP antibody. p-NPP was used as substrate 
and absorbance measured at 405 nm. The error bars indicate the standard errors of 
the means (n = 3). Asterisk denotes statistical significance (double asterisk denotes 
p<0.01; paired t test). Ag: codes for Antigen, Ab: for Antibody and Ab (IR): for 
irrelevant or non-specific antibody (4B7 scFv-0 and scFv-20).   
 
 
 
Binding of pSANG10-3F Pf-NPNA-1 scFv-0 and scFv-12 to WHcAg were 
considered statistically significant by comparison with the negative controls 
using paired t test. For scFv-0 p-values were: 0.009 compared with 4B7 scFv-
0 and 0.0076 compared with BSA. P-values for scFv-12 were 0.0015 when 
compared with 4B7 scFv-20 and 0.0017 when compared with BSA. These 
values were considered as statistically significant.   
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Figure 3.30: Specificity of soluble Pf-NPNA-1 scFv-0 and scFv-12 expressed 
from pBAK.1 to WHcAg. Antigen was coated at 100 ng per well and bound scFv 
detected with monoclonal anti-His-AP antibody. p-NPP was used as substrate and 
absorbance measured at 405 nm. The error bars indicate the standard errors of the 
means (n = 3). Asterisk denotes statistical significance (double asterisk denotes 
p<0.01 and triple asterisk denotes p<0.001; paired t test). Ag: codes for Antigen, Ab: 
for Antibody and Ab (IR): for irrelevant or non-specific antibody (4B7 scFv-0 and 
scFv-20).  
 
 
 
The pBAK.1 expressed Pf-NPNA-1 scFv-0 and scFv-12 showed specificity to 
WHcAg. Statistical significance was as described above. For scFv-0 p-values 
were: 0.0008 compared with 4B7 scFv-0 and 0.0007 compared with BSA. P-
values for scFv-12 were 0.0076 when compared with 4B7 scFv-20 and 0.0056 
when compared with BSA. These values were considered as statistically 
significant.   
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Figure 3.31: Specificity of soluble Pf-NPNA-1 scFv-0 and scFv-12 expressed 
from pBAK.1Hk to WHcAg. Antigen was coated at 100 ng per well and bound scFv 
detected with monoclonal anti-His-AP antibody. p-NPP was used as substrate and 
absorbance measured at 405 nm. The error bars indicate the standard errors of the 
means (n = 3). Asterisk denotes statistical significance (single asterisk denotes 
p<0.05, and a double asterisk denotes p<0.01; paired t test). Ag: codes for Antigen, 
Ab: for Antibody and Ab (IR): for irrelevant or non-specific antibody (4B7 scFv-0 and 
scFv-20).   
 
 
Evaluation of scFv-0Hk and scFv-12Hk samples, previously analysed (Figure 
3.28) with the (NPNA)9-MKC antigen, showed superior binding activities with 
WHcAg (Figure 3.31). The higher ELISA signals obtained with WHcAg may be 
due to the number of NPNA repeats displayed by the viral component of the 
antigen. Binding to WHcAg was determined as statistically significant. The p 
values for scFv-0Hk were 0.0131 compared with 4B7 scFv-0Hk and 0.0103 
compared with BSA. For scFv-12Hk the p-values were 0.0049 compared with 
4B7 scFv-20Hk and 0.0044 when compared with BSA.      
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3.4.5 Indirect Immunofluorescence Assay (IFA) on P. falciparum 
sporozoites 
 
The specificity of the Pf-NPNA-1 scFvs was demonstrated in an IFA using 
pBAK.1 Pf-NPNA-1 expressed scFv-0 and scFv-12. These protein samples 
were used based on an earlier observation, during this study, that some anti-
His-tag antibodies recognise only C-terminal His-tag (data not shown). 
Although the pSANG10-3F expressed scFvs showed better binding, the 
protein samples could not be used in the IFA due to an internal His-tag 
(adjacent to the C-terminal tri-FLAG). The IFA revealed the needle-like 
structure of the sporozoites but were of variable shapes and sizes. As shown 
in the figure below, the scFv antibodies (positive controls) reacted with the 
entire surface membrane of the parasite, which is in agreement with the 
predominance of CSP on sporozoites. Although DAPI stain was added during 
the incubation step, nuclei staining of the sporozoites were not seen. No 
surface labelling was observed for the negative controls. 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32: Indirect Immunofluorescence Assay (IFA) of pBAK.1 expressed Pf-
NPNA-1 scFv-0 (A) and scFv-12 (C) on P. falciparum sporozoites. B and D are 
negative controls for scFv-0 and scFv-12, respectively. Fixed sporozoites were 
incubated with the affinity purified scFv and stained with polyclonal anti-His FITC 
conjugated antibody (Green). The parasites were visualized by fluorescence 
microscopy with a Zeiss Axioskop fluorescent microscope equipped with a 100X oil 
immersion objective. Scale bars, 10 µm. 
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3.5 Discussion on expression and characterisation of Pf-NPNA-1  
 
This section of the thesis looked at the expression and functional analysis of 
the Pf-NPNA-1 antibody. The anti-PfCS protein repeat antibody, Pf-NPNA-1, 
previously isolated by repertoire cloning from individuals immunised by the 
bites of irradiated Anopheles mosquitoes, was constructed with a 27 amino 
acid linker between the VH and VL (Chappel et al., 2004b). Other sporozoite 
antibodies as such as, N2H6D5 scFv, expressed via a Sindbis virus which 
efficiently blocked sporozoite entry of the salivary glands in the avian malaria 
model encoded a 15 amino acid linker (de Lara Capurro et al., 2000). In the 
case of 13.1 scFv, the VH and VL were joined by a 20 linker peptide (Yoshida 
et al., 2001). These scFvs encoded by such long linkers would favour only 
monomeric assembly (Holliger et al., 1993). To facilitate multimeric assembly, 
two variants, scFv-0 and scFv-12, of the Pf-NPNA-1 antibody were 
constructed in the VH-VL orientation and expressed in the pET-based 
(pBAK.1, pSANG10-3F and pBAK.1Hk) expression vectors. There was no 
need to construct the scFvs in the reverse orientation (as in the case of the 
4B7 scFvs) as initial studies with the Pf-NPNA-1 scFv-12 (Figure 3.21) 
showed expression and secretion into the periplasm.  
 
The level of expression of the Pf-NPNA-1 scFv-0 was lower than that of scFv-
12 when expressed from the vectors pBAK.1 (Figure 3.22 A&B) and 
pBAK.1Hk (Figure 3.24 A&B). These observations are in agreement with the 
lower expression levels of the 4B7 scFv-0 (Figure 3.11A and Figure 3.15A) 
when compared to those of scFv-20 (Figure 3.11B and Figure 3.16 A).  Since 
scFv with no linkers are noted for their spontaneous assembly into higher 
oligomers (triabody), it is not known whether this phenomenon takes place 
before disulphide bond formation occurs. If multimeric assembly preceeds 
disulfide bond formation, it is very likely that the polypeptides with exposed 
hydrophobic surfaces may aggregate in the periplasm. This may explain the 
low levels of soluble scFv-0 isolated from the periplasm in contrast to high 
levels of proteins that were retained within the cytoplasm. The over-
expression of scFv in the cytoplasm could be attributed to the strong T7 
promoter used. This may lead to lower processing efficiency of the bacterial 
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secretory machine. Eventually, clogging of the machinery may occur, 
preventing translocation of the recombinant scFv into the periplasm. It has 
been explained in a number of reviews that polypeptide to be secreted into 
the periplasm by the general secretory are initially expressed in an unfolded 
state. Hence, those polypeptides not transported quickly would aggregate due 
to interaction between its exposed hydrophobic surfaces. Due to the high level 
of protein retained within the cytoplasm, purification under denaturating 
conditions was considered and subsequently undertaken. Although, this 
strategy resulted in the isolation and purification of active proteins, it was 
found to be cumbersome and complicated.  
 
In the study by Chappel et al. (2004b), the specificity of the monovalent scFv-
27 was evaluated against three antigens containing the NPNA repeats. In this 
study, the binding activities of the Pf-NPNA-1 scFv-0 and scFv-12 were 
evaluated using two antigens: (NPNA)9-MKC and WHcAg.  The scFv-0Hk and 
scFv-12Hk binding to (NPNA)9-MKC were first evaluated. Since both antigen 
and scFvs bear C-terminal His tags an anti-human kappa antibody was used 
to detect the scFvs. Analysis of fine specificity revealed weak binding to 
(NPNA)9-MKC (Figure 3.28) in contrast to the strong binding to WHcAg 
(Figure 3.31). Although the Pf-NAPN-1 scFv-12Hk was functional, the scFv-
0Hk did not have any antigen binding activity despite being detected on 
Western blot. Lack of scFv-0Hk binding may be attributed to incorrect folding 
of its polypeptide chains. The very high binding observed for the scFv-12Hk 
with the WHcAg, in contrast to the (NPNA)9-MKC, is probably due to the viral 
nature of the antigen. This viral antigen is capable of displaying an array of the 
repeat epitope, thus allowing a higher number of scFv antibody binding and 
retention.  
 
The fine specificity of the recombinant Pf-NPNA-1 scFv-0 and scFv-12 
proteins expressed from pBAK.1 (Figure 3.30) and pSANG10-3F (Figure 3.29) 
(Martin et al., 2006) were evaluated in an ELISA with WHc antigen. The CSP 
repeats on this antigen are displayed on a viral particle (Billaud et al., 2005). 
This antigen lacks a C-terminal His tag, thus soluble scFvs were detected with 
an anti-His tag antibody. The low signals of scFv-0 (2.5 fold higher in 
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pSANG10-3F compared to pBAK.1; Figure 3.29 and 3.30) and of scFv-12 (1.7 
fold higher in pSANG10-3F compared to pBAK.1; Figure 3.29 and 3.30) reflect 
the level of expression and secretion in these vectors. It can be surmised that 
secretion of the scFvs into the periplasm was more efficient with the 
pSANG10-3F vector although both plasmids encode a pelB SP (Erwinia 
carotovora origin) for translocation of the scFvs into the periplasm. 
Bioinformatic analysis of the nucleotide sequences of the pelB SP from both 
vectors showed differences at the mRNA level but not at the protein level 
(Figure 3.33). By introducing point mutations into the pelB coding sequence 
and possibly reducing stability of mRNA secondary structure, LeCalvez and 
colleagues showed desirable improvement in expression and secretion of 
alkaline phosphatase (Le Calvez et al., 1996). The differences observed in the 
secretion of this protein were attributed to variable translational efficiencies. In 
light of these observations, the variations in expression levels from both 
plasmids may probably be due to nucleotide differences in the signal peptides.   
 
A 
pelB (pSANG103F)                  
AUGAAAUACCUGCUGCCGACCGCUGCUGCUGGUCUGCUGCUCCUCGCUGCCCAGCCGGCG  
 
pelB (pBAK.1)            
AUGAAAUACCUAUUGCCUACGGCAGCCGCUGGAUUGUUAUUACUCGCGGCCCAGCCGGCC  
***********  **** ** ** ** *****  ** *  * ***** ***********  
 
B 
pelB (pSANG103F)      MKYLLPTAAAGLLLLAAQPA 
pelB (pBAK1)          MKYLLPTAAAGLLLLAAQPA 
                      ******************** 
 
Figure 3.33: Sequence alignment of the pelB signal sequence from pSANG10-
3F (derived from pET26+ vector) and pBAK.1 (derived from pIT2 vector). A: 
mRNA sequences (5’→3’) of pelB and ompA. B: Amino acid sequences. Identical 
nucleotides and residues are indicated with asterisks. 
 
 
The Shine Dalgarno (Scott et al., 2000) sequence, the choice of start codon 
(SC), number of nucleotides between the SD and SC, as well the region 
downstream of the SC have been suggested to be the determinants that 
influence translation initiation (Ringquist et al., 1992). Since all three plasmids 
have the same SD (AAGGAG) and SC (AUG), the subtle differences in the 
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expression level could also be attributed to the distance between their SD and 
SC. The optimal spacing between the SD and the SC required for translation 
initiation varies from 5 to 13 nucleotides with an optimum of 8 to 10 
nucleotides (Ringquist et al., 1992; Chen et al., 1994). This spacing is also 
dependent on the bases at the 3’ end of 16S rRNA that take part in the 
interaction (Chen et al., 1994). However, Scherer and colleagues suggested 
an optimum of 5 nucleotides in natural E. coli mRNA with the SD sequence 
UAAGGAGGU (Scherer et al., 1980). The pBAK.1 and pSANG10-3F have 9 
and 8 nucleotides, respectively between the SD and SC. Since secretion was 
higher for pSANG10-3F it is presumed that translation initiation may be more 
efficient in this vector. These observations agree well with the study of deBoer 
and colleagues who showed a 40% decrease in the translation efficiency of a 
chimeric leukocyte interferon when the aligned spacing between the SD and 
SC was increased from 4 to 8 or 13 nucleotides (de Boer et al., 1983) and in 
the case of the recombinant growth hormone (Dalboge et al., 1988).  
 
Further to the fine specificity shown in ELISA, the Pf-NPNA-1 recombinant 
proteins were also evaluated for binding to P. falciparum sporozoites in an 
IFA. Although the pSANG-10 3F expressed proteins showed a strong signal in 
ELISA, these were not used for the IFA as it was previously determined that 
C-terminal anti-His tag antibodies, purchased from AbCam, did not detect 
proteins with an internal His-tag (data not shown). However, the pBAK.1 
expressed proteins, which bear a C-terminal His-tag, labelled the entire 
surface of P. falciparum sporozoites when used in the IFA (Figure 3.32). 
These observations are in agreement with those of Chappel et al. (2004b). 
Sporozoites did not fluoresce when BSA was used as negative control. An 
appropriate positive control would have been the murine monoclonal anti-
falciparum repeat antibody 2A10 (Zavala et al., 1985b). A limitation of this 
study was the inability to detect the characteristic sky-blue fluorescence 
staining of the sporozoite nuclei when stained with DAPI.  
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Expression of scFv 4B7 and Pf-NPNA-1  
in Asaia sp. 
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4.0 The genus Asaia 
 
4.1 Introduction  
 
Presently, the genus is made of five species: Asaia bogorensis (Yamada et 
al., 2000), Asaia siamensis (Katsura et al., 2001) Asaia krungthepensis 
(Yukphan et al., 2004), Asaia lannaensis (Malimas et al., 2008) and Asaia 
spathodeae  (Kommanee et al., 2010). They are obligate aerobes belonging 
to the family acetobacteraceae and phylum α-proteobacterium. Strains 
belonging to the genus Asaia have mostly been isolated from tropical flowers, 
which is a source of nectar for insects such as mosquitoes. Asaia species are 
capable of tolerating acidic conditions growing at pH values lower than 5 (pH 
3.5). Phenotypically Asaia species, with the exception of Asaia lannaensis, 
exhibit no oxidation or very weak oxidation of ethanol to acetic acid as they 
lack membrane-bound NAD-dependent alcohol dehydrogenase (Ano et al., 
2008). All four species, however, do not grow on 0.35% acetic acid. These 
properties differentiate them from other acetic acid bacteria (AAB) such as 
Acetobacter and Gluconobacter (Yamada and Yukphan, 2008). The 
confirmation of the presence of NADP-dependent dehydrogenase activity for 
D-glucose and a quinoprotein glycerol dehydrogenase in As. bogorensis 
further substantiated their capability to oxidise sugars (D-glucose, D-Fructose 
and sucrose) and sugar alcohols (glycerol, mannitol and sorbitol) to produce 
acid (Ano et al., 2008).  
 
Recently Favia et al. (2007) identified an acetic acid bacterium from the 
midgut of A. stephensi. Based on 16S rRNA gene sequences, the isolated 
bacterium was identical to Asaia bogorensis (99.6%) and Asaia siamensis 
(99.8%) (Favia et al., 2007). More recently, Asaia krungthepensis has also 
been isolated from other mosquito species (Chouaia et al., 2010). Asaia sp. 
SF2.1 satisfies the prerequisites for any bacterial candidate to be considered 
for inclusion in a paratransgenic approach. Firstly, Asaia can easily be 
isolated and cultured in cell-free media and is present in high prevalence in 
mosquitoes. The ease of cultivation in the laboratory has facilitated its genetic 
manipulation, an important criterion for symbiotic control, to express a 
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recombinant GFP. Thirdly, the recombinant Asaia expressing GFP, when fed 
to mosquitoes, colonised the midgut, salivary glands and reproductive organs 
of male and female adult mosquitoes (Favia et al., 2007; Damiani et al., 2008; 
Crotti et al., 2009; Damiani et al., 2010). More recently, Chouaia et al. (2010) 
found that different strains (up to five) of Asaia can simultaneously associate 
with a single mosquito. This led them to suggest that multiple infections can 
occur during the life span of the mosquito. The authors are also of the view 
that Asaia, the leading bacterial candidate for use in paratransgenesis, does 
not exert any pathogenic effect on the host mosquito. Fourthly, fluorescently 
tagged strains have exhibited diversed modes of transmission: vertically to 
progeny via egg smearing and horizontally through feeding (Favia et al., 2007) 
and paternally by venereal transfer from male to female (Damiani et al. 2008). 
It has been suggested that these different routes of transmission could offer 
alternative ways to release engineered bacteria into mosquito populations in 
the field (Ricci et al., 2011). Lastly, Asaia is capable of colonising insects of 
diverse genera and order (Crotti et al., 2009; Crotti et al., 2010). More 
importantly, Asaia has been found in association with the malaria mosquito 
vectors An. stephensi (Favia et al., 2007), An. gambiae (Damiani et al., 2010), 
An. maculipennis, the virus vector Aedes aegypti (Crotti et al., 2009) and 
Aedes albopictus (Chouaia et al., 2010). These studies provide proof of 
principle that this bacterium can be used for symbiont contol, that is, to 
express anti-parasite molecules within the mosquito to disrupt parasite 
development. 
 
Although, transformation of Asaia sp. has been been carried out and shown to 
express GFP, heterologous expression of disulphide containing proteins, such 
as scFv, has not been investigated. On the other hand, the E. coli lacZ 
(encoding β-galactosidase) and lacY (β-galactosidase permease) genes have 
been cloned into a shuttle vector and functionally expressed in two 
phylogenetically related strains of Asaia, Gluconobacter oxydans and 
Acetobacter liquefaciens (Mostafa et al., 2002). Subsequently, El-mezawy et 
al. (2005) showed functional activity of an extracellularly expressed β-
galactosidase gene of Bifidobacterium infants in G. oxydans with the plasmid 
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pBINF1 (El-mezawy et al., 2005). In this section of the thesis, recombinant 
Asaia will be assessed for expression of the scFvs 4B7 and Pf-NPNA-1. 
 
4.2 Assessment of antibiotic resistance 
Wild type Asaia SF2.1 was streaked on a range of GLY agar kanamycin 
plates and growth monitored after two days. Growth was observed at 
kanamycin concentrations of 25 – 150 µg/mL. No growth was observed at 200 
µg/mL. Subsequently, recombinant Asaia SF2.1 was grown at kanamycin 
concentration of 200 µg/mL. 
 
Figure 4.1: Assessment of kanamycin resistance of Asaia SF2.1. Asaia SF2.1 
was streaked on GLY plates supplemented with varying concentrations of kanamycin 
(25 – 200 µg/mL). Growth was observed on GLY with kanamycin concentrations of 
25 µg/mL (A), 50 µg/mL (B) and 100 µg/mL (C). No growth was observed at 200 
µg/mL (D). E shows the characteristic pink colour of colonies of Asaia SF2.1 after 
days of storage in the frigde.  
  
Antibiotic susceptibility of Asaia SF2.1 to other antibiotics was also 
investigated. Asaia was resistant to the antibiotics ampicillin, chloramphenicol 
and streptomycin at concentrations as high as 200 µg/mL.  
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4.3 Expression of recombinant proteins in Asaia SF2.1 
The broad-host range vector pMAK031 2P (Figure 4.2) was used for 
transformation of Asaia SF2.1. The plasmid was constructed using pHM2 
vector (Mostafa et al., 2002) as the parental plasmid. This plasmid differs from 
pHM2 (8.86 kb), in that the lacZ and lacY genes were replaced with a GFP 
cassette, a gram negative (ORI) and gram positive (OriR) bacterial origin from 
the plasmid pRR1.1. The nptII kanamycin promoter (PnptII) allows constitutive 
expression of recombinant proteins. The plasmid also has a C-terminal His-
tag and Tri-FLAG for purification and detection. It bears the NcoI, NdeI and 
NotI for directional cloning of recombinant protein genes.  
 
Figure 4.2: Vector map of plasmid pMAK031 2P with a GFP gene. ORI: origin of 
replication for gram-negative bacteria; OriR: origin of replication for gram-positive 
bacteria; mobilProt: mobilisation protein; PnptII: constitutive kanamycin (neomycin) 
phosphotransferase promoter; Trrn terminator: rrnB rRNA T1 transcriptional 
terminator; kanamycin: kanamycin resistance gene. Restriction sites (NcoI, NotI, 
NdeI) for cloning of scFv genes are coloured red. The 6X His and Tri-FLAG tags are 
shown.  
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The functionality of the pMAK031 2P plasmid was assessed by cloning a GFP 
gene into the NdeI and NotI and the resulting construct used to transform both 
gram negative (E. coli and Asaia SF2.1) and gram positive (R. rhodnii and R. 
cornyebacterioides) bacteria. Recombinant GFP expression was observed in 
both gram negative (Figure 4.3) and gram positive bacteria (data not shown). 
 
Figure 4.3: Fluorescence images of E. coli (A) and Asaia sp SF2.1 (B) 
transformed with pMAK031(2P)-GFP. A single colony of E. coli and Asaia sp SF2.1 
were mounted on a glass slide using 20% glycerol in PBS and a coverslip. The 
fluorescent bacteria were visualized by fluorescence microscopy with a Zeiss 
Axioskop fluorescent microscope equipped with a 100X oil immersion objective.  
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4.3.2 Carbon utilisation of Asaia 
Glycerol and glucose were used to evaluate the capability of Asaia to grow on 
different carbon sources. The glucose medium (LB-Glu) consisted of LB broth 
(pH 7.0) supplemented with 2% (v/v) glucose whereas glycerol formed the 
carbon component of GLY medium (pH 5.5). The growth of Asaia SF2.1 was 
examined in 100 ml of each medium in a 500-ml Erlenmyer flask at 30°C with 
rotary shaking at 200 rpm. After 48 hours of growth the final pH in both media 
was ~4.6. As shown in Figure 4.4 growth of Asaia in GLY was higher 
compared to LB-Glu. GLY was subsequently used for recombinant expression 
of scFvs in Asaia.      
 
Figure 4.4: Growth profile of pMAK031 2P 4B7 scFv-0 transformed Asaia sp 
SF1 on different carbon sources. GLY (25 g/L glycerol, 10 g/L yeast extract, pH 5); 
LB + Glu (LB medium supplemented with 2% v/v glucose). Optical density 
measurements were taken over 48 hours. Mean values from two independent 
cultures are shown. 
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4.3.3 Cloning of 4B7 and Pf-NPNA-1 scFvs into pMAK031 2P 
 
The pMAK031 2P-GFP was digested NdeI/NotI to facilitate cloning of the scFv 
genes. 
 
Figure 4.5: Restriction enzyme digestion of pMAK031 2P-GFP. 50 µL of the 
digested reaction was loaded and subjected to electrophoresis on a 1.5% agarose at 
100 V for 1 hour. The DNA was visualised using ethidium bromide under UV light at 
wavelength of 200 nm. The digested plasmid (~5.8kb) was excised and agarose gel 
purified. Lane 1: 1 kb DNA ladder, Lane 2: NdeI/NotI digested pMAK031 2P-GFP. 
 
The Pf-NPNA-1 (scFv-0 and 12) and 4B7AJ (scFv-0 and 20) were digested 
from pSANG10-3F and subcloned into the NdeI/NotI digested pMAK031 2P 
plasmid (Figure 4.5). During this cloning step the pelB signal peptide, from the 
pSANG10-3F vector, was cloned along with the scFvs. E. coli transformants 
were screened by colony PCR with primers T7ABATG (GC AGC TAA TAC 
GAC TCA CTA TAG GAA CAG ACC ACC ATG GCC) and PfVLR (TTT AAT 
TCC ACT TTG GTG CCG CCG CC) for Pf-NPNA-1 scFvs and 4B7VLNco 
and 4B7VHNot for 4B7AJ scFvs, respectively. Plasmids were then purified 
from positive clones, sequenced (Appendix) and used to transform Asaia.  
 
Subsequently, constitutive expression in Asaia of each scFv was then 
evaluated in small scale cultures over three days, to detetmine optimal 
expression time. Constitutive expression was observed in 48 and 72 hours 
with optimal expression seen by day 2 (48 hours) for all scFvs (Figure 4.6). 
Protease degradation of the 4B7 scFv-20 was observed on a western blot 
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during this investigation. As a result, further characterisation of this construct 
was not assessed. Subsequently, recombinant expressions of the scFvs were 
carried out over 2 days.  
 
Figure 4.6: Impact of production time on expression scFv in small scale culture 
of Asaia. Aliquots (1 mL) of Asaia culture were collected at days 2 and 3 and 
centrifuged. Cell pellets were separated by reducing SDS-PAGE on a 12% gel and 
transferred onto PVDF membranes. Lane 1: molecular weight marker; lane 2: Asaia 
expressed 4B7 scFv-0 under reducing conditions (day 2) and lane 3: Asaia 
expressed 4B7 scFv-0 under reducing conditions (day 3). Proteins were probed with 
goat anti-tri FLAG antibody as primary antibody and mouse anti-rabbit IgG 
conjugated to alkaline phosphatise (AP) as secondary antibody. BCIP/NBT was used 
as substrate. 
 
The 4B7 (AJ) scFv-0, Pf-NPNA-1 scFv-0 and scFv-12 were expressed and 
purified from 200 mL of GLY medium. The constitutively expressed 4B7 scFv-
0 in Asaia was compared to that expressed in E. coli. Under reducing 
conditions, the molecular weight of the purified 4B7 scFv-0 was comparable in 
both expression systems (Figure 4.7B, Lanes 2 and 3). However, different 
multimeric patterns of the scFv-0 were observed under non-reducing 
conditions (Figure 4.7B, Lanes 4 and 5). The multimeric assembly (monomer, 
dimer and higher multimer) of the E. coli expressed scFv-0 was consitent with 
previous result (Figure 3.14). The Asaia expressed scFv-0 showed monomer 
and dimer formation under non-reducing conditions (Figure 4.7B, Lane 4).   
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Figure 4.7: Purification of 4B7 scFv-0 on a 1 mL Ni2+ column (A) and Western 
blot of E. coli and Asaia sp. SF1 expressed and purified 4B7(AJ) scFv-0 under 
reducing and non-reducing conditions. (A) Crude lysate was loaded onto a 1 mL 
nickel resin at a flow rate of 1 mL/min and fractions were collected at 1 mL intervals. 
The blue line shows the absorbance at 280 nm, the green line shows addition of 
elution buffer and the fractions collected are shown in red. Peak 1 indicates unbound 
protein (flow through) and peak 2: bound proteins eluted with elution buffer (100 mM 
NaHPO4, 500 mM NaCl, 500 mM Imidazole, pH 8). (B) Lane 1: molecular weight 
marker; lane 2: Asaia expressed 4B7 scFv-0 under reducing conditions; lane 3: E. 
coli expressed 4B7 scFv-0 under reducing conditions; lane 4: Asaia expressed 4B7 
scFv-0 under non-reducing conditions and lane 5: E. coli expressed 4B7 scFv-0 
under non-reducing conditions. Proteins were probed with goat anti-tri FLAG 
antibody as primary antibody and mouse anti-rabbit IgG conjugated to alkaline 
phosphatise (AP) as secondary antibody. BCIP/NBT was used as substrate. 
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The Pf-NPNA-1 scFv-0 and scFv-12 were also expressed in Asaia, purified 
and characterised. The chromatogram generated during purification and 
analyses of the purified scFv-0 and 12 on SDS-PAGE are shown in Figure 4.8 
and 4.9, respectively. 
  
 
Figure 4.8: Purification of Pf-NPNA-1 scFv-0 on a 1 mL Ni2+ column (A) and 
SDS-PAGE of purified proteins under reducing conditions (B).  (A) Crude lysate 
was loaded onto a 1 mL nickel resin at a flow rate of 1 mL/min and fractions were 
collected at 1 mL intervals. The blue line shows the absorbance at 280 nm, the green 
line shows addition of elution buffer and the fractions collected are shown in red. 
Peak 1 indicates unbound protein (flow through) and peak 2: bound proteins eluted 
with elution buffer (100 mM NaHPO4, 500 mM NaCl, 500 mM Imidazole, pH 8). (B) 
20µL of proteins fractions were electrophoresed on a 12% gel and stained with 
Coomassie brilliant blue R-250. Lane1: molecular weight maker; Lane 2: 
untransformed Asaia; Lane 3: transformed Asaia; Lane 4: crude lysate; Lane 5: flow 
through; Lane 6: wash; Lanes 7 - 9: elutions 1-3.  
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Figure 4.9: Purification of Pf-NPNA-1 scFv-12 on a 1 mL Ni2+ column (A) and 
SDS-PAGE of purified proteins under reducing conditions (B). (A) Crude lysate 
was loaded onto a 1 mL nickel resin at a flow rate of 1 mL/min and fractions were 
collected at 1 mL intervals. The blue line shows the absorbance at 280 nm, the green 
line shows addition of elution buffer and the fractions collected are shown in red. 
Peak 1 indicates unbound protein (flow through) and peak 2: bound proteins eluted 
with elution buffer (100 mM NaHPO4, 500 mM NaCl, 500 mM Imidazole, pH 8). (B) 
Proteins were electrophoresed on a 12% gel and stained with Coomassie brilliant 
blue R-250. Lane1: molecular weight maker; Lane 2: untransformed Asaia; Lane 3: 
transformed Asaia; Lane 4: crude lysate; Lane 5: flow through; Lane 6: wash; Lanes 
7 - 9: elutions 1-3.  
 
The peak fractions 2 (Lane 8 in Figures 4.8B and 4.9B) were run under 
reducing conditions, transferred onto PVDF membrane and probed with rabbit 
anti-tri FLAG antibody and goat anti-rabbit IgG-AP. The predicted molecular 
weight of the Asaia purified Pf-NPNA-1 scFv-0 (28.8 kDa) and scFv-12 (30.1 
kDa) were consistent with those on the Western blot. A twin-arginine 
translocation (TAT) signal peptide was cloned from the CA19.9 scFv (donated 
by Dr. Anatoliy Markiv, UoW) and its expression analysed alongside that of 
pelB-Sec dependant signal peptide. Both signal peptides were efficiently 
processed in Asaia resulting in similar molecular weights of Pf-NPNA-1 scFv-0 
and 12 (Figure 4.10).   
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Figure 4.10: Western blot of purified Pf-NPNA-1 scFv-0 and 12 from Asaia sp. 
SF.1 with different signal peptides. Lane 1: molecular weight marker, lanes 2 and 
3: Pf-NPNA-1 scFv-0 expressed with pelB and TAT signal peptides, respectively; 
lanes 4 and 5: Pf-NPNA-1 scFv-12 expressed with pelB and TAT signal peptides. 
Proteins were probed with rabbit anti-tri FLAG antibody as primary antibody and goat 
anti-rabbit IgG conjugated to alkaline phosphatise (AP) as secondary antibody. 
BCIP/NBT was used as substrate.   
 
Binding of the constitutively expressed Pf-NPNA-1 scFv-0 and scFv-12 were 
evaluated in an ELISA (Figure 4.11) with WHcAg as antigen. The ELISA 
signals are lower than those obtained in chapter 3 (Figure 3.29 and 3.30).  
 
Figure 4.11: Specificity evaluation of Pf-NPNA-1 pMAK031 2P expressed scFv-0 
and scFv-12 to WHcAg. Antigen was coated at 100ng per well and bound scFv 
detected with a rabbit anti-tri FLAG antibody (primary antibody) and mouse anti-
rabbit IgG-AP (secondary antibody). BSA was used as a negative control. p-NPP 
was used as substrate and absorbance measured at 405 nm. The error bars indicate 
the standard errors of the means (n = 3). Double asterisk denotes p<0.01. 
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4.4 Discussion on recombinant expression of scFvs in Asaia SF2.1 
Recombinant expression of scFv 4B7 and Pf-NPNA-1 in Asaia, described in 
this chapter and the first of its kind, has shown that Asaia SF2.1 has the 
capacity to express disulphide containing proteins. Initial stages of the study 
examined the antibiotic susceptibility and resistance of Asaia to some 
commonly used antibiotics. Asaia was resistant to the antibiotics ampicillin, 
chloramphenicol, streptomycin and tetracycline. Susceptibility to kanamycin 
was only observed at a high concentration of 200 µg/mL. This is in contrast to 
the concentration of kanamycin (100 µg/mL) used by Favia et al. (2007). 
These observations, during the susceptibility and resistant studies, are in 
agreement with previous observations (Katsura et al., 2001; Yukphan et al., 
2004; Malimas et al., 2008; and Kommanee et al., 2010). The natural habitiat 
of Asaia is tropical flowers and fruits of south-east Asia. As a ubiquitous 
bacterium in the environment, Asaia could have acquired its antibiotic 
resistance through promiscuous exchange and shuffling of genes, genetic 
platforms and genetic vectors among other environmental bacteria isolates 
(Baquero et al., 2008). 
For the expression studies, two carbon sources (glucose and glycerol) were 
evaluated to study the growth kinetics of Asaia. Asaia has the capacity to 
oxidise both sugars and sugar alcohols. The overall growth of Asaia on both 
carbon sources was similar during the exponential phase, however, the final 
bacterial cell densities at the stationary phase was higher for glycerol 
compared to glucose. This indicates that glucose is quickly utilised during 
bacterial growth whereas glycerol may provide a steady source of carbon.    
After cultivation the final pH of both culture media was 4.6, which is similar to 
that observed by Ano et al. (2008). Yamada et al. (2002) have indicated that 
Asaia has the ability to produce acid from glucose and glycerol. In other AAB, 
the oxidation of D-glucose to D-gluconic acid and 2- or 5-keto-D-gluconic acid, 
are catalysed by the membrane-bound D-glucose dehydrogenase and 2-keto-
D-gluconate dehydrogenase. On the other hand, oxidation of glycerol to 
dihydroxyacetone is catalysed by glycerol dehydrogenase. The confirmation 
of the presence of NADP-dependent dehydrogenase activity for D-glucose 
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and a quinoprotein glycerol dehydrogenase in As. bogorensis further 
substantiated their versatility to oxidise sugars and sugar alcohols to produce 
acid (Ano et al., 2008).  
The optimum expression time of 48 hours was chosen based on the fact that 
Asaia SF2.1 is a slow growing bacterium, with an estimated doubling time of 2 
hours (Crotti et al., 2009) and on the observations made in this study during 
the small scale expression studies. This slow growth rate was evident during 
transformational and growth curve studies (Figure 4.4). During the 
transformational studies, Asaia transformants could only be observed after 48 
hours of incubation at 30°C. In addition, growth in  GLY medium showed a 
higher cell density beyond 24 hours. An important consideration during 
heterlogous expression is the translation of rare codons, as gram negative 
bacteria exhibit differential codon usage. In the case of Asaia, the fact that 
recombinant GFP (previously expressed in numerous E. coli strains) could be 
expressed (Favia et al., 2007) indicated that the codon usage of this 
bacterium may be similar to that of E. coli.  However, disulphide containing 
protein expression has not been attempted. In this study, the disulphide 
containing scFv antibodies (4B7 and Pf-NPNA-1) were successfully 
expressed and formed intact disulphide bonds, which were cleaved under 
reducing conditions (Figure 4.7 and Figure 4.10, respectively). In the case of 
the 4B7 scFv-0, comparative analyses of Asaia and E. coli expressed proteins 
showed the same molecular weight of 30 kDa (Figure 4.7, lanes 2 and 3, 
respectively). This observation indicates the presence of a signal peptidase in 
Asaia, which resulted in the correct processing of the Sec-dependent pelB 
signal peptide. On the other hand, recombinant protein expression was 
compared between the Sec-dependent pelB and a twin-arginine translocation 
(TAT) signal peptides (SP). The former SP transports an unfolded polypeptide 
from the cytoplasm into the periplasm via the Sec pathway, whereas the latter 
translocates folded proteins across the inner membrane independent of the 
Sec pathway (DeLisa et al., 2003; Choi and Lee, 2004). Using the Pf-NPNA-1 
scFv-0 and 12 as model proteins similar molecular weights were observed for 
the pelB and TAT fusion proteins (Figure 4.9). These observations further 
confirm that the Sec secretory and TAT pathways are functional in Asaia. 
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Although these preliminary studies have shown the presence of these 
secretory pathways in Asaia, further studies are required to identify the gene 
clusters that form the components of these pathways.    
An interesting observation was made regarding the oligomeric patterns of the 
Asaia and E. coli expressed 4B7 scFv-0 recombinant proteins. Under 
reducing conditions, both proteins had the same predicted molecular weight of 
30 kDa. Under non-reducing conditions the E. coli 4B7 scFv-0 protein showed 
monomer, dimer and multimeric forms, as previously observed (Chapter 3, 
Figure 3.12 and 3.13). However, the Asaia expressed 4B7 scFv-0 showed 
monomer, dimer and other multimeric species (Figure 4.7). Arndt et al. (1998) 
suggested that multimeric assembly of scFvs is dependent on factors such as 
the expression conditions, bacterial strain, folding methods and association 
constant for domain-domain interaction. Although the bacterial strains, the 
expression conditions (cultivation at 30°C compared  to 20°C in E. coli; 
duration of cultivation for 48 hours compared to 24 hours) and protein isolation 
(osmotic shock compared to ultrasonic vibrations) differ, further studies are 
required to delineate the oligomeric patterns of recombinantly expressed 
scFvs in both strains.  
Binding of the Asaia expressed 4B7 scFv-0 was not determined as previous 
binding studies of E. coli expressed and purified proteins did not show 
effective binding. However, Pf-NPNA-1 scFv-0 and 12, which effectively 
bound WHcAg after E. coli expression (Chapter 3, Figure 3.29), failed to show 
similar binding when expressed in Asaia SF2.1 (Figure 4.11). It is not clear 
whether the acidic extracellular medium, resulting from the oxidation of 
glycerol, had any effect on the binding of the scFv. Although the final pH of the 
extracelluar medium was 4.6, purifications of the scFvs were conducted in 
buffers with basic pH (pH 8). As a result a small difference of 1.5 fold in ELISA 
signal was observed when crude Pf-NPNA-1 scFv-12 crude extract was 
compared to that of purified scFv. Low pH (2.3) environments have been 
shown to affect scFv binding. However, binding is restored by adjusting to 
neutral pH (6.3) (Yuan et al., 2000). The observations of Yuan et al. (2000) 
are in agreement with other studies in which phage displayed scFvs are 
eluted with acidic pH buffers and then neutralised with basic buffers. 
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Therefore, further experiments in the form of stability studies, are required to 
investigate possible effects of pH on the structure and function of the scFv 
antibodies. 
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5.1 Discussion 
 
Malaria remains a global health problem. The causative agent, Plasmodium, 
remains elusive as current control strategies are incapable of curtailing 
transmission. Novel vector control strategies are being developed to block 
development of the parasite within the arthropod vector. Paratransgenesis, 
which utilises mosquito symbiotic microorganism to secrete anti-parasite 
molecules that block parasite development, is one proposed approach (Beard 
et al., 1992; Beard et al., 1998; Yoshida et al., 2001; Riehle and Jacobs-
Lorena, 2005; Riehle et al., 2007). It has gained considerable interest and is 
being developed to control transmission. However, the success of this 
approach depends on identification of suitable symbiotic bacteria and efficient 
anti-parasite molecules. Recently an acetic acid bacterium, Asaia sp., was 
identified and shown to be associated with Anopheles mosquitoes (Favia et 
al., 2007; Damiani et al., 2008; Damiani et al., 2010). Genetically modified 
Asaia expressing GFP was capable of colonising the gut, salivary gland, male 
and female reproduct organs. The GFP-tagged bacteria also showed similar 
distribution in both A. stephensi and A. gambiae (Damiani et al., 2010). These 
characteristics make Asaia a suitable bacterial candidate for the delivery of 
anti-parasite molecules.  
 
Although numerous anti-parasite molecules have been identified (Nirmala and 
James, 2003), there is the need to identify and evaluate other anti-parasite 
molecules that target surface ligands required by the parasite for successful 
establishment within the mosquito. The use of multiple effector molecules will 
also ensure the long term effectiveness of the approach by preventing 
development of resistant pathogens. The best targets have been identified as 
the midgut or late ookinete stages, because of the low numbers, and the 
salivary glands. Pfs25 expressed on the ookinetes and CS proteins expressed 
on the sporozoites are potential targets for blocking transmission. Parasite 
ligands are important targets for effector molecules (Barreau et al., 1995; de 
Lara Capurro et al., 2000) and has been suggested that targeting the parasite 
with effector molecules may be more beneficial, imposing less genetic load, 
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than targeting mosquito tissues (James, 2003). However, no ideal effector 
molecule has yet been found against P. falciparum. 
 
Antibodies hold promise due to their specificity and affinity. The antibodies 
4B7 (Barr et al., 1991) and Pf-NPNA-1 (Chappel et al., 2004b) have been 
isolated against Pfs25 and the repeats of Pf-CS protein, respectively. 
Application of these antibodies as effector molecules requires prior evaluation 
in a bacterial system (E. coli and subsequently Asaia SF2.1) for secretion and 
functional analysis. Thus, the first and foremost aim of this study was the 
construction of the antibodies 4B7 and Pf-NPNA-1 in the scFv format with 
different linker length connecting the variable domains. Varying the linker 
length between the variable domains has in previous studies, resulted in 
multimeric assembly.  Secondly, the constructed scFvs were expressed in E. 
coli and secreted proteins evaluated for antigen binding. The third aim was 
evaluation of multimeric assembly by size exclusion chromatography of the 
purified proteins. Evidence of these multimeric assemblies will facilitate 
investigation into the contributive effects of antibody avidity to antigen binding. 
Finally, the scFvs were transferred into a broad-host range vector for 
expression in the acetic acid bacterium, Asaia. 
 
All the scFv constructs were successfully expressed in E. coli. Two variants of 
the 4B7 antibody were expressed. Initial expression of the 4B7 scFv (VH-VL) 
did not show detectable secretion, which was attributed to the presence of 
charged residues in the N-terminus of the mature protein. The possibility of 
these charged residues to bind the cell membrane of E. coli and cause 
translocation impairment of the signal peptide were considered. Thus, the 
scFv constructed in the reverse orientation (VL-VH) showed slightly detectable 
secretion with no antigen binding. After extensive bioinformatic analyses and 
sequence comparisons, a second variant 4B7 (AJ) obtained by site-directed 
mutagenesis of framework residues showed detectable levels of secretion and 
slight antigen binding. These experiments were the first time soluble and 
functional 4B7 proteins had been produced in E. coli. On the other hand, the 
Pf-NPNA-1 scFv-0 and scFv-12 (VH-VL) variants could easily be expressed 
and secreted without changing the orientation of the variable domains. These 
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were purified by IMAC and antigen binding evaluated. Specificities of the 
purified proteins to the repeats of Pf-CS protein were observed in an ELISA. 
Furthermore, the purified proteins were able to label the entire surface of 
sporozoites in an IFA. These observations were in agreement with those 
observed for the Pf-NPNA-1 scFv-27. Unfortunately the low yield of 
recombinant proteins precluded kinetic analysis by SPR.  
 
In this study, a two-step purification strategy was carried out to purify protein 
samples to homogeneity. IMAC, which has widespread acceptance and 
application, was used as the first purification step. It failed to sufficiently purify 
proteins expressed at low levels compared to proteins expressed at high 
levels. Contamination or co-elution of low level expressed proteins with E. coli 
native proteins, which exhibit high affinity for divalent cations, has been the 
subject of many reviews (Bolanos-Garcia and Davies, 2006; Robichon et al., 
2011). Native proteins such as wondrous histidine-rich protein (Whp/SlyD, 196 
aa, 20.8 kDa, 18 histidines), chloramphenicol acetyltransferase (Cat, 219 aa, 
25.5 kDa ,12 histidine), superoxide dismutase (SodA, 195 aa, 8 histidines), 
Glucosamine-6-phosphate synthase (Glms, 609 aa, 67kDa, 24 histidines), 
Formyl transferase (YfbG, 660 aa, 74.2 kDa, ) and carbonic anhydrase (YadF, 
220 aa, 25 kDa, 12 histidines) have been identified as problematic 
contaminants during IMAC purification (Muller et al., 1998; Bolanos-Garcia 
and Davies, 2006; Robichon et al., 2011). Most of these proteins were 
identified as contaminants during purification in this study. Experimental 
observations made by Bolanos-Garcia and Davies (2006) indicate that these 
E. coli native proteins do not elute under the wash conditions (Imidazole 
concentration of 20 mM) used in this study but rather at imidazole 
concentrations greater than 50 mM. Elution with low pH or organic solvents 
(Franken et al., 2000), in order to eliminate these contaminants, were not 
tested as these strategies might inactivate the proteins. On the other hand, 
the low pH approach, which results in protonation of the histidine side chain 
and eventual loss of affinity for divalent metals, may not be capable of 
discriminating between the eluted protein and contaminant. To address this 
problem, ion exchange chromatography, anion or cation based on the 
estimated pI of the protein, was chosen as the second purification strategy. 
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This strategy also failed to provide homogeneously purified protein except for 
proteins that were highly expressed. Alternatively, immunoaffinity 
chromatography using anti-His monoclonal antibodies, could have been used 
as the second purification step for the proteins expressed at low levels. This 
approach was employed by Muller et al. (1998) to sufficiently purify proteins to 
homogeneity. However, the approach is time-consuming and has to be 
optimised based on the properties of each protein. To improve the purity of 
target protein, genetic engineering of E. coli BL21(DE3) has successfully been 
performed to express native protein contaminants with tags that allowed their 
rapid removal during the flow through step of IMAC (Robichon et al., 2011). 
Further studies are needed, in terms of purification strategy, to enhance the 
yield of recombinant scFv antibodies.  
  
The different scFv antibody constructs facilitated the use of different detection 
methods. When scFvs are expressed from the pSANG10-3F plasmid, the His-
tag was detected on blots and in ELISA with either the rabbit anti-hexa-
histidine tag antibody conjugated to HRP or the murine monoclonal anti-
polyhistidine AP antibody. The tri-FLAG was detected on blots with rabbit anti-
tri FLAG antibody as primary antibody and goat anti-rabbit IgG conjugated to 
AP as secondary antibody. Finally, the HuCk fusion proteins could be 
detected on blots and ELISA with the goat anti-human kappa light chain 
antibody conjugated to AP. 
    
Since the recombinant scFv to be expressed via the symbiotic bacteria would 
lack natural effector functions, it is reasoned that an ability to agglutinate the 
target could be incorporated by creating a functional self assembling multimer. 
The multivalent scFv, through site-specific inhibition and cross-linking, could 
further enhance the potential to reduce vector competence. These cross- 
linking antibodies would function to immobilise the parasite, thus preventing it 
from reaching and invading the salivary glands. Reducing the peptide linker 
length between the VH and VL domains has previously been shown to favour 
spontaneous multimeric assembly (Hudson and Kortt, 1999; Power and 
Hudson, 2000; Kortt et al., 2001; Power et al., 2001; Power et al., 2003) . 
Moreover, it has been suggested that the shorter linkers in dimers and trimers 
                           General Discussion 
133 
 
are inaccessible to proteases (Hudson and Kortt, 1999) and may protect the 
antibody from degradation in the harsh environment of the midgut and salivary 
glands. The 4B7(AJ) scFv-0 and 20, when expressed in E. coli and purified, 
both showed similar oligomeric patterns: monomer, dimer and higher 
molecular weight forms. On the contrary, the Asaia expressed 4B7(AJ) scFv-0 
showed a different oligomeric pattern: monomer and dimer. This observation 
was attributed to the differences in bacterial strains, expression conditions and 
folding methods (Arndt et al., 1998). Oligomeric pattern of the Asaia 
expressed 4B7(AJ) scFv-20 could not be assessed as this construct got 
degraded. The degradation of this construct may possibly indicate the 
presence of proteases in Asaia, different from those of E. coli, that may have 
recognised a sequence within the 4B7 (AJ) scFv-20 gene fragment, which led 
to its degradation during expression.  
 
After successful expression of the scFv antibodies in E. coli, the scFv DNA 
fragments were cloned into a newly constructed vector, pMAK031 2P. This 
new vector maintained the advantageous features of the original vector, 
pHM2- a constitutive kanamycin promoter and a broad-host range origin of 
replication that allowed switching between expression hosts (E. coli and 
Asaia). The new vector also allowed the direct cloning of VH and Vk with the 
introduction of two rare-cutting restriction enzyme sites (NcoI and NotI). In this 
investigation scFv antibodies were successfully expressed in the acetic acid 
bacterium Asaia SF2.1. To my knowledge, this is the first report of 
recombinant expression of scFvs in Asaia. Western blots of expressed 
proteins indicated that the pelB signal peptide was correctly processed 
facilitating the scFv antibodies into the periplasm for correct folding. Although 
cysteine oxidation by Dsb proteins in the periplasm of E. coli have been 
investigated in greater detail, correct disulphide bond formation of scFv 
antibodies in Asaia have not been demonstrated. Proteolytic fragmentation 
and mass spectrometric analysis of the fragments would have been the most 
accurate procedure to demonstrate the correct intramolecular disulphide bond 
formation in the Asaia secreted scFv antibodies. This approach was not 
undertaken due to the low amounts of proteins secreted. However, 
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comparison of the electrophorectic mobility of E. coli and Asaia secreted 
proteins by reducing and non-reducing SDS-PAGE showed similar mobilities, 
an indication of correctly formed intramolecular disulphide bonds. On the other 
hand, the Asaia expressed Pf-NPNA-1 scFvs did not demonstrate similar 
binding properties to those of E. coli produced scFv antibodies. 
    
Finally, it can be concluded that the recombinant 4B7 and Pf-NPNA-1 scFv 
antibodies cloned and expressed in these studies could potentially be 
included in the arsenal of effector molecules for application in symbiotic 
control of malaria.  
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6.1 Conclusion 
 
The aim of the study was to use E. coli as a model bacterium and the acetic 
acid bacterium, Asaia SF2.1, for expression, secretion and functional analysis 
of two scFv antibodies (4B7 and Pf-NPNA-1) previously identified as effector 
molecules. Plasmid constructs of both scFvs were first expressed in E. coli 
and subsequently in Asaia.    
 
For the scFv 4B7, in the VH-VL orientation, periplasmic secretion could not be 
attained due to association of the protein to the bacterial cell wall and the 
presence of N-terminal charged residues. Subsequent orientation of the 
variable domains (VL-VH) led to detectable levels of secretion into the 
periplasm but no antigen binding. Site-directed mutagenesis of seven 
framework residues, obtained by sequence comparison of two 4B7 gene 
sequences that have 95% sequence identity between them, did not show 
significant improvement in antigen binding. However, two variants of the 
mutant 4B7, scFv-0 and scFv-20, both formed monomers, dimers and higher 
molecular weight forms. Fusion of the human kappa constant domain resulted 
in higher secretion of recombinant scFv-20. The fusion proteins, scFv-0Hk 
and scFv-20 both formed monomer and higher molecular multimer. Very low 
antigen binding was also observed for these fusion proteins.    
 
The two variants of Pf-NPNA-1, scFv-0 and scFv-12, in the VH-VL format could 
easily be expressed and secreted in E. coli without the need to swap variable 
domains. The pSANG-103F expression plasmid showed a higher level of 
expression compared to the other two expression plasmids. This was in 
agreement with the ELISA studies. The fusion of HuCk did not improve the 
expression levels of the Pf-NPNA-1 scFv-0 and scFv-12. However, both scFv 
variants labelled the entire surface of sporozoites in an IFA. 
 
Transfer of the 4B7 and Pf-NPNA-1 scFv gene fragments into the broad-host 
range plasmid, pMAK0312P, and transformation into Asaia SF2.1 showed the 
capability of this acetic acid bacterium to express disulphide containing 
proteins. Moreover, Asaia efficiently processed the pelB signal peptide to 
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allow translocation of the scFv antibodies into the periplasm for proper 
disulphide bond formation. Although the Asaia expressed Pf-NPNA-1 scFv-12 
showed antigen binding, the binding was not comparable to those of E. coli 
expressed ones.   
 
 
 
6.2 Future work 
 
6.2.1 Multimeric assembly of scFv 
 
Evidence from this study has shown that the 4B7 and Pf-NPNA-1 scFvs are 
capable of multimeric assembly. However, the higher ordered multimers could 
not be evaluated for antigen binding due to the low yield of recombinant 
proteins obtained after isolation and purification. A limitation of IMAC was the 
inability to efficiently purify proteins expressed at very low levels. For further 
characterisation of scFv multimers large scale expression as described by 
Power et al. (2003) could be carried out and the purification strategies 
optimised to obtain high yields of recombinant proteins. To avoid co-elution of 
native E. coli proteins during the purification process, the BL21(DE3) E. coli 
strains engineered by Robichon et al. (2011) could be used for expression of 
the recombinant proteins. The immunoaffinity chromatography strategy of 
Muller et al. (1998) could then be adopted for efficient and homogenous 
protein purification. After purification of the protein to homogeneity, multimeric 
assembly could be evaluated by size exclusion chromatography. Multimers 
may then be assayed for antigen binding by ELISA and competitive ELISA. 
Furthermore, the avidity effects of the multimers could be evaluated by SPR 
on a BIACORE.      
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6.2.2 Homology modelling and affinity enhancement of scFv 4B7 
 
For antibodies that do not have completely resolved three dimensional 
structures, the availability of data on the canonical structures of previously 
resolved antibody structures has facilitated their structural prediction through 
homology modelling. Homology modelling has previously been used to 
change the binding properties or increase the affinity of antibodies by 
identifying key amino acids involved in the antigen-antibody interaction. Based 
on these models, mutational analysis studies by application of site-directed or 
random mutagenesis have helped in the identification of antibodies with 
improved properties (Casipit et al., 1998; Hemminki et al., 1998; Kusharyoto 
et al., 2002; Farady et al., 2009). In agreement with the study by Stura et al. 
(1994), Sharma (2008) through computer-aided modelling and docking 
experiments identified a major interaction of the EGF III domain of Pfs25 with 
the heavy chain of scFv 4B7. According to the model of the complex, six 
hydrogen bonds were formed in the heavy chain and one in the light of the 
antibody; outlined in the Table 6.1 below.  
Amino acid Position on antibody Fv 
Thr 28 VH FR1 
Asn 53 VH CDR2 
Asn 74 VH FR3 
Leu 101 VH CDR3 
Asp 106 VH CDR3 
Tyr 49 VL FR2 
 
Table 6.1: Amino acids identified to form hydrogen bonds with the third EGF domain 
during interaction of scFv 4B7 with Pfs25 (Sharma, 2008). 
 
Based on Sharma (2008) model, the amino acids listed above may be key 
residues that contribute to antigen binding. A rational design could then be 
undertaken to investigate the molecular basis of the antibody’s specificity and 
to improve its affinity by site-directed mutagenesis. Hence, mutations of both 
heavy chain and light chain residues within the predicted binding pockets can 
be modelled and the corresponding effect experimentally determined by 
ELISA and surface Plasmon resonance (SPR). 
                           Conclusion and Future prospects                                                                                                                                
139 
 
 
6.2.3 Extracellular secretion of recombinant scFvs in Asaia sp. SF2.1 
 
Evidence from the preliminary expression studies showed that Asaia sp. 
SF2.1 is capable of expressing the recombinant scFvs and proteolytic 
processing of the signal peptide. For paratransgenic application the pelB 
signal peptide used may not be useful as the expressed scFv would 
accumulate in periplasm and will be released only upon bacterial death.  
Ultimately, extracellular secretion of the scFv from Asaia into the surroundings 
of the midgut or salivary glands would bring the recombinant scFv in direct 
contact with the parasite. Currently, bacterial leader sequences known to 
transport proteins into the extracellular medium are being evaluated. 
Alternatively, three other strategies could be adopted for extracellular 
secretion or display of the scFv antibodies. Firstly, the extracellular proteome 
of Asaia could be analysed using proteomic techniques such as two-
dimensional electrophoresis (2-DE) to identify naturally secreted proteins. 
Potentially, these proteins may be utilised as fusion partners for extracellular 
production of the recombinant scFvs. Recently, Qian and colleagues reported 
extracellular secretion of three model proteins from E. coli by fusing them to 
naturally excreted protein that were identified by a proteome-based approach 
(Qian et al., 2008). Secondly, extracellular delivery of the scFv antibodies 
could be achieved by utilising the hemolysin export apparatus (Fernandez et 
al., 2000; Fernandez and de Lorenzo, 2001; Li et al., 2002; Fraile et al., 
2004). Proteins secreted by this pathway are directed to the extracellular 
medium without a periplasmic intermediate. This secretion system has been 
shown to support secretion of disulphide-containing proteins (Fernandez et 
al., 2000; Fernandez and de Lorenzo, 2001). Advantages of the hemolysin 
secretion system are its low toxicity on the producing cell and reduction in 
protein aggregation (Fernández et al., 2000). Thirdly, the Lpp’OmpA 
(lipoprotein-outer membrane protein A) surface display approach used by 
Riehle et al. (2007) could be also adopted. The display of peptides or proteins 
is facilitated by the fusion of a truncated form of OmpA and the signal peptide 
of the outer membrane lipoprotein. This approach was successfully used to 
display SM1 and PLA2 on the surface of E. coli.       
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6.2.4 Evaluation of scFv expression in Anopheles and its impact on 
parasite load  
 
In this study, in vitro experiments have demonstrated the capability of Asaia to 
express disulphide-containing proteins. Overall, the expression and secretion 
studies satisfy two of the three key components of paratransgensis suggested 
by Riehle et al. (2007): effector molecules that inhibit Plasmodium 
development; mechanism for expressing and secreting the effector molecule 
in the symbiotic bacterium. Further in vivo expression studies, within 
Anopheles midgut and salivary glands, could then be conducted to assess 
expression and the effect of the effector molecule on Plasmodium 
development. Colonisation of the mosquito by recombinant Asaia could be 
performed according to the method outlined by Favia et al. (2007). A time 
course experiment could be carried out by preparing gut and salivary gland 
extracts of Asaia fed mosquitoes (control and test strains) and the 
homogenates assayed by PCR and Western blot for the presence of 
recombinant Asaia SF2.1 and expression of recombinant scFvs. 
Subsequently, the impact of the in vivo expressed antibodies on Plasmodium 
development can be investigated in transmission blocking experiments as 
described (Lobo et al., 1999). 
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APPENDIX 
  
Plasmid Source 
pSANG103F Martin et al. (2006) 
pET41b(+) Dr. Mark Clements (Univ. of Westminster) 
pBSK CA19.9 Dr. Anatoliy Markiv (Univ. of Westminster) 
pBAK1 This study 
pBAK1.HK This study 
pMAK031 2P This study 
Table I: Plasmids used in this study and their sources.  
 
 
Primer Name Sequence 
 PCR of HuCk from Phage library as NotI/HindIII 
BAK.1 ACT GCG GCC GCA CCA TCT GTC TTC ATC TTC 
BAK.2 AGA AGC TTG CTC GAG TCC CCT GTT GAA GCT CTT 
TGT GAC 
 4B7 Primers 
4B7VHNot AAGCTTGCGGCCGCGCTGCTCACGGTCAGGGTGGTGC
CCTGGCC 
4B7VLNcoI GCCATGGCCGATATTCAGATGATTCAGAGCCCGAGC 
4B7VLR CGCTTTATTTTCCAGTTTGGTGCCGCTGCC 
4B7VHF GAAGTGAAACTGGTGGAAAGCGGCGGCGGC 
4B7VHR CGC GCT GCT CAC  GGT CAG GGT GG 
4B7VLF GAT ATT CAG ATG ATT CAG AGC C 
4B7VHLink5F GGAGGTGGCGGAAGCGAAGTGAAACTGGTGGAAAGC
GGCGGCGGC 
4B7VLLink5R CTACCGCCACCTCCCGCTTTAATTTCCAGTTTGGTG 
CCGCTGCC 
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4B7VLVHLink3
0 
GGAGGTGGCGGTAGTGGAGGTGGCGGAAGCGGAGG 
TGGCGGTAGTGGAGGTGGCGGAAGCGGAGGTGGCG 
GTAGTGGAGGTGGCGGAAGC 
 4B7 Site-directed mutagenesis 
4B7VLQ3EI5TF GATATTGAGATGACCCAGAGCCCGAGCAGCATGTTTG
CG 
4B7VLQ3EI5T
R 
GCTCTGGGTCATCTCAATATCGGCCATGGCCGGCTGG
GC 
4B7VLL85FG8
6AF 
GCGAAGATTTTGCCGATTATTATTGCCTGCAGCGCAAC 
4B7VLL85FG8
6AR 
GCAATAATAATCGGCAAAATCTTCGCTTTCCAGGCTGC 
4B7VHQ20RF GGCGGCAGCCGCAAACTGAGCTGCGCGGCGAGCGGC 
4B7VHQ20RR GCTCAGTTTGCGGCTGCCGCCCGGCTGCACCAGGCC 
4B7VHT94AF GAAGATACCGCCATGTATTATTGCGCGCGCGGC 
4B7VHT94AR GCAATAATACATGGCGGTATCTTCGCTGCGCAG 
4B7VH GGCACCACCGTGACCGTGAGCAGCGCGGCCGCATCC
GC 
4B7VHL114VN
otIR 
GCGGATGCGGCCGCGCTGCTCACGGTCACGGTGGTG
CC 
 Pf-NPNA-1 Primers 
NcoF   TCT AGA GCG GCC CAG CCG GCC ATG GCC 
PfVHR  GCT GCT CAC GGT CAC CAG GGT GCC 
PfVLF  GAA ATT GTG CTG  ACC  CAG AGC CCG 
PfVLR TTT AAT TCC ACT TTG GTG CCG CCG CC  
Not R  ATT ACG CCA AGC TTG CGG CCG C 
 pMAK031 2P plasmid 
KANF TAA CCG GAA TTG CCA GCT GG 
KANR GCG TTC ACC GAC AAA CAA CA 
T7ABATG GC AGC TAA TAC GAC TCA CTA TAG GAA CAG ACC 
ACC ATG GCC 
Table II: Primers used in this study 
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Figure I: Restriction enzyme digestion of (A) pORFES-IT and pET41b(+) and (B) 
PCR amplified HuCk gene. 50 µL of each digested reaction was loaded and 
subjected to electrophoresis on a 1% agarose at 100 V for 1 hour. The DNA was 
visualised using ethidium bromide under UV light at wavelength of 200 nm. A: Lane 
1: 1 kb DNA step ladder, Lane 2: XbaI/NotI digested pORFES-IT, Lane 3: XbaI/NotI 
digested pET41b(+); Lane 4: 100 bp DNA ladder. Inserts were excised and agarose 
gel purified. B:  Lane 1: 100 bp DNA ladder, Lane 2: NotI/XhoI digested PCR 
amplified HuCk.   
 
 
     XbaI                 pelB leader sequence    
    1 TCTAGATCAG GAGAACAGTC ATAATGAAAT ACCTATTGCC TACGGCAGCC 
                               M  K  Y   L  L  P   T  A  A    Frame 3                               
                            SfiI        NcoI                                 
   51 GCTGGATTGT TATTACTCGC GGCCCAGCCG GCCATGGCCG AGGTGCAGCT 
      A  G  L  L   L  L  A   A  Q  P   A  M  A  E   V  Q  L   Frame 3 
 
  101 GTTGGAGTCT GGGGGAGGCT TGGTACAGCC TGGGGGGTCC CTGAGACTCT 
       L  E  S   G  G  G  L   V  Q  P   G  G  S   L  R  L  S  Frame 3 
                                               
  151 CCTGTGCAGC CTCTGGATTC ACCTTTAGCA GCTATGCCAT GAGCTGGGTC 
        C  A  A   S  G  F   T  F  S  S   Y  A  M   S  W  V    Frame 3 
 
  201 CGCCAGGCTC CAGGGAAGGG GCTGGAGTGG GTCTCAATTA TTGGGTCTGA 
      R  Q  A  P   G  K  G   L  E  W   V  S  I  I   G  S  E   Frame 3 
 
  251 GGGTTGGCCT ACAATTTACG CAGACTCCGT GAAGGGCAGG TTCACCATCT 
       G  W  P   T  I  Y  A   D  S  V   K  G  R   F  T  I  S  Frame 3 
 
  301 CCAGAGACAA TTCCAAGAAC ACGCTGTATC TGCAAATGAA CAGCCTGAGA 
        R  D  N   S  K  N   T  L  Y  L   Q  M  N   S  L  R    Frame 3 
                 
  351 GCCGAGGACA CGGCCGTATA TTACTGTGCG AAAGGTGGGT CGATGTTTGA 
      A  E  D  T   A  V  Y   Y  C  A   K  G  G  S   M  F  D   Frame 3 
                                       XhoI                                     
  401 CTACTGGGGC CAGGGAACCC TGGTCACCGT CTCGAGCGGT GGAGGCGGTT 
       Y  W  G   Q  G  T  L   V  T  V   S  S  G   G  G  G  S  Frame 3 
                                   
  451 CAGGCGGAGG TGGCAGCGGC GGTGGCGGGT CGACGGACAT CCAGATGACC 
        G  G  G   G  S  G   G  G  G  S   T  D  I   Q  M  T    Frame 3 
 
  501 CAGTCTCCAT CCTCCCTGTC TGCATCTGTA GGAGACAGAG TCACCATCAC 
      Q  S  P  S   S  L  S   A  S  V   G  D  R  V   T  I  T   Frame 3 
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  551 TTGCCGGGCA AGTCAGAGCA TTAGCAGCTA TTTAAATTGG TATCAGCAGA 
       C  R  A   S  Q  S  I   S  S  Y   L  N  W   Y  Q  Q  K  Frame 3 
 
  601 AACCAGGGAA AGCCCCTAAG CTCCTGATCT ATCGTGCATC CAGCTTGCAA 
        P  G  K   A  P  K   L  L  I  Y   R  A  S   S  L  Q    Frame 3 
 
  651 AGTGGGGTCC CATCAAGGTT CAGTGGCAGT GGATCTGGGA CAGATTTCAC 
      S  G  V  P   S  R  F   S  G  S   G  S  G  T   D  F  T   Frame 3 
 
  701 TCTCACCATC AGCAGTCTGC AACCTGAAGA TTTTGCAACT TACTACTGTC 
       L  T  I   S  S  L  Q   P  E  D   F  A  T   Y  Y  C  Q  Frame 3 
       
  751 AACAGTCGAG TAATACGCCT TATACGTTCG GCCAAGGGAC CAAGGTGGAA 
        Q  S  S   N  T  P   Y  T  F  G   Q  G  T   K  V  E    Frame 3      
                   NotI             
  801 ATTAAACGCA CTGCGGCCGC ACCATCTGTC TTCATCTTCC CGCCATCTGA 
      I  K  R  T   A  A  A   P  S  V   F  I  F  P   P  S  D   Frame 3 
         
  851 TGAGCAGTTG AAATCTGGAA CTGCCTCTGT TGTGTGCCTG CTGAATAACT 
       E  Q  L   K  S  G  T   A  S  V   V  C  L   L  N  N  F  Frame 3 
       
  901 TCTATCCCAG AGAGGCCAAA GTACAGTGGA AGGTGGATAA CGCCCTCCAA 
        Y  P  R   E  A  K   V  Q  W  K   V  D  N   A  L  Q    Frame 3 
        
  951 TCGGGTAACT CCCAGGAGAG TGTCACAGAG CAGGACAGCA AGGACAGCAC 
      S  G  N  S   Q  E  S   V  T  E   Q  D  S  K   D  S  T   Frame 3 
         
 1001 CTACAGCCTC AGCAACACCC TGACGCTGAG CAAAGCAGAC TACGAGAAAC 
       Y  S  L   S  N  T  L   T  L  S   K  A  D   Y  E  K  H  Frame 3 
       
 1051 ACAAAGTCTA CGCCTGCGAA GTCACCCATC AGGGCCTGAG CTCGCCCGTC 
        K  V  Y   A  C  E   V  T  H  Q   G  L  S   S  P  V    Frame 3       
                             XhoI                             
 1101 ACAAAGAGCT TCAACAGGGG ACTCGAGCAC CACCACCACC ACCACCACCA 
      T  K  S  F   N  R  G   L  E  H   H  H  H  H   H  H  H   Frame 3 
 
 1151 CTAA                                                   
       *  Frame 3 
 
Figure II: Nucleotide and deduced amino acid sequence of pBAK.1Hk plasmid. 
The leader sequence, restriction sites and octa his tag are indicated. The sequence 
for the human kappa constant domain is represented by the purple colour.    
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      XbaI                         pelB leader sequence    
    1 TCTAGATCAG GAGAACAGTC ATAATGAAAT ACCTATTGCC TACGGCAGCC 
                               M  K  Y   L  L  P   T  A  A    Frame 3 
                                 
                            SfiI       NcoI                             
   51 GCTGGATTGT TATTACTCGC GGCCCAGCCG GCCATGGCCG AGGTGCAGCT 
      A  G  L  L   L  L  A   A  Q  P   A  M  A  E   V  Q  L   Frame 3 
                            
  101 GTTGGAGTCT GGGGGAGGCT TGGTACAGCC TGGGGGGTCC CTGAGACTCT 
       L  E  S   G  G  G  L   V  Q  P   G  G  S   L  R  L  S  Frame 3 
                                            
  151 CCTGTGCAGC CTCTGGATTC ACCTTTAGCA GCTATGCCAT GAGCTGGGTC 
        C  A  A   S  G  F   T  F  S  S   Y  A  M   S  W  V    Frame 3 
 
  201 CGCCAGGCTC CAGGGAAGGG GCTGGAGTGG GTCTCAATTA TTGGGTCTGA 
      R  Q  A  P   G  K  G   L  E  W   V  S  I  I   G  S  E   Frame 3 
 
  251 GGGTTGGCCT ACAATTTACG CAGACTCCGT GAAGGGCAGG TTCACCATCT 
       G  W  P   T  I  Y  A   D  S  V   K  G  R   F  T  I  S  Frame 3 
 
  301 CCAGAGACAA TTCCAAGAAC ACGCTGTATC TGCAAATGAA CAGCCTGAGA 
        R  D  N   S  K  N   T  L  Y  L   Q  M  N   S  L  R    Frame 3 
              
  351 GCCGAGGACA CGGCCGTATA TTACTGTGCG AAAGGTGGGT CGATGTTTGA 
      A  E  D  T   A  V  Y   Y  C  A   K  G  G  S   M  F  D   Frame 3 
                                       XhoI       
  401 CTACTGGGGC CAGGGAACCC TGGTCACCGT CTCGAGCGGT GGAGGCGGTT 
       Y  W  G   Q  G  T  L   V  T  V   S  S  G   G  G  G  S  Frame 3 
                              
  451 CAGGCGGAGG TGGCAGCGGC GGTGGCGGGT CGACGGACAT CCAGATGACC 
        G  G  G   G  S  G   G  G  G  S   T  D  I   Q  M  T    Frame 3 
 
  501 CAGTCTCCAT CCTCCCTGTC TGCATCTGTA GGAGACAGAG TCACCATCAC 
      Q  S  P  S   S  L  S   A  S  V   G  D  R  V   T  I  T   Frame 3 
                                       
  551 TTGCCGGGCA AGTCAGAGCA TTAGCAGCTA TTTAAATTGG TATCAGCAGA 
       C  R  A   S  Q  S  I   S  S  Y   L  N  W   Y  Q  Q  K  Frame 3 
 
  601 AACCAGGGAA AGCCCCTAAG CTCCTGATCT ATCGTGCATC CAGCTTGCAA 
        P  G  K   A  P  K   L  L  I  Y   R  A  S   S  L  Q    Frame 3 
 
  651 AGTGGGGTCC CATCAAGGTT CAGTGGCAGT GGATCTGGGA CAGATTTCAC 
      S  G  V  P   S  R  F   S  G  S   G  S  G  T   D  F  T   Frame 3 
 
  701 TCTCACCATC AGCAGTCTGC AACCTGAAGA TTTTGCAACT TACTACTGTC 
       L  T  I   S  S  L  Q   P  E  D   F  A  T   Y  Y  C  Q  Frame 3 
                             
  751 AACAGTCGAG TAATACGCCT TATACGTTCG GCCAAGGGAC CAAGGTGGAA 
        Q  S  S   N  T  P   Y  T  F  G   Q  G  T   K  V  E    Frame 3                                       
               NotI      XhoI            His8 Tag 
  801 ATCAAACGGG CGGCCGCACT CGAGCACCAC CACCACCACC ACCACCACTAA 
      I  K  R  A   A  A  L   E  H  H   H  H  H  H   H  H  *   Frame 3 
 
 
Figure III: Nucleotide and deduced amino acid sequence of pBAK.1 plasmid. 
The leader sequence, restriction sites and octa his tag are indicated.   
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Figure IV: NcoI/NotI restriction enzyme digestion of expression plasmids: 
pBAK1 (A), pSANG10-3F (B) and pBAK1Hk (C). 50 µL of each digested reaction 
was loaded and subjected to electrophoresis on a 1% agarose at 100 V for 1 hour. 
The DNA was visualised using ethidium bromide under UV light at wavelength of 200 
nm. (A) Lane 1: 1 kb DNA ladder, Lane 2: digested pBAK1 (B) Lane 1: 1 kb DNA 
ladder, Lane 2: digested pSANG10-3F, (C) Lane 1: 1 kb DNA ladder, Lane 2: 
digested pBAK1Hk. 
 
 
 
 
 
                
Figure V: PCR amplification of variable domains (A) and overlap extension PCR 
(B) of 4B7. 25 µL of each PCR product was loaded and subjected to electrophoresis 
on a 1.5% agarose at 100 V for 1 hour. The DNA was visualised using ethidium 
bromide under UV light at wavelength of 200 nm. (A) Lane 1: 100 bp DNA ladder, 
Lane 2: 4B7 VH (370 bp), Lane 3: 4B7 VL (330 bp); (B) Lane 1: 100 bp DNA ladder, 
Lane 2: 4B7 VH – VL (700 bp). 
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Figure VI: NcoI/NotI restriction enzyme digestion of pUC19-PfNPNA scFv-12 
(A), PCR amplification of variable domains (B) and overlap extension PCR (C) 
of Pf-NPNA scFv-0. 50 µL of digested reaction and 25 µL of each PCR product was 
loaded and subjected to electrophoresis on a 1% and 1.5% agarose at 100 V for 1 
hour. The DNA was visualised using ethidium bromide under UV light at wavelength 
of 200 nm. (A) Lane 1: 1 kb DNA ladder, Lane 2: digested pUC19-PfNPNA scFv-12 
and Lane 3: 100 bp DNA ladder (B) Lane 1: 100 bp DNA ladder, Lane 2: Pf-NPNA VH 
(380 bp), Lane 3: Pf-NPNA VL (370 bp); (C) Lane 1: 100 bp DNA ladder, Lane 2: Pf-
NPNA scFv-0 VH – VL (700 bp). 
 
 
                       
 
               
Figure VII: Physical maps of 4B7 scFv-0 VH– VL in pBAK.1. The plasmid is based 
on the pET41b(+) plasmid system and has the T7 promoter for expression of scFv. 
Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin of 
replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and lacI 
gene.  
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      XbaI                        pelB leader sequence    
   1 TCTAGATCAG GAGAACAGTC ATAATGAAAT ACCTATTGCC TACGGCAGCC 
                              M  K  Y   L  L  P   T  A  A     Frame 3 
                            
                           SfiI          NcoI  VH 
  51 GCTGGATTGT TATTACTCGC GGCCCAGCCG GCCATGGCCG AAGTGAAACT 
     A  G  L  L   L  L  A   A  Q  P   A  M  A  E   V  K  L    Frame 3 
 
 101 GGTGGAAAGC GGCGGCGGCC TGGTGCAGCC GGGCGGCAGC CAGAAACTGA 
      V  E  S   G  G  G  L   V  Q  P   G  G  S   Q  K  L  S   Frame 3 
   CDR-H1 
 151 GCTGCGCGGC GAGCGGCTTT ACCTTTAGCG ATTATGGCAT GGCGTGGTTT 
       C  A  A   S  G  F   T  F  S  D   Y  G  M   A  W  F     Frame 3 
           
 201 CGCCAGGCGC CGGGCAAAGG CCCGGAATGG GTGGCGTTTA TTAACAACCT 
     R  Q  A  P   G  K  G   P  E  W   V  A  F  I   N  N  L    Frame 3 
                  CDR-H2                       
 251 GGCGTATAGC ATTTATTATG CGGATACCGT GACCGGCCGC TTTACCATTA 
      A  Y  S   I  Y  Y  A   D  T  V   T  G  R   F  T  I  S   Frame 3 
 
 301 GCCGCGAAAA CGCGAAAAAC ACCCTGTATC TGGAAATGAG CAGCCTGCGC 
       R  E  N   A  K  N   T  L  Y  L   E  M  S   S  L  R     Frame 3 
  CDR-H3 
 351 AGCGAAGATA CCACCATGTA TTATTGCGCG CGCGGCAACC TGTATTATGG 
     S  E  D  T   T  M  Y   Y  C  A   R  G  N  L   Y  Y  G    Frame 3 
  VL 
 401 CCTGGATTAT TGGGGCCAGG GCACCACCCT GACCGTGAGC AGCGCGGATA 
      L  D  Y   W  G  Q  G   T  T  L   T  V  S   S  A  D  I   Frame 3 
 
 451 TTCAGATGAT TCAGAGCCCG AGCAGCATGT TTGCGAGCCT GGGCGATCGC 
       Q  M  I   Q  S  P   S  S  M  F   A  S  L   G  D  R     Frame 3 
  CDR-L1 
 501 GTGAGCCTGA GCTGCCGCGC GAGCCAGGAT ATTCGCGGCA ACCTGGATTG 
     V  S  L  S   C  R  A   S  Q  D   I  R  G  N   L  D  W    Frame 3 
 
 551 GTTTCAGCAG AAACCGGGCG GCACCATTAA ACTGCTGATT TATAGCACCA 
      F  Q  Q   K  P  G  G   T  I  K   L  L  I   Y  S  T  S   Frame 3 
 CDR-L2 
 601 GCAACCTGAA CAGCGGCGTG CCGAGCCGCT TTAGCGGCAG CGGCAGCGGC 
       N  L  N   S  G  V   P  S  R  F   S  G  S   G  S  G     Frame 3 
 
 651 AGCGATTATA GCCTGACCAT TAGCAGCCTG GAAAGCGAAG ATCTGGGCGA 
     S  D  Y  S   L  T  I   S  S  L   E  S  E  D   L  G  D    Frame 3 
      CDR-L3 
 701 TTATTATTGC CTGCAGCGCA ACGCGTATCC GCTGACCTTT GGCAGCGGCA 
      Y  Y  C   L  Q  R  N   A  Y  P   L  T  F   G  S  G  T   Frame 3                                                                                                     
                       NotI      XhoI 
 751 CCAAACTGGA AATTAAAGCG GCCGCACTCG AGCACCACCA CCACCACCAC 
       K  L  E   I  K  A   A  A  L  E   H  H  H   H  H  H     Frame 3 
          
 801 CACCACTAG                                              
     H  H  *   Frame 3 
 
Figure VIII: Nucleotide and deduced amino acid sequence of pBAK.1 4B7 scFv-
0 (VH – VL). The amino acid sequences corresponding to the complementary 
determining regions (CDRs) are in green. The leader sequence, restriction sites and 
octa his tag are indicated.    
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Figure IX: Physical maps of 4B7 scFv-0 VH– VL in pBAK.1HK. The plasmid is 
based on the pET41b(+) plasmid system and has the T7 promoter for expression of 
scFvHK. Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin of 
replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and lacI 
gene.  
 
 
      XbaI                      
    1 TCTAGATCAG GAGAACAGTC ATAATGAAAT ACCTATTGCC TACGGCAGCC 
                               M  K  Y   L  L  P   T  A  A    Frame 3                                
                                        NcoI                           
   51 GCTGGATTGT TATTACTCGC GGCCCAGCCG GCCATGGCCG AAGTGAAACT 
      A  G  L  L   L  L  A   A  Q  P   A  M  A  E   V  K  L   Frame 3 
                      
  101 GGTGGAAAGC GGCGGCGGCC TGGTGCAGCC GGGCGGCAGC CAGAAACTGA 
       V  E  S   G  G  G  L   V  Q  P   G  G  S   Q  K  L  S  Frame 3 
       
  151 GCTGCGCGGC GAGCGGCTTT ACCTTTAGCG ATTATGGCAT GGCGTGGTTT 
        C  A  A   S  G  F   T  F  S  D   Y  G  M   A  W  F    Frame 3 
        
  201 CGCCAGGCGC CGGGCAAAGG CCCGGAATGG GTGGCGTTTA TTAACAACCT 
      R  Q  A  P   G  K  G   P  E  W   V  A  F  I   N  N  L   Frame 3 
         
  251 GGCGTATAGC ATTTATTATG CGGATACCGT GACCGGCCGC TTTACCATTA 
       A  Y  S   I  Y  Y  A   D  T  V   T  G  R   F  T  I  S  Frame 3 
       
  301 GCCGCGAAAA CGCGAAAAAC ACCCTGTATC TGGAAATGAG CAGCCTGCGC 
        R  E  N   A  K  N   T  L  Y  L   E  M  S   S  L  R    Frame 3 
        
  351 AGCGAAGATA CCACCATGTA TTATTGCGCG CGCGGCAACC TGTATTATGG 
      S  E  D  T   T  M  Y   Y  C  A   R  G  N  L   Y  Y  G   Frame 3 
         
  401 CCTGGATTAT TGGGGCCAGG GCACCACCCT GACCGTGAGC AGCGCGGATA 
       L  D  Y   W  G  Q  G   T  T  L   T  V  S   S  A  D  I  Frame 3 
       
  451 TTCAGATGAT TCAGAGCCCG AGCAGCATGT TTGCGAGCCT GGGCGATCGC 
        Q  M  I   Q  S  P   S  S  M  F   A  S  L   G  D  R    Frame 3 
 
  501 GTGAGCCTGA GCTGCCGCGC GAGCCAGGAT ATTCGCGGCA ACCTGGATTG 
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      V  S  L  S   C  R  A   S  Q  D   I  R  G  N   L  D  W   Frame 3 
 
  551 GTTTCAGCAG AAACCGGGCG GCACCATTAA ACTGCTGATT TATAGCACCA 
       F  Q  Q   K  P  G  G   T  I  K   L  L  I   Y  S  T  S  Frame 3 
       
  601 GCAACCTGAA CAGCGGCGTG CCGAGCCGCT TTAGCGGCAG CGGCAGCGGC 
        N  L  N   S  G  V   P  S  R  F   S  G  S   G  S  G    Frame 3 
        
  651 AGCGATTATA GCCTGACCAT TAGCAGCCTG GAAAGCGAAG ATCTGGGCGA 
      S  D  Y  S   L  T  I   S  S  L   E  S  E  D   L  G  D   Frame 3 
         
  701 TTATTATTGC CTGCAGCGCA ACGCGTATCC GCTGACCTTT GGCAGCGGCA 
       Y  Y  C   L  Q  R  N   A  Y  P   L  T  F   G  S  G  T  Frame 3 
                        NotI                 
  751 CCAAACTGGA AATTAAAGCG GCCGCACCAT CTGTCTTCAT CTTCCCGCCA 
        K  L  E   I  K  A   A  A  P  S   V  F  I   F  P  P    Frame 3 
        
  801 TCTGATGAGC AGTTGAAATC TGGAACTGCC TCTGTTGTGT GCCTGCTGAA 
      S  D  E  Q   L  K  S   G  T  A   S  V  V  C   L  L  N   Frame 3 
         
  851 TAACTTCTAT CCCAGAGAGG CCAAAGTACA GTGGAAGGTG GATAACGCCC 
       N  F  Y   P  R  E  A   K  V  Q   W  K  V   D  N  A  L  Frame 3 
 
  901 TCCAATCGGG TAACTCCCAG GAGAGTGTCA CAGAGCAGGA CAGCAAGGAC 
        Q  S  G   N  S  Q   E  S  V  T   E  Q  D   S  K  D    Frame 3 
        
  951 AGCACCTACA GCCTCAGCAG CACCCTGACG CTGAGCAAAG CAGACTACGA 
      S  T  Y  S   L  S  S   T  L  T   L  S  K  A   D  Y  E   Frame 3 
         
 1001 GAAACACAAA CTCTACGCCT GCGAAGTCAC CCATCAGGGC CTGAGCTCGC 
       K  H  K   L  Y  A  C   E  V  T   H  Q  G   L  S  S  P  Frame 3       
                                  XhoI 
 1051 CCGTCACAAA GAGCTTCAAC AGGGGACTCG AGCACCACCA CCACCACCAC 
        V  T  K   S  F  N   R  G  L  E   H  H  H   H  H  H    Frame 3 
                             
 1101 CACCACTAAT                 
      H  H  *   Frame 3 
 
Figure X: Nucleotide and deduced amino acid sequence of pBAK.1Hk 4B7 
scFv-0 (VH – VL). The amino acid sequences corresponding to the complementary 
determining regions (CDRs) are in green. The leader sequence, restriction sites and 
octa his tag are indicated.    
 
 
 
 
 
                           Appendix                                                                                                                     
172 
 
 
 
Figure XI: Physical map of 4B7 scFv-0 VL–VH in pSANG10-3F. The plasmid is 
based on the pET26(+) plasmid system and has the T7 promoter for expression of 
scFv-0. Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin of 
replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and lacI 
gene.  
 
 
     XbaI                                     NdeI        
   1 TCTAGAATAA TTTTGTTTAA CTTTAAGAAG GAGATATACA TATGAAATAC 
                                                  M  K  Y     Frame 3     
        pelB leader sequence                            NcoI     
  51 CTGCAGCCGA CCGCTGCTGC TGGTCTGCTG CTCCTCGCTG CCCAGCCGGC 
     L  Q  P  T   A  A  A   G  L  L   L  L  A  A   Q  P  A    Frame 3 
 
 VL 
 101 CATGGCCGAT ATTCAGATGA TTCAGAGCCC GAGCAGCATG TTTGCGAGCC 
      M  A  D   I  Q  M  I   Q  S  P   S  S  M   F  A  S  L   Frame 3 
         CDR-L1 
 151 TGGGCGATCG CGTGAGCCTG AGCTGCCGCG CGAGCCAGGA TATTCGCGGC 
       G  D  R   V  S  L   S  C  R  A   S  Q  D   I  R  G     Frame 3 
 
 201 AACCTGGATT GGTTTCAGCA GAAACCGGGC GGCACCATTA AACTGCTGAT 
     N  L  D  W   F  Q  Q   K  P  G   G  T  I  K   L  L  I    Frame 3 
 CDR-L2 
 251 TTATAGCACC AGCAACCTGA ACAGCGGCGT GCCGAGCCGC TTTAGCGGCA 
      Y  S  T   S  N  L  N   S  G  V   P  S  R   F  S  G  S   Frame 3 
      
 301 GCGGCAGCGG CAGCGATTAT AGCCTGACCA TTAGCAGCCT GGAAAGCGAA 
       G  S  G   S  D  Y   S  L  T  I   S  S  L   E  S  E     Frame 3 
                  CDR-L3 
 351 GATCTGGGCG ATTATTATTG CCTGCAGCGC AACGCGTATC CGCTGACCTT 
     D  L  G  D   Y  Y  C   L  Q  R   N  A  Y  P   L  T  F    Frame 3 
                                     VH 
 401 TGGCAGCGGC ACCAAACTGG AAATTAAAGC GGAAGTGAAA CTGGTGGAAA 
      G  S  G   T  K  L  E   I  K  A   E  V  K   L  V  E  S   Frame 3 
 
 451 GCGGCGGCGG CCTGGTGCAG CCGGGCGGCA GCCAGAAACT GAGCTGCGCG 
       G  G  G   L  V  Q   P  G  G  S   Q  K  L   S  C  A     Frame 3 
                           Appendix                                                                                                                     
173 
 
       CDR-H1 
 501 GCGAGCGGCT TTACCTTTAG CGATTATGGC ATGGCGTGGT TTCGCCAGGC 
     A  S  G  F   T  F  S   D  Y  G   M  A  W  F   R  Q  A    Frame 3 
          CDR-H2 
 551 GCCGGGCAAA GGCCCGGAAT GGGTGGCGTT TATTAACAAC CTGGCGTATA 
      P  G  K   G  P  E  W   V  A  F   I  N  N   L  A  Y  S   Frame 3 
      
 601 GCATTTATTA TGCGGATACC GTGACCGGCC GCTTTACCAT TAGCCGCGAA 
       I  Y  Y   A  D  T   V  T  G  R   F  T  I   S  R  E     Frame 3 
       
 651 AACGCGAAAA ACACCCTGTA TCTGGAAATG AGCAGCCTGC GCAGCGAAGA 
     N  A  K  N   T  L  Y   L  E  M   S  S  L  R   S  E  D    Frame 3 
        CDR-H3 
 701 TACCACCATG TATTATTGCG CGCGCGGCAA CCTGTATTAT GGCCTGGATT 
      T  T  M   Y  Y  C  A   R  G  N   L  Y  Y   G  L  D  Y   Frame 3    
                                           NotI    
 751 ATTGGGGCCA GGGCACCACC CTGACCGTGA GCAGCGCGGC CGCATCCGCA 
       W  G  Q   G  T  T   L  T  V  S   S  A  A   A  S  A     Frame 3 
         His6 tag                  Tri-FLAG 
 801 CATCATCATC ACCATCACAA GCTGGACTAC AAAGACCATG ACGGTGATTA 
     H  H  H  H   H  H  K   L  D  Y   K  D  H  D   G  D  Y    Frame 3 
                   
                  HindIII 
 851 TAAAGATCAT GACATCGATT ACAAGGATGA CGATGACAAG TAATAAAAGC 
      K  D  H   D  I  D  Y   K  D  D   D  D  K   *  Frame 3 
      
 
Figure XII: Nucleotide and deduced amino acid sequence of pSANG10-3F 4B7 
scFv-0 (VL–VH). The amino acid sequences corresponding to the complementary 
determining regions (CDRs) are in green. The sequences coding for the six histidines 
and the Tri-FLAG in the carboxy terminal part of the scFv are underlined. 
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Figure XIII: Physical map of 4B7 scFv-20 VL–VH in pSANG10-3F. The plasmid is 
based on the pET26(+) plasmid system and has the T7 promoter for expression of 
scFv-20. Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin of 
replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and lacI 
gene.  
 
      XbaI                                     NdeI        
    1 TCTAGAATAA TTTTGTTTAA CTTTAAGAAG GAGATATACA TATGAAATAC 
                                                   M  K  Y    Frame 3                                                     
             pelB leader sequence                       NcoI                                      
   51 CTGCTGCCGA CCGCTGCTGC TGGTCTGCTG CTCCTCGCTG CCCAGCCGGC 
      L  L  P  T   A  A  A   G  L  L   L  L  A  A   Q  P  A   Frame 3 
           VL 
  101 CATGGCCGAT ATTCAGATGA TTCAGAGCCC GAGCAGCATG TTTGCGAGCC 
       M  A  D   I  Q  M  I   Q  S  P   S  S  M   F  A  S  L  Frame 3 
    CDR-L1 
  151 TGGGCGATCG CGTGAGCCTG AGCTGCCGCG CGAGCCAGGA TATTCGCGGC 
        G  D  R   V  S  L   S  C  R  A   S  Q  D   I  R  G    Frame 3 
  201 AACCTGGATT GGTTTCAGCA GAAACCGGGC GGCACCATTA AACTACTGAT 
      N  L  D  W   F  Q  Q   K  P  G   G  T  I  K   L  L  I   Frame 3 
               CDR-L2                                         
  251 TTATAGCACC AGCAACCTGA ACAGCGGCGT GCCGAGCCGC TTTAGCGGCA 
       Y  S  T   S  N  L  N   S  G  V   P  S  R   F  S  G  S  Frame 3     
  301 GCGGCAGCGG CAGCGATTAT AGCCTGACCA TTAGCAGCCT GGAAAGCGAA 
        G  S  G   S  D  Y   S  L  T  I   S  S  L   E  S  E    Frame 3 
                                     CDR-L3 
  351 GATCTGGGCG ATTATTATTG CCTGCAGCGC AACGCGTATC CGCTGACCTT 
      D  L  G  D   Y  Y  C   L  Q  R   N  A  Y  P   L  T  F   Frame 3       
  401 TGGCAGCGGC ACCAAACTGG AAATTAAAGC GGGAGGTGGC GGTAGTGGAG 
       G  S  G   T  K  L  E   I  K  A   G  G  G   G  S  G  G  Frame 3 
               20 aa linker                       VH 
  451 GTGGCGGAAG CGGAGGTGGC GGTAGTGGAG GTGGCGGAAG CGAAGTGAAA 
        G  G  S   G  G  G   G  S  G  G   G  G  S   E  V  K    Frame 3      
  501 CTGGTGGAAA GCGGCGGCGG CCTGGTGCAG CCGGGCGGCA GCCAGAAACT 
      L  V  E  S   G  G  G   L  V  Q   P  G  G  S   Q  K  L   Frame 3 
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             CDR-H1 
  551 GAGCTGCGCA GCGAGCGGCT TTACCTTTAG CGATTATGGC ATGGCGTGGT 
       S  C  A   A  S  G  F   T  F  S   D  Y  G   M  A  W  F  Frame 3 
      CDR-H2 
  601 TTCGCCAGGC GCCGGGCAAA GGCCCGGAAT GGGTGGCGTT TATTAACAAC 
        R  Q  A   P  G  K   G  P  E  W   V  A  F   I  N  N    Frame 3       
  651 CTGGCGTATA GCATTTATTA TGCGGATACC GTGACCGGCC GCTTTACCAT 
      L  A  Y  S   I  Y  Y   A  D  T   V  T  G  R   F  T  I   Frame 3       
  701 TAGCCGCGAA AACGCAAAAA ACACCCTGTA TCTGGAAATG AGCAGCCTGC 
       S  R  E   N  A  K  N   T  L  Y   L  E  M   S  S  L  R  Frame 3 
       CDR-H3 
  751 GCAGCGAAGA TACCACCATG TATTATTGCG CGCGCGGCAA CCTGTATTAT 
        S  E  D   T  T  M   Y  Y  C  A   R  G  N   L  Y  Y    Frame 3      
                                                      NotI 
  801 GGCCTGGATT ATTGGGGCCA GGGCACCACC CTGACCGTGA GCAGCGCGGC 
      G  L  D  Y   W  G  Q   G  T  T   L  T  V  S   S  A  A   Frame 3 
                     His6 tag                 Tri-FLAG 
  851 CGCATCCGCA CATCATCATC ACCATCACAA GCTGGACTAC AAAGACCATG 
       A  S  A   H  H  H  H   H  H  K   L  D  Y   K  D  H  D  Frame 3      
  901 ACGGTGATTA TAAAGATCAT GACATCGATT ACAAGGATGA CGATGACAAG 
        G  D  Y   K  D  H   D  I  D  Y   K  D  D   D  D  K    Frame 3      
            HindIII           
  951 TAATAAAAGC TT 
      *   Frame 3 
 
Figure XIV: Nucleotide and deduced amino acid sequence of pSANG10-3F 4B7 
scFv-20 (VL–VH). The amino acid sequences corresponding to the complementary 
determining regions (CDRs) are in green. The sequences coding for the six histidines 
and the Tri-FLAG in the carboxy terminal part of the scFv are underlined. 
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Figure XV: Physical maps of 4B7 scFv-0 VL–VH in pBAK.1Hk. The plasmid is 
based on the pET41b(+) plasmid system and has the T7 promoter for expression of 
scFv-Hk. Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin 
of replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and 
lacI gene.  
 
 
XbaI                 
    1 TCTAGATCAG GAGAACAGTC ATAATGAAAT ACCTATTGCC TACGGCAGCC 
                               M  K  Y   L  L  P   T  A  A    Frame 3  
                                        NcoI 
   51 GCTGGATTGT TATTACTCGC GGCCCAGCCG GCCATGGCCG ATATTGAGAT 
      A  G  L  L   L  L  A   A  Q  P   A  M  A  D   I  E  M   Frame 3 
                      
  101 GACCCAGAGC CCGAGCAGCA TGTTTGCGAG CCTGGGCGAT CGCGTGAGCC 
       T  Q  S   P  S  S  M   F  A  S   L  G  D   R  V  S  L  Frame 3 
       
  151 TGAGCTGCCG CGCGAGCCAG GATATTCGCG GCAACCTGGA TTGGTTTCAG 
        S  C  R   A  S  Q   D  I  R  G   N  L  D   W  F  Q    Frame 3 
        
  201 CAGAAACCGG GCGGCACCAT TAAACTGCTG ATTTATAGCA CCAGCAACCT 
      Q  K  P  G   G  T  I   K  L  L   I  Y  S  T   S  N  L   Frame 3 
         
  251 GAACAGCGGC GTGCCGAGCC GCTTTAGCGG CAGCGGCAGC GGCAGCGATT 
       N  S  G   V  P  S  R   F  S  G   S  G  S   G  S  D  Y  Frame 3 
       
  301 ATAGCCTGAC CATTAGCAGC CTGGAAAGCG AAGATTTTGT CGATTATTAT 
        S  L  T   I  S  S   L  E  S  E   D  F  V   D  Y  Y    Frame 3 
        
  351 TGCCTGCAGC GCAACGCGTA TCCGCTGACC TTTGGCAGCG GCACCAAACT 
      C  L  Q  R   N  A  Y   P  L  T   F  G  S  G   T  K  L   Frame 3 
         
  401 GGAAATTAAA GCGGAAGTGA AACTGGTGGA AAGCGGCGGC GGCCTGGTGC 
       E  I  K   A  E  V  K   L  V  E   S  G  G   G  L  V  Q  Frame 3 
       
  451 AGCCGGGCGG CAGCCAGAAA CTGAGCTGCG CGGCGAGCGG CTTTACCTTT 
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        P  G  G   S  Q  K   L  S  C  A   A  S  G   F  T  F    Frame 3 
        
  501 AGCGATTATG GCATGGCGTG GTTTCGCCAG GCGCCGGGCA AAGGCCCGGA 
      S  D  Y  G   M  A  W   F  R  Q   A  P  G  K   G  P  E   Frame 3 
         
  551 ATGGGTGGCG TTTATTAACA ACCTGGCGTA TAGCATTTAT TATGCGGATA 
       W  V  A   F  I  N  N   L  A  Y   S  I  Y   Y  A  D  T  Frame 3 
       
  601 CCGTGACCGG CCGCTTTACC ATTAGCCGCG AAAACGCGAA AAACACCCTG 
        V  T  G   R  F  T   I  S  R  E   N  A  K   N  T  L    Frame 3 
        
  651 TATCTGGAAA TGAGCAGCCT GCGCAGCGAA GATACCACCA TGTATTATTG 
      Y  L  E  M   S  S  L   R  S  E   D  T  T  M   Y  Y  C   Frame 3 
         
  701 CGCGCGCGGC AACCTGTATT ATGGCCTGGA TTATTGGGGC CAGGGCACCA 
       A  R  G   N  L  Y  Y   G  L  D   Y  W  G   Q  G  T  T  Frame 3       
                        NotI              
  751 CCCTGACCGT GAGCAGCGCG GCCGCACCAT CTGTCTTCAT CTTCCCGCCA 
        L  T  V   S  S  A   A  A  P  S   V  F  I   F  P  P    Frame 3 
        
  801 TCTGATGAGC AGTTGAAATC TGGAACTGCC TCTGTTGTGT GCCTGCTGAA 
      S  D  E  Q   L  K  S   G  T  A   S  V  V  C   L  L  N   Frame 3 
         
  851 TAACTTCTAT CCCAGAGAGG CCAAAGTACA GTGGAAGGTG GATAACGCCC 
       N  F  Y   P  R  E  A   K  V  Q   W  K  V   D  N  A  L  Frame 3 
 
  901 TCCAATCGGG TAACTCCCAG GAGAGTGTCA CAGAGCAGGA CAGCAAGGAC 
        Q  S  G   N  S  Q   E  S  V  T   E  Q  D   S  K  D    Frame 3 
        
  951 AGCACCTACA GCCTCAGCAG CACCCTGACG CTGAGCAAAG CAGACTACGA 
      S  T  Y  S   L  S  S   T  L  T   L  S  K  A   D  Y  E   Frame 3 
         
 1001 GAAACACAAA CTCTACGCCT GCGAAGTCAC CCATCAGGGC CTGAGCTCGC 
       K  H  K   L  Y  A  C   E  V  T   H  Q  G   L  S  S  P  Frame 3      
                                  XhoI 
 1051 CCGTCACAAA GAGCTTCAAC AGGGGACTCG AGCACCACCA CCACCACCAC 
        V  T  K   S  F  N   R  G  L  E   H  H  H   H  H  H    Frame 3 
                            
 1101 CACCACTAAT                  
      H  H  *   Frame 3 
 
Figure XVI: Nucleotide and deduced amino acid sequence of pBAK.1 4B7 scFv-
0 VL–VH. The amino acid sequences corresponding to the complementary 
determining regions (CDRs) are in green. The leader sequence, restriction sites and 
octa his tag are indicated.    
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Figure XVII: Physical maps of 4B7 scFv-20 VL–VH in pBAK.1Hk. The plasmid is 
based on the pET41b(+) plasmid system and has the T7 promoter for expression of 
scFv-Hk. Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin 
of replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and 
lacI gene.  
 
 
      XbaI                                    
    1 TCTAGATCAG GAGAACAGTC ATAATGAAAT ACCTATTGCC TACGGCAGCC 
                               M  K  Y   L  L  P   T  A  A    Frame 3                                                     
                            SfiI        NcoI 
   51 GCTGGATTGT TATTACTCGC GGCCCAGCCG GCCATGGCCG ATATTGAGAT 
      A  G  L  L   L  L  A   A  Q  P   A  M  A  D   I  E  M   Frame 3 
                      
  101 GACCCAGAGC CCGAGCAGCA TGTTTGCGAG CCTGGGCGAT CGCGTGAGCC 
       T  Q  S   P  S  S  M   F  A  S   L  G  D   R  V  S  L  Frame 3 
       
  151 TGAGCTGCCG CGCGAGCCAG GATATTCGCG GCAACCTGGA TTGGTTTCAG 
        S  C  R   A  S  Q   D  I  R  G   N  L  D   W  F  Q    Frame 3 
        
  201 CAGAAACCGG GCGGCACCAT TAAACTGCTG ATTTATAGCA CCAGCAACCT 
      Q  K  P  G   G  T  I   K  L  L   I  Y  S  T   S  N  L   Frame 3 
         
  251 GAACAGCGGC GTGCCGAGCC GCTTTAGCGG CAGCGGCAGC GGCAGCGATT 
       N  S  G   V  P  S  R   F  S  G   S  G  S   G  S  D  Y  Frame 3 
       
  301 ATAGCCTGAC CATTAGCAGC CTGGAAAGCG AAGATTTTGT CGATTATTAT 
        S  L  T   I  S  S   L  E  S  E   D  F  V   D  Y  Y    Frame 3 
        
  351 TGCCTGCAGC GCAACGCGTA TCCGCTGACC TTTGGCAGCG GCACCAAACT 
      C  L  Q  R   N  A  Y   P  L  T   F  G  S  G   T  K  L   Frame 3 
 
  401 GGAAATTAAA GCGGGAGGTG GCGGTAGTGG AGGTGGCGGA AGCGGAGGTG 
       E  I  K   A  G  G  G   G  S  G   G  G  G   S  G  G  G  Frame 3 
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  451 GCGGTAGCGG AGGTGGCGGA AGCGAAGTGA AACTGGTGGA AAGCGGCGGC 
        G  S  G   G  G  G   S  E  V  K   L  V  E   S  G  G    Frame 3 
        
  501 GGCCTGGTGC AGCCGGGCGG CAGCCGCAAA CTGAGCTGCG CGGCGAGCGG 
      G  L  V  Q   P  G  G   S  R  K   L  S  C  A   A  S  G   Frame 3 
         
  551 CTTTACCTTT AGCGATTATG GCATGGCGTG GTTTCGCCAG GCGCCGGGCA 
       F  T  F   S  D  Y  G   M  A  W   F  R  Q   A  P  G  K  Frame 3 
       
  601 AAGGCCCGGA ATGGGTGGCG TTTATTAACA ACCTGGCGTA TAGCATTTAT 
        G  P  E   W  V  A   F  I  N  N   L  A  Y   S  I  Y    Frame 3 
        
  651 TATGCGGATA CCGTGACCGG CCGCTTTACC ATTAGCCGCG AAAACGCGAA 
      Y  A  D  T   V  T  G   R  F  T   I  S  R  E   N  A  K   Frame 3 
         
  701 AAACACCCTG TATCTGGAAA TGAGCAGCCT GCGCAGCGAA GATACCGCCA 
       N  T  L   Y  L  E  M   S  S  L   R  S  E   D  T  A  M  Frame 3 
       
  751 TGTATTATTG CGCGCGCGGC AACCTGTATT ATGGCCTGGA TTATTGGGGC 
        Y  Y  C   A  R  G   N  L  Y  Y   G  L  D   Y  W  G    Frame 3 
        
                                  NotI              
  801 CAGGGCACCA CCGTGACCGT GAGCAGCGCG GCCGCACCAT CTGTCTTCAT 
      Q  G  T  T   V  T  V   S  S  A   A  A  P  S   V  F  I   Frame 3 
         
  851 CTTCCCGCCA TCTGATGAGC AGTTGAAATC TGGAACTGCC TCTGTTGTGT 
       F  P  P   S  D  E  Q   L  K  S   G  T  A   S  V  V  C  Frame 3 
       
  901 GCCTGCTGAA TAACTTCTAT CCCAGAGAGG CCAAAGTACA GTGGAAGGTG 
        L  L  N   N  F  Y   P  R  E  A   K  V  Q   W  K  V    Frame 3       
   
  951 GATAACGCCC TCCAATCGGG TAACTCCCAG GAGAGTGTCA CAGAGCAGGA 
      D  N  A  L   Q  S  G   N  S  Q   E  S  V  T   E  Q  D   Frame 3 
         
 1001 CAGCAAGGAC AGCACCTACA GCCTCAGCAG CACCCTGACG CTGAGCAAAG 
      S  K  D   S  T  Y  S   L  S  S   T  L  T   L  S  K  A   Frame 3 
       
 1051 CAGACTACGA GAAACACAAA CTCTACGCCT GCGAAGTCAC CCATCAGGGC 
       D  Y  E   K  H  K   L  Y  A  C   E  V  T   H  Q  G     Frame 3 
                                                  
                                             XhoI 
 1101 CTGAGCTCGC CCGTCACAAA GAGCTTCAAC AGGGGACTCG AGCACCACCA 
      L  S  S  P   V  T  K   S  F  N   R  G  L  E   H  H  H   Frame 3 
                                        
 1151 CCACCACCAC CACCACTAAT TGATTAATAC CTAGGCTGCT AAAC       
       H  H  H   H  H  *  Frame 3 
 
 
Figure XVIII: Nucleotide and deduced amino acid sequence of pBAK.1Hk 4B7 
scFv-20 (VL–VH). The amino acid sequences corresponding to the complementary 
determining regions (CDRs) are in green. The sequences coding for the six histidines 
and the Tri-FLAG in the carboxy terminal part of the scFv are underlined. 
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Figure XIX: Physical pBAK.1 with Pf-NPNA-1 scFv-0 insert. The plasmid is based 
on the pET41b(+) plasmid system and has the T7 promoter for expression of scFv-0. 
Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin of 
replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and lacI 
gene.  
 
 
     XbaI                           pelB leader sequence                       
   1 TCTAGATCAA GGAGAACAGT CATAATGAAA TACCTATTGC CTACGGCAGC 
                               M  K   Y  L  L  P   T  A  A    Frame 1                                       
                            SfiI        NcoI    VH 
  51 CGCTGGATTG TTATTACTCG CGGCCCAGCC GGCCATGGCC CAGGTGCAGC 
      A  G  L   L  L  L  A   A  Q  P   A  M  A   Q  V  Q  L   Frame 1 
                                                         
 101 TGGTGCAGAG CGGCGGCGGC GTGGTGCAGC CGGGCCGCAG CCTGCGCCTG 
       V  Q  S   G  G  G   V  V  Q  P   G  R  S   L  R  L     Frame 1 
                                         CDR-H1      
 151 AGCTGCGCGG CGAGCGGCTT TATTTTTAGC AACTATGCGA TGGATTGGGT 
     S  C  A  A   S  G  F   I  F  S   N  Y  A  M   D  W  V    Frame 1 
            
 201 GCGCCAGGCG CCGGGCAAAG GCCTGGATTG GGTGGCGGTG GTGAGCTATG 
      R  Q  A   P  G  K  G   L  D  W   V  A  V   V  S  Y  D   Frame 1 
                   CDR-H2   
 251 ATGCGCGCAA CCAGTATTAT GCGGATAGCG TGAAAGGCCG CTTTACCATT 
       A  R  N   Q  Y  Y   A  D  S  V   K  G  R   F  T  I     Frame 1 
                                            
 301 AGCCGCGATA ACAGCAAAAA CACCCTGTAT CTGCGCATGA ACAGCCTGCG 
     S  R  D  N   S  K  N   T  L  Y   L  R  M  N   S  L  R    Frame 1                                            
                                           CDR-H3     XhoI 
 351 CGCGGAAGAT ACCGCGGTGT ATTATTGCGC GCGCGATCGC GATAGCTCGA 
      A  E  D   T  A  V  Y   Y  C  A   R  D  R   D  S  S  S   Frame 1 
                                            VL  
 401 GCTATTTTGA TAGCTGGGGC CAGGGCACCC TGGTGACCGT GAGCAGCGAA 
       Y  F  D   S  W  G   Q  G  T  L   V  T  V   S  S  E     Frame 1 
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 451 ATTGTGCTGA CCCAGAGCCC GAGCACCCTG AGCGCGAGCG TGGGCGATCG 
     I  V  L  T   Q  S  P   S  T  L   S  A  S  V   G  D  R    Frame 1 
              CDR-L1   
 501 CGTGACCACC ACCTGCCGCG CGAGCCAGGG CATTAGCAAC TGGCTGGCGT 
      V  T  T   T  C  R  A   S  Q  G   I  S  N   W  L  A  W   Frame 1 
 
 551 GGTATCAGCA GAAACCGGGC CGCGCGCCGA AACTGCTGAT TGTGAAAGCG 
       Y  Q  Q   K  P  G   R  A  P  K   L  L  I   V  K  A     Frame 1 
         CDR-L2              
 601 AGCAGCCTGG AAAGCGACGT GCCGAGCCGC TTTAGCGGCA GCGGCAGCGG 
     S  S  L  E   S  D  V   P  S  R   F  S  G  S   G  S  G    Frame 1 
                                    
 651 CACCGAATTT ACCCTGACCA TTAGCAGCCT GCAGCCGGAT GATTTTGCGA 
      T  E  F   T  L  T  I   S  S  L   Q  P  D   D  F  A  T   Frame 1 
                           CDR-L3      
 701 CCTATTATTG CCAGCAGTAT AACAGCTATA GCGGCCTGAC CTTTGGCGGC 
       Y  Y  C   Q  Q  Y   N  S  Y  S   G  L  T   F  G  G     Frame 1                                           
                               NotI      XhoI   His8 Tag 
 751 GGCACCAAAG TGGAAATTAA ACGCGCGGCC GCACTCGAGC ACCACCACCA 
     G  T  K  V   E  I  K   R  A  A   A  L  E  H   H  H  H    Frame 1 
                                   
 801 CCACCACCAC CACTAA 
      H  H  H   H  *  Frame 1 
             
Figure XX: Nucleotide and deduced amino acid sequence of pBAK.1 Pf-NPNA 
scFv-0 (VH – VL). The amino acid sequences corresponding to the complementary 
determining regions (CDRs) are in green. The leader sequence, restriction sites and 
octa his tag are indicated.   
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Figure XXI: Physical pBAK.1 with Pf-NPNA-1 scFv-12 insert. The plasmid is 
based on the pET41b(+) plasmid system and has the T7 promoter for expression of 
scFv-12. Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin of 
replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and lacI 
gene.  
 
 
 
 
       XbaI                          pelB leader sequence                        
   1 TCTAGATCAA GGAGAACAGT CATAATGAAA TACCTATTGC CTACGGCAGC 
                               M  K   Y  L  L  P   T  A  A    Frame 1 
                            SfiI        NcoI    VH 
  51 CGCTGGATTG TTATTACTCG CGGCCCAGCC GGCCATGGCC CAGGTGCAGC 
      A  G  L   L  L  L  A   A  Q  P   A  M  A   Q  V  Q  L   Frame 1 
 
 101 TGGTGCAGAG CGGCGGCGGC GTGGTGCAGC CGGGCCGCAG CCTGCGCCTG 
       V  Q  S   G  G  G   V  V  Q  P   G  R  S   L  R  L     Frame 1 
  CDR-H1 
 151 AGCTGCGCGG CGAGCGGCTT TATTTTTAGC AACTATGCGA TGGATTGGGT 
     S  C  A  A   S  G  F   I  F  S   N  Y  A  M   D  W  V    Frame 1 
 
 201 GCGCCAGGCG CCGGGCAAAG GCCTGGATTG GGTGGCGGTG GTGAGCTATG 
      R  Q  A   P  G  K  G   L  D  W   V  A  V   V  S  Y  D   Frame 1 
                CDR-H2   
 251 ATGCGCGCAA CCAGTATTAT GCGGATAGCG TGAAAGGCCG CTTTACCATT 
       A  R  N   Q  Y  Y   A  D  S  V   K  G  R   F  T  I     Frame 1 
                                            
 301 AGCCGCGATA ACAGCAAAAA CACCCTGTAT CTGCGCATGA ACAGCCTGCG 
     S  R  D  N   S  K  N   T  L  Y   L  R  M  N   S  L  R    Frame 1                                           
                    CDR-H3   XhoI 
 351 CGCGGAAGAT ACCGCGGTGT ATTATTGCGC GCGCGATCGC GATAGCTCGA 
      A  E  D   T  A  V  Y   Y  C  A   R  D  R   D  S  S  S   Frame 1 
                                            
 401 GCTATTTTGA TAGCTGGGGC CAGGGCACCC TGGTGACCGT GAGCAGCGGC 
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       Y  F  D   S  W  G   Q  G  T  L   V  T  V   S  S  G     Frame 1 
          12 aa linker VL  
 451 GGTGGCAGCG GTGGCGGTAG CGGCGGTGGC AGCGAAATTG TGCTGACCCA 
     G  G  S  G   G  G  S   G  G  G   S  E  I  V   L  T  Q    Frame 1 
 
 501 GAGCCCGAGC ACCCTGAGCG CGAGCGTGGG CGATCGCGTG ACCACCACCT 
      S  P  S   T  L  S  A   S  V  G   D  R  V   T  T  T  C   Frame 1 
        CDR-L1   
 551 GCCGCGCGAG CCAGGGCATT AGCAACTGGC TGGCGTGGTA TCAGCAGAAA 
       R  A  S   Q  G  I   S  N  W  L   A  W  Y   Q  Q  K     Frame 1 
  CDR-L2  
 601 CCGGGCCGCG CGCCGAAACT GCTGATTGTG AAAGCGAGCA GCCTGGAAAG 
     P  G  R  A   P  K  L   L  I  V   K  A  S  S   L  E  S    Frame 1 
 
 651 CGGCGTGCCG AGCCGCTTTA GCGGCAGCGG CAGCGGCACC GAATTTACCC 
      G  V  P   S  R  F  S   G  S  G   S  G  T   E  F  T  L   Frame 1 
 
 701 TGACCATTAG CAGCCTGCAG CCGGATGATT TTGCGACCTA TTATTGCCAG 
       T  I  S   S  L  Q   P  D  D  F   A  T  Y   Y  C  Q     Frame 1 
     CDR-L3 
 751 CAGTATAACA GCTATAGCGG CCTGACCTTT GGCGGCGGCA CCAAAGTGGA 
     Q  Y  N  S   Y  S  G   L  T  F   G  G  G  T   K  V  E    Frame 1 
                NotI     XhoI            His8 Tag 
 801 AATTAAACGC GCGGCCGCAC TCGAGCACCA CCACCACCAC CACCACCACT 
      I  K  R   A  A  A  L   E  H  H   H  H  H   H  H  H  *   Frame 1 
 
 851 AA  
                                              
Figure XXII: Nucleotide and deduced amino acid sequence of pBAK.1 Pf-NPNA 
scFv-12 (VH – VL). The amino acid sequences corresponding to the complementary 
determining regions (CDRs) are in green. The leader sequence, restriction sites and 
octa his tag are indicated.   
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Figure XXIII: Physical map of Pf-NPNA-1 scFv-0 VH–VL in pSANG10-3F. The 
plasmid is based on the pET26(+) plasmid system and has the T7 promoter for 
expression of scFv-20. Relevant genetic elements are: lac operator, pelB signal 
peptide, f1 origin of replication, T7 terminator, kanamycin resistance gene, 
ColE1pBR322 gene and lacI gene.  
 
 
 
     XbaI                                     NdeI       
   1 TCTAGAATAA TTTTGTTTAA CTTTAAGAAG GAGATATACA TATGAAATAC 
                                                  M  K  Y     Frame 3       
                                                       NcoI 
  51 CTGCTGCCGA CCGCTGCTGC TGGTCTGCTG CTCCTCGCTG CCCAGCCGGC 
     L  L  P  T   A  A  A   G  L  L   L  L  A  A   Q  P  A    Frame 3 
        
 101 CATGGCCCAG GTGCAGCTGG TGCAGAGCGG CGGCGGCGTG GTGCAGCCGG 
      M  A  Q   V  Q  L  V   Q  S  G   G  G  V   V  Q  P  G   Frame 3 
      
 151 GCCGCAGCCT GCGCCTGAGC TGCGCGGCGA GCGGCTTTAT TTTTAGCAAC 
       R  S  L   R  L  S   C  A  A  S   G  F  I   F  S  N     Frame 3 
       
 201 TATGCGATGG ATTGGGTGCG CCAGGCGCCG GGCAAAGGCC TGGATTGGGT 
     Y  A  M  D   W  V  R   Q  A  P   G  K  G  L   D  W  V    Frame 3 
        
 251 GGCGGTGGTG AGCTATGATG CGCGCAACCA GTATTATGCG GATAGCGTGA 
      A  V  V   S  Y  D  A   R  N  Q   Y  Y  A   D  S  V  K   Frame 3 
      
 301 AAGGCCGCTT TACCATTAGC CGCGATAACA GCAAAAACAC CCTGTATCTG 
       G  R  F   T  I  S   R  D  N  S   K  N  T   L  Y  L     Frame 3 
       
 351 CGCATGAACA GCCTGCGCGC GGAAGATACC GCGGTGTATT ATTGCGCGCG 
     R  M  N  S   L  R  A   E  D  T   A  V  Y  Y   C  A  R    Frame 3 
        
 401 CGATCGCGAT AGCTCGAGCT ATTTTGATAG CTGGGGCCAG GGCACCCTGG 
      D  R  D   S  S  S  Y   F  D  S   W  G  Q   G  T  L  V   Frame 3 
      
 451 TGACCGTGAG CAGCGAAATT GTGCTGACCC AGAGCCCGAG CACCCTGAGC 
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       T  V  S   S  E  I   V  L  T  Q   S  P  S   T  L  S     Frame 3 
       
 501 GCGAGCGTGG GCGATCGCGT GACCACCACC TGCCGCGCGA GCCAGGGCAT 
     A  S  V  G   D  R  V   T  T  T   C  R  A  S   Q  G  I    Frame 3 
        
 551 TAGCAACTGG CTGGCGTGGT ATCAGCAGAA ACCGGGCCGC GCGCCGAAAC 
      S  N  W   L  A  W  Y   Q  Q  K   P  G  R   A  P  K  L   Frame 3 
      
 601 TGCTGATTGT GAAAGCGAGC AGCCTGGAAA GCGACGTGCC GAGCCGCTTT 
       L  I  V   K  A  S   S  L  E  S   D  V  P   S  R  F     Frame 3 
       
 651 AGCGGCAGCG GCAGCGGCAC CGAATTTACC CTGACCATTA GCAGCCTGCA 
     S  G  S  G   S  G  T   E  F  T   L  T  I  S   S  L  Q    Frame 3 
        
 701 GCCGGATGAT TTTGCGACCT ATTATTGCCA GCAGTATAAC AGCTATAGCG 
      P  D  D   F  A  T  Y   Y  C  Q   Q  Y  N   S  Y  S  G   Frame 3 
      
                                                  NotI   
 751 GCCTGACCTT TGGCGGCGGC ACCAAAGTGG AAATTAAACG CGCGGCCGCA 
       L  T  F   G  G  G   T  K  V  E   I  K  R   A  A  A     Frame 3 
       
 801 TCCGCACATC ATCATCACCA TCACAAGCTG GACTACAAAG ACCATGACGG 
     S  A  H  H   H  H  H   H  K  L   D  Y  K  D   H  D  G    Frame 3 
        
 851 TGATTATAAA GATCATGACA TCGATTACAA GGATGACGAT GACAAGTAAT 
      D  Y  K   D  H  D  I   D  Y  K   D  D  D   D  K  *  Frame 3 
     
      HindIII          
 901 TAAGCTTTAA TAAGTCGAGC ACCACCACCA CCACCACTGA GATCCGGCTG 
 
Figure XXIV: Nucleotide and deduced amino acid sequence of pSANG10-3F 
NPNA scFv-0 (VH–VL). The amino acid sequences corresponding to the 
complementary determining regions (CDRs) are in green. The sequences coding for 
the six histidines and the Tri-FLAG in the carboxy terminal part of the scFv are 
underlined. 
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Figure XXV: Physical map of Pf-NPNA-1 scFv-12 VH–VL in pSANG10-3F. The 
plasmid is based on the pET26(+) plasmid system and has the T7 promoter for 
expression of scFv-20. Relevant genetic elements are: lac operator, pelB signal 
peptide, f1 origin of replication, T7 terminator, kanamycin resistance gene, 
ColE1pBR322 gene and lacI gene.  
 
 
            XbaI 
    1 TCTAAGAATA ATTTTGTTTA ACTTTAAGAA GGAGATATAC ATATGAAATA 
                                                    M  K  Y   Frame 1 
                                                        
   51 CCTGCTGCCG ACCGCTGCTG CTGGTCTGCT GCTCCTCGCT GCCCAGCCGG 
       L  L  P   T  A  A  A   G  L  L   L  L  A   A  Q  P  A  Frame 1 
       
      NcoI            
  101 CCATGGCCCA GGTGCAGCTG GTGCAGAGCG GCGGCGGCGT GGTGCAGCCG 
        M  A  Q   V  Q  L   V  Q  S  G   G  G  V   V  Q  P    Frame 1 
        
  151 GGCCGCAGCC TGCGCCTGAG CTGCGCGGCG AGCGGCTTTA TTTTTAGCAA 
      G  R  S  L   R  L  S   C  A  A   S  G  F  I   F  S  N   Frame 1 
         
  201 CTATGCGATG GATTGGGTGC GCCAGGCGCC GGGCAAAGGC CTGGATTGGG 
       Y  A  M   D  W  V  R   Q  A  P   G  K  G   L  D  W  V  Frame 1 
       
  251 TGGCGGTGGT GAGCTATGAT GCGCGCAACC AGTATTATGC GGATAGCGTG 
        A  V  V   S  Y  D   A  R  N  Q   Y  Y  A   D  S  V    Frame 1 
        
  301 AAAGGCCGCT TTACCATTAG CCGCGATAAC AGCAAAAACA CCCTGTATCT 
      K  G  R  F   T  I  S   R  D  N   S  K  N  T   L  Y  L   Frame 1 
         
  351 GCGCATGAAC AGCCTGCGCG CGGAAGATAC CGCGGTGTAT TATTGCGCGC 
       R  M  N   S  L  R  A   E  D  T   A  V  Y   Y  C  A  R  Frame 1 
       
                    XhoI                                          
  401 GCGATCGCGA TAGCTCGAGC TATTTTGATA GCTGGGGCCA GGGCACCCTG 
        D  R  D   S  S  S   Y  F  D  S   W  G  Q   G  T  L    Frame 1 
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  451 GTGACCGTGA GCAGCGGCGG TGGCAGCGGT GGCGGTAGCG GCGGTGGCAG 
      V  T  V  S   S  G  G   G  S  G   G  G  S  G   G  G  S   Frame 1 
         
  501 CGAAATTGTG CTGACCCAGA GCCCGAGCAC CCTGAGCGCG AGCGTGGGCG 
       E  I  V   L  T  Q  S   P  S  T   L  S  A   S  V  G  D  Frame 1 
       
  551 ATCGCGTGAC CACCACCTGC CGCGCGAGCC AGGGCATTAG CAACTGGCTG 
        R  V  T   T  T  C   R  A  S  Q   G  I  S   N  W  L    Frame 1 
        
  601 GCGTGGTATC AGCAGAAACC GGGCCGCGCG CCGAAACTGC TGATTGTGAA 
      A  W  Y  Q   Q  K  P   G  R  A   P  K  L  L   I  V  K   Frame 1 
         
  651 AGCGAGCAGC CTGGAAAGCG GCGTGCCGAG CCGCTTTAGC GGCAGCGGCA 
       A  S  S   L  E  S  G   V  P  S   R  F  S   G  S  G  S  Frame 1 
       
  701 GCGGCACCGA ATTTACCCTG ACCATTAGCA GCCTGCAGCC GGATGATTTT 
        G  T  E   F  T  L   T  I  S  S   L  Q  P   D  D  F    Frame 1 
        
  751 GCGACCTATT ATTGCCAGCA GTATAACAGC TATAGCGGCC TGACCTTTGG 
      A  T  Y  Y   C  Q  Q   Y  N  S   Y  S  G  L   T  F  G   Frame 1       
                                    NotI    
  801 CGGCGGCACC AAAGTGGAAA TTAAACGCGC GGCCGCATCC GCACATCATC 
       G  G  T   K  V  E  I   K  R  A   A  A  S   A  H  H  H  Frame 1 
                                                                    
  851 ATCACCATCA CAAGCTGGAC TACAAAGACC ATGACGGTGA TTATAAAGAT 
        H  H  H   K  L  D   Y  K  D  H   D  G  D   Y  K  D    Frame 1 
   
                                                HindIII 
  901 CATGACATCG ATTACAAGGA TGACGATGAC AAGTAATAAA AGCTTTAATA 
      H  D  I  D   Y  K  D   D  D  D   K  *   Frame 1 
 
Figure XXVI: Nucleotide and deduced amino acid sequence of pSANG10-3F 
NPNA scFv-12 (VH–VL). The amino acid sequences corresponding to the 
complementary determining regions (CDRs) are in green. The sequences coding for 
the six histidines and the Tri-FLAG in the carboxy terminal part of the scFv are 
underlined. 
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Figure XXVII: Physical pBAK.1HK with Pf-NPNA-1 scFv-0 insert. The plasmid is 
based on the pET41b(+) plasmid system and has the T7 promoter for expression of 
scFv-0Hk. Relevant genetic elements are: lac operator, pelB signal peptide, f1 origin 
of replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene and 
lacI gene.  
 
 
 
      XbaI                                           
    1 TCTAGATCAA GGAGAACAGT CATAATGAAA TACCTATTGC CTACGGCAGC 
                                M  K   Y  L  L  P   T  A  A   Frame 1 
 
                             SfiI        NcoI 
   51 CGAAGGGGTG TTATTACTCG CGGCCCAGCC GGCCATGGCC CAGGTGCAGC 
       E  G  V   L  L  L  A   A  Q  P   A  M  A   Q  V  Q  L  Frame 1 
                              
  101 TGGTGCAGAG CGGCGGCGGC GTGGTGCAGC CGGGCCGCAG CCTGCGCCTG 
        V  Q  S   G  G  G   V  V  Q  P   G  R  S   L  R  L    Frame 1 
        
  151 AGCTGCGCGG CGAGCGGCTT TATTTTTAGC AACTATGCGA TGGATTGGGT 
      S  C  A  A   S  G  F   I  F  S   N  Y  A  M   D  W  V   Frame 1 
 
  201 GCGCCAGGCG CCGGGCAAAG GCCTGGATTG GGTGGCGGTG GTGAGCTATG 
       R  Q  A   P  G  K  G   L  D  W   V  A  V   V  S  Y  D  Frame 1 
       
  251 ATGCGCGCAA CCAGTATTAT GCGGATAGCG TGAAAGGCCG CTTTACCATT 
        A  R  N   Q  Y  Y   A  D  S  V   K  G  R   F  T  I    Frame 1 
        
  301 AGCCGCGATA ACAGCAAAAA CACCCTGTAT CTGCGCATGA ACAGCCTGCG 
      S  R  D  N   S  K  N   T  L  Y   L  R  M  N   S  L  R   Frame 1                                            
                                                       XhoI 
  351 CGCGGAAGAT ACCGCGGTGT ATTATTGCGC GCGCGATCGC GATAGCTCGA 
       A  E  D   T  A  V  Y   Y  C  A   R  D  R   D  S  S  S  Frame 1 
       
  401 GCTATTTTGA TAGCTGGGGC CAGGGCACCC TGGTGACCGT GAGCAGCGAA 
        Y  F  D   S  W  G   Q  G  T  L   V  T  V   S  S  E    Frame 1 
        
  451 ATTGTGCTGA CCCAGAGCCC GAGCACCCTG AGCGCGAGCG TGGGCGATCG 
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      I  V  L  T   Q  S  P   S  T  L   S  A  S  V   G  D  R   Frame 1 
         
  501 CGTGACCACC ACCTGCCGCG CGAGCCAGGG CATTAGCAAC TGGCTGGCGT 
       V  T  T   T  C  R  A   S  Q  G   I  S  N   W  L  A  W  Frame 1 
 
  551 GGTATCAGCA GAAACCGGGC CGCGCGCCGA AACTGCTGAT TGTGAAAGCG 
        Y  Q  Q   K  P  G   R  A  P  K   L  L  I   V  K  A    Frame 1 
 
  601 AGCAGCCTGG AAAGCGGCGT GCCGAGCCGC TTTAGCGGCA GCGGCAGCGG 
      S  S  L  E   S  G  V   P  S  R   F  S  G  S   G  S  G   Frame 1 
         
  651 CACCGAATTT ACCCTGACCA TTAGCAGCCT GCAGCCGGAT GATTTTGCGA 
       T  E  F   T  L  T  I   S  S  L   Q  P  D   D  F  A  T  Frame 1 
       
  701 CCTATTATTG CCAGCAGTAT AACAGCTATA GCGGCCTGAC CTTTGGCGGC 
        Y  Y  C   Q  Q  Y   N  S  Y  S   G  L  T   F  G  G    Frame 1 
        
                                NotI             
  751 GGCACCAAAG TGGAAATTAA ACGCGCGGCC GCACCATCTG TCTTCATCTT 
      G  T  K  V   E  I  K   R  A  A   A  P  S  V   F  I  F   Frame 1 
         
  801 CCCGCCATCT GATGAGCAGT TGAAATCTGG AACTGCCTCT GTTGTGTGCC 
       P  P  S   D  E  Q  L   K  S  G   T  A  S   V  V  C  L  Frame 1 
       
  851 TGCTGAATAA CTTCTATCCC AGAGAGGCCA AAGTACAGTG GAAGGTGGAT 
        L  N  N   F  Y  P   R  E  A  K   V  Q  W   K  V  D    Frame 1 
        
  901 AACGCCCTCC AATCGGGTAA CTCCCAGGAG AGTGTCACAG AGCAGGACAG 
      N  A  L  Q   S  G  N   S  Q  E   S  V  T  E   Q  D  S   Frame 1 
 
  951 CAAGGACAGC ACCTACAGCC TCAGCAGCAC CCTGACGCTG AGCAAAGCAG 
       K  D  S   T  Y  S  L   S  S  T   L  T  L   S  K  A  D  Frame 1 
       
 1001 ACTACGAGAA ACACAAACTC TACGCCTGCG AAGTCACCCA TCAGGGCCTG 
        Y  E  K   H  K  L   Y  A  C  E   V  T  H   Q  G  L    Frame 1 
        
                                          XhoI                                        
 1051 AGCTCGCCCG TCACAAAGAG CTTCAACAGG GGACTCGAGC ACCACCACCA 
      S  S  P  V   T  K  S   F  N  R   G  L  E  H   H  H  H   Frame 1 
 
                                    
 1101 CCACCACCAC CACTAATTGA TTAATACCTA GGCTGCTAAA CAAAGCCCGA 
       H  H  H   H  *  Frame 1 
 
Figure XXVIII: Nucleotide and deduced amino acid sequence of pBAK.1Hk Pf-
NPNA scFv-0 (VH – VL). The amino acid sequences corresponding to the 
complementary determining regions (CDRs) are in green. The leader sequence, 
restriction sites and octa his tag are indicated.   
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Figure XXIX: Physical pBAK.1HK with Pf-NPNA-1 scFv-12 insert. The plasmid is 
based on the pET41b(+) plasmid system and has the T7 promoter for expression of 
scFv-12Hk. Relevant genetic elements are: lac operator, pelB signal peptide, f1 
origin of replication, T7 terminator, kanamycin resistance gene, ColE1pBR322 gene 
and lacI gene. 
 
 
 
      XbaI                                          
    1 TCTAGATCAG GAGAACAGTC ATAATGAAAT ACCTATTGCC TACGGCAGCC 
                               M  K  Y   L  L  P   T  A  A    Frame 3                                                                            
                            SfiI        NcoI 
   51 GCTGGATTGT TATTACTCGC GGCCCAGCCG GCCATGGCCC AGGTGCAGCT 
      A  G  L  L   L  L  A   A  Q  P   A  M  A  Q   V  Q  L   Frame 3 
                      
  101 GGTGCAGAGC GGCGGCGGCG TGGTGCAGCC GGGCCGCAGC CTGCGCCTGA 
       V  Q  S   G  G  G  V   V  Q  P   G  R  S   L  R  L  S  Frame 3 
       
  151 GCTGCGCGGC GAGCGGCTTT ATTTTTAGCA ACTATGCGAT GGATTGGGTG 
        C  A  A   S  G  F   I  F  S  N   Y  A  M   D  W  V    Frame 3 
        
  201 CGCCAGGCGC CGGGCAAAGG CCTGGATTGG GTGGCGGTGG TGAGCTATGA 
      R  Q  A  P   G  K  G   L  D  W   V  A  V  V   S  Y  D   Frame 3 
         
  251 TGCGCGCAAC CAGTATTATG CGGATAGCGT GAAAGGCCGC TTTACCATTA 
       A  R  N   Q  Y  Y  A   D  S  V   K  G  R   F  T  I  S  Frame 3 
       
  301 GCCGCGATAA CAGCAAAAAC ACCCTGTATC TGCGCATGAA CAGCCTGCGC 
        R  D  N   S  K  N   T  L  Y  L   R  M  N   S  L  R    Frame 3      
                                                      XhoI 
  351 GCGGAAGATA CCGCGGTGTA TTATTGCGCG CGCGATCGCG ATAGCTCGAG 
      A  E  D  T   A  V  Y   Y  C  A   R  D  R  D   S  S  S   Frame 3 
         
  401 CTATTTTGAT AGCTGGGGCC AGGGCACCCT GGTGACCGTG AGCAGCGGCG 
       Y  F  D   S  W  G  Q   G  T  L   V  T  V   S  S  G  G  Frame 3 
       
                           Appendix                                                                                                                     
191 
 
  451 GTGGCAGCGG TGGCGGTAGC GGCGGTGGCA GCGAAATTGT GCTGACCCAG 
        G  S  G   G  G  S   G  G  G  S   E  I  V   L  T  Q    Frame 3 
        
  501 AGCCCGAGCA CCCTGAGCGC GAGCGTGGGC GATCGCGTGA CCACCACCTG 
      S  P  S  T   L  S  A   S  V  G   D  R  V  T   T  T  C   Frame 3 
         
  551 CCGCGCGAGC CAGGGCATTA GCAACTGGCT GGCGTGGTAT CAGCAGAAAC 
       R  A  S   Q  G  I  S   N  W  L   A  W  Y   Q  Q  K  P  Frame 3 
 
  601 CGGGCCGCGC GCCGAAACTG CTGATTGTGA AAGCGAGCAG CCTGGAAAGC 
        G  R  A   P  K  L   L  I  V  K   A  S  S   L  E  S    Frame 3 
        
  651 GGCGTGCCGA GCCGCTTTAG CGGCAGCGGC AGCGGCACCG AATTTACCCT 
      G  V  P  S   R  F  S   G  S  G   S  G  T  E   F  T  L   Frame 3 
         
  701 GACCATTAGC AGCCTGCAGC CGGATGATTT TGCGACCTAT TATTGCCAGC 
       T  I  S   S  L  Q  P   D  D  F   A  T  Y   Y  C  Q  Q  Frame 3 
       
  751 AGTATAACAG CTATAGCGGC CTGACCTTTG GCGGCGGCAC CAAAGTGGAA 
        Y  N  S   Y  S  G   L  T  F  G   G  G  T   K  V  E    Frame 3   
               NotI              
  801 ATTAAACGCG CGGCCGCACC ATCTGTCTTC ATCTTCCCGC CATCTGATGA 
      I  K  R  A   A  A  P   S  V  F   I  F  P  P   S  D  E   Frame 3 
         
  851 GCAGTTGAAA TCTGGAACTG CCTCTGTTGT GTGCCTGCTG AATAACTTCT 
       Q  L  K   S  G  T  A   S  V  V   C  L  L   N  N  F  Y  Frame 3 
       
  901 ATCCCAGAGA GGCCAAAGTA CAGTGGAAGG TGGATAACGC CCTCCAATCG 
        P  R  E   A  K  V   Q  W  K  V   D  N  A   L  Q  S    Frame 3 
 
  951 GGTAACTCCC AGGAGAGTGT CACAGAGCAG GACAGCAAGG ACAGCACCTA 
      G  N  S  Q   E  S  V   T  E  Q   D  S  K  D   S  T  Y   Frame 3 
 
 1001 CAGCCTCAGC AGCACCCTGA CGCTGAGCAA AGCAGACTAC GAGAAACACA 
       S  L  S   S  T  L  T   L  S  K   A  D  Y   E  K  H  K  Frame 3 
       
 1051 AACTCTACGC CTGCGAAGTC ACCCATCAGG GCCTGAGCTC GCCCGTCACA 
        L  Y  A   C  E  V   T  H  Q  G   L  S  S   P  V  T    Frame 3       
                         XhoI 
 1101 AAGAGCTTCA ACAGGGGACT CGAGCACCAC CACCACCACC ACCACCACTA 
      K  S  F  N   R  G  L   E  H  H   H  H  H  H   H  H  *   Frame 3 
 
Figure XXX: Nucleotide and deduced amino acid sequence of pBAK.1Hk Pf-
NPNA scFv-12 (VH – VL). The amino acid sequences corresponding to the 
complementary determining regions (CDRs) are in green. The leader sequence, 
restriction sites and octa his tag are indicated.   
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Figure XXXI: Physical map of pBAK.1-(NPNA)9-MKC. The plasmid is based on the 
pET41b(+) plasmid system and has the T7 promoter for expression of the antigen 
(NPNA)9-MKC. MKC stands for mouse kappa constant chain. Relevant genetic 
elements are: lac operator, pelB signal peptide, f1 origin of replication, T7 terminator, 
kanamycin resistance gene, ColE1pBR322 gene and lacI gene. 
 
 
 
 
     XbaI                         pelB leader sequence 
   1 TCTAGATCAA GGAGAACAGT CATAATGAAA TACCTATTGC CTACGGCAGC 
                               M  K   Y  L  L  P   T  A  A    Frame 1                                                                                                     
                            SfiI        NcoI                     
  51 CGCTGGATTG TTATTACTCG CGGCCCAGCC GGCCATGGCG AACGCAAATC 
      A  G  L   L  L  L  A   A  Q  P   A  M  A   N  A  N  P   Frame 1 
 
 101 CGAACGCCAA TCCGAACGCT AATCCGAACG CTAATCCGAA CGCAAATCCG 
       N  A  N   P  N  A   N  P  N  A   N  P  N   A  N  P     Frame 1 
 
 151 AACGCGAATC CGAACGCTAA TCCGAACGCA AATCCGAACG CGAATCCGAA 
     N  A  N  P   N  A  N   P  N  A   N  P  N  A   N  P  N    Frame 1       
      NotI             
 201 CGCGGCCGCA CCAACTGTAT CCATCTTCCC ACCATCCAGT GAGCAGTTAA 
      A  A  A   P  T  V  S   I  F  P   P  S  S   E  Q  L  T   Frame 1 
 
 251 CATCTGGAGG TGCCTCAGTC GTGTGCTTCT TGAACAACTT CTACCCCAAA 
       S  G  G   A  S  V   V  C  F  L   N  N  F   Y  P  K     Frame 1 
                                                            
 301 GACATCAATG TCAAGTGGAA GATTGATGGC AGTGAACGAC AAAATGGCGT 
     D  I  N  V   K  W  K   I  D  G   S  E  R  Q   N  G  V    Frame 1 
                      
 351 CCTGAACAGT TGGACTGATC AGGACAGCAA AGACAGCACC TACAGCATGA 
      L  N  S   W  T  D  Q   D  S  K   D  S  T   Y  S  M  S   Frame 1 
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 401 GCAGCACCCT CACGTTGACC AAGGACGAGT ATGAACGACA TAACAGCTAT 
       S  T  L   T  L  T   K  D  E  Y   E  R  H   N  S  Y     Frame 1 
                                        
 451 ACCTGTGAGG CCACTCACAA GACATCAACT TCACCCATTG TCAAGAGCTT 
     T  C  E  A   T  H  K   T  S  T   S  P  I  V   K  S  F    Frame 1                         
                      XhoI          His8 Tag         
 501 CAACAGGAAT GAGTCTCTCG AGCACCACCA CCACCACCAC CACCACTAA  
      N  R  N   E  S  L  E   H  H  H   H  H  H   H  H  *  Frame 1 
 
Figure XXXII: Nucleotide and deduced amino acid sequence of pBAK.1(NPNA)9-
MKC. MKC sequence is in green. The leader sequence, restriction sites and octa his 
tag are indicated.   
 
 
 
 
 
Figure XXXIII: Vector map of plasmid pMAK031 2P Pf-NPNA-1 scFv-12 insert. 
ORI: origin of replication for gram-negative bacteria; OriR: origin of replication for 
gram-positive bacteria; mobilProt: mobilisation protein; PnptII: constitutive kanamycin 
(neomycin) phosphotransferase promoter; Trrn terminator: rrnB rRNA T1 
transcriptional terminator; kanamycin: kanamycin resistance gene. Restriction sites 
(NcoI, NotI, NdeI) for cloning of scFv genes are coloured red. The 6X His and Tri-
FLAG tags are shown.  
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      FalI 
    1 AAGGGAGGCT TACCTTGACA GGTGTGTGGA GCCTGCAAGT AACTGGATGG 
 
   51 CTTTCTTGCC GCCAAGGATC TGATGGCGCA GGGGATCAAG ATCTGATCAA                                          
                       XbaI                          EcoRI 
  101 GAGACAGGAT GTCAACTCTA GAAGATGGCC GGGTACCGAG CTCGAATTCG 
                                                               
                                                        NdeI 
  151 GCTTATTCCC TAACTAACTA AAGATTAACT TTATAGGGAG GAAAAACATA 
                                                           M  Frame 2 
  201 TGAAATACCT GCTGCCGACC GCTGCTGCTG GTCTGCTGCT CCTCGCTGCC 
        K  Y  L   L  P  T   A  A  A  G   L  L  L   L  A  A    Frame 2      
             NcoI 
  251 CAGCCGGCCA TGGCCCAGGT GCAGCTGGTG CAGAGCGGCG GCGGCGTGGT 
      Q  P  A  M   A  Q  V   Q  L  V   Q  S  G  G   G  V  V   Frame 2 
         
  301 GCAGCCGGGC CGCAGCCTGC GCCTGAGCTG CGCGGCGAGC GGCTTTATTT 
       Q  P  G   R  S  L  R   L  S  C   A  A  S   G  F  I  F  Frame 2 
       
  351 TTAGCAACTA TGCGATGGAT TGGGTGCGCC AGGCGCCGGG CAAAGGCCTG 
        S  N  Y   A  M  D   W  V  R  Q   A  P  G   K  G  L    Frame 2 
        
  401 GATTGGGTGG CGGTGGTGAG CTATGATGCG CGCAACCAGT ATTATGCGGA 
      D  W  V  A   V  V  S   Y  D  A   R  N  Q  Y   Y  A  D   Frame 2 
         
  451 TAGCGTGAAA GGCCGCTTTA CCATTAGCCG CGATAACAGC AAAAACACCC 
       S  V  K   G  R  F  T   I  S  R   D  N  S   K  N  T  L  Frame 2 
       
  501 TGTATCTGCG CATGAACAGC CTGCGCGCGG AAGATACCGC GGTGTATTAT 
        Y  L  R   M  N  S   L  R  A  E   D  T  A   V  Y  Y    Frame 2 
        
  551 TGCGCGCGCG ATCGCGATAG CTCGAGCTAT TTTGATAGCT GGGGCCAGGG 
      C  A  R  D   R  D  S   S  S  Y   F  D  S  W   G  Q  G   Frame 2 
         
  601 CACCCTGGTG ACCGTGAGCA GCGGCGGTGG CAGCGGTGGC GGTAGCGGCG 
       T  L  V   T  V  S  S   G  G  G   S  G  G   G  S  G  G  Frame 2 
       
  651 GTGGCAGCGA AATTGTGCTG ACCCAGAGCC CGAGCACCCT GAGCGCGAGC 
        G  S  E   I  V  L   T  Q  S  P   S  T  L   S  A  S    Frame 2 
        
  701 GTGGGCGATC GCGTGACCAC CACCTGCCGC GCGAGCCAGG GCATTAGCAA 
      V  G  D  R   V  T  T   T  C  R   A  S  Q  G   I  S  N   Frame 2 
         
  751 CTGGCTGGCG TGGTATCAGC AGAAACCGGG CCGCGCGCCG AAACTGCTGA 
       W  L  A   W  Y  Q  Q   K  P  G   R  A  P   K  L  L  I  Frame 2 
       
  801 TTGTGAAAGC GAGCAGCCTG GAAAGCGGCG TGCCGAGCCG CTTTAGCGGC 
        V  K  A   S  S  L   E  S  G  V   P  S  R   F  S  G    Frame 2 
        
  851 AGCGGCAGCG GCACCGAATT TACCCTGACC ATTAGCAGCC TGCAGCCGGA 
      S  G  S  G   T  E  F   T  L  T   I  S  S  L   Q  P  D   Frame 2 
         
  901 TGATTTTGCG ACCTATTATT GCCAGCAGTA TAACAGCTAT AGCGGCCTGA 
       D  F  A   T  Y  Y  C   Q  Q  Y   N  S  Y   S  G  L  T  Frame 2     
                                            NotI 
  951 CCTTTGGCGG CGGCACCAAA GTGGAAATTA AACGCGCGGC CGCATCCGCA 
        F  G  G   G  T  K   V  E  I  K   R  A  A   A  S  A    Frame 2 
        
 1001 CATCATCATC ACCATCACAA GCTGGACTAC AAAGACCATG ACGGTGATTA 
      H  H  H  H   H  H  K   L  D  Y   K  D  H  D   G  D  Y   Frame 2 
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                                                        HindIII 
 1051 TAAAGATCAT GACATTGATT ACAAGGATGA CGATGACAAG TAATAAAAGC 
       K  D  H   D  I  D  Y   K  D  D   D  D  K   *  Frame 2 
       
Figure XXXIV: Nucleotide and deduced amino acid sequence of pMAK031 2P 
Pf-NPNA scFv-12 (VH – VL). The amino acid sequences corresponding to the 
complementary determining regions (CDRs) are in green. The leader sequence, 
restriction sites and octa his tag are indicated 
 
 
 
 
     
 
 
 
 
Figure XXXV: Bradford protein calibration curve. Protein standards were prepared in 
the range of 0 to 500 µg/mL. Absorbance was measured at 590 nm. 
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Figure XXXVI: Chromatographic separation of protein standards on HiLoad 16/60 
Superdex column. The protein standards, cytochrome c (12.4 kDa), carbonic 
anhydrase (29 kDa), bovine serum albumin (66 kDa) and β-Amylase (200 kDa) were 
run under the conditions described in section. The column was eluted with 240 mL of 
1X PBS (3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH 8.0), 
run at a flow rate of 1.0 ml/min. 
    
 
Figure XXXVII: SDS-PAGE (A) and Western blot (B) analyses of Ni-NTA affinity 
purified scFv NPNA VH12VL Hk. A: Proteins were electrophoresed on a 12% gel and 
stained with Coomassie brilliant blue R-250. M: protein marker (kDa); NI: non-
induced cell pellets; I: induced cell pellets; P: periplasmic fraction; FT: flow through; 
W: wash; E1- E4: Elutions 1-4. Arrow indicates expressed protein (37 kDa). B: Semi-
native and western blot demonstrating multimerisation of scFv NPNA VH12VL Hk. Ni-
NTA purified protein (elution 2, Figure A) was analysed under reducing (lane 1) and 
non-reducing conditions (lane 2). M: molecular weight maker (kDa); Protein was 
probed with goat Anti-Human kappa light chain monoclonal antibody (1:30000) 
conjugated to alkaline phosphatase (AP). BCIP/NBT was used as substrate. Arrows 
indicate the monomeric and dimeric forms of the NPNA scFv-12Hk.  
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Figure XXXVIII: Cation exchange chromatography profile of Ni-NTA purified scFv 
NPNA VH12VL Hk. The Ni-NTA purified proteins were desalted on a Sephadex G-20 
column before being applied on a 1 mL HiTrapTM SP FF cation exchange column. 
Proteins were eluted with a 1 M NaCl gradient. Eluted fractions (13 to 18) were 
analysed on SDS-PAGE (Insert).  
 
 
Figure XXXIX: Size exclusion HPLC on a calibrated Hi-Load 16/60 Superdex column 
of purified NPNA scFv fused to HuCk (fractions 13 – 18, Fig. ). The column was 
eluted with 1X PBS (3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, 
pH 8.0), run at a flow rate of 1.0 ml/min. The dimer (peak 1) and monomer (peak 2) 
of the protein were analysed on SDS-PAGE (insert). 
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Figure XL: Agarose gel electrophoresis of PCR screened Pf-NPNA-1 scFv-0 
and 12 (A) and 4B7 scFv-0 (B and C) scFvs in Asaia SF2.1. 25 µL of each 
digested reaction was loaded and subjected to electrophoresis on a 1% agarose at 
100 V for 1 hour. The DNA was visualised using ethidium bromide under UV light at 
wavelength of 200 nm. A: Pf-NPNA-1 scFv-0 (lane 2 and 3) and scFv-12 (lane 4 and 
5) amplified with T7ABATG and PfVLR primers, B: 4B7(AJ) scFv-0 (lane 2 and 3) 
and C: 4B7(AJ) scFv-20 (lane 2 and 3) amplified with primers 4B7VLNco and 
4B7VHNot. Lane 1: 100 bp DNA ladder (in all gels).  
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